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ABSTRACT
Ulcerative Colitis (UC) is a chronic illness under the umbrella of Inflammatory
Bowel Disease (IBD). IBD is becoming a global health issue as incidence rates are rising
throughout the world. UC is characterized by chronic inflammation and ulcerations in
the colon’s mucosal lining due to abnormal inflammatory and immune system responses.
Patients with UC experience a range of gastrointestinal and extraintestinal symptoms as
well as psychosocial challenges throughout the course of illness that generate a
significant burden on daily life. Periods of active disease, or flares, present exacerbations
of disease symptoms and the greatest burden on daily functioning, yet disease activity
often fluctuates in symptom severity over the disease course and much of the
extraintestinal burden continues throughout periods of remission as well. Many of those
diagnosed with UC seek out a combination of medical, lifestyle, and/or alternative
treatment and management methods in efforts to mitigate disease symptoms, reduce
dependence upon pharmaceuticals, and respond to the challenges of living with chronic
health condition.
Current literature is lacking sufficient description of how individuals use
treatment and management methods on a daily basis and over the disease course, as well
as examination of the perspectives, resources, and motivations supporting utilization of
various methods. Despite limited evidence to support consistent dietary
recommendations for the management of UC, dietary change is a popular selfmanagement method among UC patients. Popular diets currently recommended for UC
iv

lack evidence of effective healing of the inflamed and ulcerated mucosal lining of the
colon. The Energy-Adjusted Dietary Inflammatory Index (E-DIITM) measures the
inflammatory potential of food intake and has never been studied among the UC
population. Additionally, physical activity is highly likely to contribute to a reduced
burden of illness among individuals with UC, yet few studies have examined physical
activity among this population. Recommendations for physical activity among the UC
population do not currently exist. Two specific aims were proposed for this dissertation
and addressed using two distinct studies.
The specific aim of study 1 was to examine how treatment and management
methods are used by individuals who have been living with UC for at least 5 years and
how patients make decisions regarding the use of these treatment and management
methods for UC. Qualitative data were collected using individual semi-structured
interviews addressing the participant’s retrospective illness trajectory, the impact of UC
on daily life, experiences with medical and complementary or alternative treatment
methods used to control disease activity, methods for self-managing the impact of UC on
daily living, and processes of making decisions regarding treatment and management of
UC of the course of illness. Eligibility criteria included: 1) diagnosis of UC; 2) duration
of illness ≥5 years; and 3) a minimum of one disease flare during the course of illness.
Patients (n=21) were recruited in collaboration with a large gastroenterology clinic in
South Carolina, a support group for individuals experiencing Crohn’s and UC, an
integrative medicine clinic in South Carolina, and through posting study fliers in two UC
focused Facebook support groups. Thematic analysis was conducted using NVivo 12
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software. Iterative coding led to the organization of meaningful themes and sub-themes
across all interviews to capture key elements the participants’ experiences.
The specific aim of study 2 was to examine associations between dietary
inflammatory potential, physical activity, and health outcomes associated with the burden
of living with UC. Data obtained from participants in the IBD Partners e-cohort who selfreported UC (n=2,052) were analyzed using a cross-sectional, secondary data analysis.
Dietary data collected through a National Cancer Institute dietary screener were
converted into an E-DII score. Physical activity data were collected using the GodinShephard Leisure Time Activity Index. Outcome variables included the Simple Clinical
Colitis Activity Index (SCCAI), Short Inflammatory Bowel Disease Questionnaire
(SIBDQ), and PROMIS domains of anxiety, depression, fatigue, sleep disturbance, and
social satisfaction. Multivariable regression models controlled for age, sex, body mass
index (BMI), race, education, diet, physical activity, smoking status, medication class,
and disease duration.
From study 1, we observed that decisions are shaped by a patient’s approach
towards disease management, personal experiences, sources of information, and
individual motivating factors. A driving factor in decision making is personal suffering.
Patients are willing to try new methods of management and overlook long-term
implications in order to reduce suffering and be able to ‘function’ in the present day.
Suffering may motivate long term behavior change, but the majority of participants tend
to utilize most treatment and management methods as responses to flares and UC
suffering instead of as preventative health behaviors. While patients identify some
medications and overall stress reduction as important methods to avoid UC flares,
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treatment and management methods are predominantly employed as efforts to recover
from flares and reduce existing symptoms.
Findings from study 2 showed that pro-inflammatory dietary intake, indicated by
E-DII score, was associated with increased disease activity (β=0.166; p<0.001), anxiety
(β=0.342; p=0.006), depression (β=0.408; p=0.004), fatigue (β=0.386; p=0.005), sleep
disturbance (β=0.339; p=0.003), and decreased social satisfaction (β= -0.370; p=0.004)
and IBD-related quality of life (β= -0.056; p<0.001). Leisure time activity was inversely
associated with disease activity (β= -0.108; p<0.001), anxiety (β= -0.025; p=0.001),
depression (β= -0.025; p=0.001), fatigue (β= -0.058; p<0.001), and sleep disturbance (β=
-0.019; p=0.008), while positively associated with social satisfaction (β=0.063; p<0.001),
and IBD-related quality of life (β=0.005; p<0.001). The benefit among health outcomes,
excluding depression, was greater for strenuous exercise intensity than for moderate or
mild intensities. For all outcomes, interaction effects between E-DII and physical activity
were not significant.
This dissertation offers added insight into how and why treatment and
management methods are used to reduce the physical and psychosocial burden of illness
associated with UC. Findings suggest that an anti-inflammatory diet and physical
activity are each complementary lifestyle methods that may contribute to decreases in
disease activity, anxiety, depression, and fatigue, and improvements in health-related
quality of life, sleep, and social satisfaction. Such modalities may aid in managing
systemic and localized inflammation associated with UC and reduce the burden of UC on
daily living. More research in this area will contribute to creating evidence-based dietary
and physical activity recommendations for the UC population. Findings from this
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dissertation can aid in framing patient education and behavioral interventions that assist
patients with UC in adopting and sustaining self-management behaviors to reduce and
prevent disease activity. Future research is needed to design and evaluate ways to shift
treatment and management approaches away from reactive behaviors and promote
preventative self-management.
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CHAPTER 1
INTRODUCTION
Ulcerative Colitis (UC) is a chronic illness under the umbrella of Inflammatory
Bowel Disease (IBD) characterized by chronic inflammation and ulcerations of the
colon’s mucosal lining due to abnormal immune system responses (Crohn’s and Colitis
Foundation, 2022; Porter et al., 2020). Reports estimate that over 6.8 million people are
living with IBD across the world and indicate over 2 million Europeans and 1.5 million
North Americans are currently diagnosed with IBD (Alatab et al., 2020; Jairath &
Feagan, 2020; Ng et al., 2017). Despite the complexity of the condition and irregularities
in reporting and data collection (Mulder et al., 2014), IBD is becoming a global health
issue as incidence rates are rising throughout the world (Jairath & Feagan, 2020; Windsor
& Kaplan, 2019). North America is reported to hold one of the highest reported
prevalence values of Ulcerative Colitis in the world, with 286 cases per 100,000 people
(Ng et al., 2017). Reports suggests that incidence rates are stabilizing in western countries
while prevalence continues to rise due to improved survival, and rising incidence rates
are evident across, South America, Eastern Europe, Asia, and Africa (Alatab et al., 2020;
Ng et al., 2017; Olfatifar et al., 2021). The cause of UC is unknown. Current frameworks
suggest the development and progression of UC is a complex combination of
environmental factors, abnormal immune response, gut microbiota, and genetic
predisposition (Porter et al., 2020).
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Individuals with UC experience lifelong unpredictable fluctuations between
periods of disease remission and exacerbations of disease activity (Falvo & Holland,
2018). Disease activity generates physical symptoms such as abdominal pain, rectal
bleeding, bowel urgency, bowel frequency, diarrhea, and fatigue, along with various
extraintestinal manifestations of disease, which interfere with maintaining normal daily
activities (Fourie et al., 2018; Hall et al., 2005; Matini & Ogden, 2016; McMullan et al.,
2017; Wickman et al., 2016; Wolfe & Sirois, 2008). Regardless of whether disease is
active, the majority of individuals with UC report decreased work productivity, anxiety
and depression, isolation, strained relationships, ‘brain fog’, poor sleep quality, and
negative body image (Falvo & Holland, 2018; Fedosiejew et al., 2016; López-Sanromán
et al., 2017; McMullan et al., 2017). UC has been found to influence choices regarding
employment status, career planning and development, family planning, and social
engagement (Fourie et al., 2018; Hall et al., 2005; Matini & Ogden, 2016; McMullan et
al., 2017; Wickman et al., 2016; Wolfe & Sirois, 2008)
Medical treatments for UC aim to reduce symptoms and induce a state of
remission through reducing inflammation using pharmaceutical therapies. While certain
drugs can lead to improvements in reducing disease activity, many patients report that
pharmaceuticals, overall, provide insufficient treatment to induce or maintain remission
and overcome the burden of UC in everyday life (Matini & Ogden, 2016; McMullan et
al., 2017; Wickman et al., 2016; Wolfe & Sirois, 2008). Additionally, the cost of
medication is a key driver of healthcare spending on UC (Beard et al., 2020), which has
implications for patient affordability and access to new medicines.
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Many of those diagnosed with UC seek out a combination of medical, lifestyle
(e.g., diet, physical activity), and/or alternative treatment and management methods in
efforts to mitigate disease symptoms, reduce dependence upon pharmaceuticals, avoid
medication side effects, achieve disease remission, reduce the burden of illness on the
activities of every-day life, and improve overall quality of life (Fourie et al., 2018; le
Berre et al., 2020; McCormick et al., 2012; McMullan et al., 2017; Wolfe & Sirois,
2008). While existing research has indicated the use of various treatment and
management methods among individuals with UC, current literature is lacking sufficient
description of how individuals use treatment and management methods on a daily basis
and over the disease course, and examination of the perspectives, resources, and
motivations supporting utilization of various methods (Crooks et al., 2021).
Despite limited evidence to support consistent dietary recommendations for the
management of UC, dietary change is a popular self-management method among UC
patients (Rizzello et al., 2019). With varying success, many patients attempt to identify
and avoid foods that seem to trigger gastrointestinal symptoms or adopt highly restrictive
diets in response to a disease flare (Cohen et al., 2014; Jowett et al., 2004). Exclusionary
diet practices can result in healthier dietary intake, but also can result in malnutrition,
disengagement from social activities, excessive cognitive energy spent on food choices,
frustration with the desire for excluded foods, and significant distress after straying from
dietary exclusion goals (Nazarenkov et al., 2019). Low fiber diets are often suggested to
help ease the roughage passing through an inflamed colon during UC flares. Indeed, lowfiber and exclusion diets tend to be strongly pro-inflammatory (Khayyatzadeh et al.,
2017; Krishnamurthy et al., 2012; Y. Ma et al., 2008). So, this prescription could tend to
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exacerbate the problem and amplify symptoms when adopted for an extended period of
time. There is very limited evidence about the effectiveness of these recommended
exclusion diets in healing the inflamed and ulcerated mucosal lining of the colon.
A successful approach to food choice among individuals with UC may be the
adoption of an anti-inflammatory dietary lifestyle to manage the burden of living with
UC. Outside of the development of the IBD Anti-Inflammatory Diet (IBD-AID) protocol
and subsequent examination of its interaction with the microbiome (Olendzki et al., 2022;
Olendzki et al., 2014), the adoption of an anti-inflammatory dietary lifestyle has not been
otherwise examined as a complementary treatment approach and self-management
method for UC. An anti-inflammatory diet may play a role in managing the localized
and systemic inflammation associated with UC and therefore may decrease disease
activity and associated extraintestinal manifestations of illness.
The Dietary Inflammatory Index (DII®) is a literature-derived dietary index
developed to measure the inflammatory potential of one’s food intake (Shivappa, et al.,
2014a). Outside of a study showing that a pro-inflammatory diet was a risk factor for
developing UC (Shivappa, et al., 2016a and another one producing suggestive results
(Mirmiran et al., 2019), the DII has never been studied among the UC population.
In addition to diet, physical activity (PA) is another behavioral method UC
patients use for reduction and management of the physical and psychosocial burden of
illness. PA is widely known to reduce stress and depression, regulate systemic
inflammation, reduce the risk of co-morbidities, improve social relationships, and
demonstrate quality of life benefits among the general population. Physical activity is
highly likely to contribute to a reduced burden of illness among individuals with UC, yet
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few studies have examined PA among this population. Existing studies on PA and IBD
suggest that although patients struggle with motivation to exercise during periods of
active disease, engagement in PA or structured exercise is associated with improvements
in quality of life, fatigue, and mental health (Eckert et al., 2019; Lamers et al., 2021;
Raman et al., 2021; Wiestler et al., 2019). Additionally, evidence suggests that physical
activity also may be an effective modifier in the disease course of UC (Eckert et al.,
2019; Engles et al., 2018). However, recommendations for PA and maintenance of
health among the UC population do not currently exist. Research is needed to determine
the magnitude of effect physical activity has on decreasing the burden of illness
associated with UC. Additionally, recent reviews call for data on the intensity and
frequency of exercise that would generate the greatest benefit among individuals with UC
in order to determine exercise recommendations for this population (Eckert et al., 2019;
Engles et al., 2018; Nathan et al., 2013; Raman et al., 2021).
This work is a mixed-methods design that utilizes both qualitative and
quantitative approaches to understand the effect of treatment and management methods
on the daily burden of Ulcerative Colitis. To address the aims of this dissertation two
separate studies are presented. Study 1 examines how treatment and management
methods are used by individuals with UC and how patients make decisions regarding the
use of these methods throughout the disease course. Study 2 examines associations
between diet-related inflammation, as indicated by the DII, physical activity at varying
intensities, and both physical and psychosocial health outcomes associated with the
burden of living with UC.
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This study offers added insight regarding why patients use various treatment and
management methods and how behavioral methods of diet and physical activity may
impact the physical and psychosocial burden of illness on daily life. To our knowledge,
this is the first study to use the DII to examine dietary inflammatory potential and UCrelated physical and psychosocial health outcomes. Findings from this study contribute
to the development of dietary and physical activity recommendations for the UC
population and may inform evidence-based models of patient care and behavioral health
methods for reducing the burden of UC in daily life.
Research Objectives and Aims
This research aims to:
1. Examine how treatment and management methods are used by individuals who have
been living with UC for at least 5 years and how patients make decisions regarding
the use of these treatment and management methods for UC.
a. What treatment and management methods do those living with UC for at
least 5 years report using over the disease course?
b. In what ways do patients utilize treatment and management methods in
their daily life?
c. In what ways do patients with UC perceive the influence of treatment and
management methods on the burden of illness associated with UC?
i. How do individuals with UC describe the impact of illness on their
quality of life?
d. How do those living with UC for at least 5 years make decisions about the
use of treatment and management methods for UC?
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i. How do individuals living with UC perceive their self-efficacy and
agency in self-managing their illness experience?
ii. Where do individuals with UC learn about treatment and
management methods?
iii. How do those living with UC describe the incentives for the use of
treatment and management methods?
iv. How do those living with UC describe the deterrents and barriers
for the use of treatment and management methods?
2. Examine associations between dietary inflammatory potential, physical activity, and
health outcomes associated with the burden of living with UC.
Hypothesis 1. Anti-inflammatory dietary intake will be negatively associated with
disease activity scores, symptoms of anxiety, symptoms of depression, fatigue, and sleep
disturbance, and positively associated with satisfaction with social role, and IBD-related
quality of life.
Hypothesis 2. Physical activity will be negatively associated with disease activity scores,
symptoms of anxiety, symptoms of depression, fatigue, and sleep disturbance, and
positively associated with satisfaction with social role, and IBD-related quality of life.
Hypothesis 2a. Increased engagement in physical activity at a moderate intensity will
have a stronger inverse association with disease activity scores, anxiety, depression,
fatigue, and sleep disturbance, and a stronger positive association with satisfaction
with social role, and IBD-related quality of life than an increase in physical activity at
a strenuous or mild intensity.
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Hypothesis 3. Physical activity will amplify the relationship between an antiinflammatory diet and disease activity scores, IBD-related quality of life, and patient
reported outcomes (anxiety, depression, fatigue, sleep disturbance, and satisfaction with
social role).
Hypothesis 3a. The interaction between moderate physical activity and high antiinflammatory dietary intake will have the strongest associations with low disease
activity scores, high IBD-related quality of life, low anxiety, low depression, low
fatigue, low sleep disturbance, high satisfaction with social role.
Overview
The next chapter (Chapter 2) includes a review of the literature regarding
Ulcerative Colitis, the burden of illness associated with UC, and treatment for the
management of UC. Chapter 2 also describes the conceptual framework guiding this
work and reviews the significance of this research contribution. Chapter 3 describes the
study design and methodology used to address the aims of this research. Chapter 4
presents the results of the research in two distinct manuscripts. Chapter 5 presents a
summary of the main findings and a discussion about the implications for future research.
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CHAPTER 2
BACKGROUND AND SIGNIFICANCE
This chapter will describe Ulcerative Colitis (UC), the impact of UC on patients’
lives, and existing treatment and management methods. An overview of UC and rates of
prevalence and incidence will be described, followed by a discussion of the potential
etiology of UC. The burden of illness that accompanies UC is presented, followed by a
discussion of treatment and management methods available to patients. The conceptual
framework for this work is presented followed by a discussion of this dissertation’s
significance.
Background
2.1 Ulcerative Colitis
Ulcerative Colitis (UC) is a chronic illness under the umbrella of Inflammatory
Bowel Disease (IBD) characterized by chronic inflammation and ulcerations of the
colon’s mucosal lining due to abnormal immune system responses (Crohn’s and Colitis
Foundation, 2022; Porter et al., 2020). Individuals with UC may experience disease
severity ranging from mild to moderate or severe (Peyrin-Biroulet et al., 2016) with
lifelong unpredictable fluctuations between periods of disease remission and
exacerbations of disease activity (Falvo & Holland, 2018). Patients suffer from
gastrointestinal (GI) symptoms associated with UC, predominantly rectal bleeding,
abdominal pain, bowel urgency, bowel frequency, and diarrhea that interfere with
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maintaining normal daily activities (Fourie et al., 2018; Matini & Ogden, 2016;
McMullan et al., 2017; Wickman et al., 2016) as well as extraintestinal manifestations of
illness affecting joints, skin, and the eyes (Ghosh et al., 2021; Wolfe & Sirois, 2008).
Patients also report considerable physical and cognitive fatigue, isolation, reduced
productivity, limited professional development, ‘brain fog’, diminished self-concept,
anxiety, depression, strained relationships, as well as strained physical, emotional, and
social functioning (Devlen et al., 2014; Fedosiejew et al., 2016; Fourie et al., 2018;
López-Sanromán et al., 2017; Matini & Ogden, 2016; Yarlas et al., 2018). Overall, living
with UC generates a significant burden on daily functioning and long-term well-being.
2.1.1 Prevalence/Incidence
Reports estimate that over 6.8 million people are living with IBD across the
world, and indicate over 2 million Europeans and 1.5 million North Americans are
currently diagnosed with IBD (Alatab et al., 2020; Jairath & Feagan, 2020; Ng et al.,
2017). The majority of cases are currently diagnosed in Western societies, reflecting to
some extent reporting and diagnosis bias (Delgado-Rodríguez & Llorca, 2004; Jairath &
Feagan, 2020; Solomon, 1992). Despite the complexity of the condition and
irregularities in reporting and data collection (Mulder et al., 2014), IBD is becoming a
global health issue as incidence rates are rising throughout the world (Jairath & Feagan,
2020; Windsor & Kaplan, 2019). Reports suggest that incidence rates are stabilizing in
western countries while prevalence continues to rise due to improved survival, while
rising incidence rates are evident across South America, Eastern Europe, Asia, and Africa
(Alatab et al., 2020; Ng et al., 2017). Indeed, IBD is known to be grossly underreported
in India (Amarapurkar et al., 2018; Banarjee et al., 2020; Jain & Venkataraman, 2021;
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Maroo et al., 1974; Olfatifar et al., 2021; Patel et al., 2013) where UC has been
determined to be a “sleeping giant” (Juyal et al., 2018). Compounding prevalence is due,
in part, to improved survival rates (due to development of new therapies and improved
surgical outcomes), increases in early-onset IBD, and the resulting lengthened disease
duration, creating a potential for complex disease trajectories (Jairath & Feagan, 2020;
Kaplan & Windsor, 2021; Windsor & Kaplan, 2019).
In western regions (i.e. developed economies; regions predominantly colonized
by Europeans), the incidence range for UC is 23.1-57.9 per 100,000 (Crohn’s disease
range is 23.8-29.3 per 100,000) (Kaplan & Windsor, 2021; Ng et al., 2017). North
America currently holds one of the highest reported prevalence values of Ulcerative
Colitis in the world, with 286 cases per 100,000 people (Ng et al., 2017). Studies have
previously found a higher prevalence of UC among high income White Americans, with
prevalence rates among minority racial groups around 50-75% of those rates among
White individuals (Aniwan et al., 2019; Sonnenberg et al., 2017), but adequate evaluation
of current racial and ethnic distribution is lacking (Aniwan et al., 2019). Sonnenberg et
al., (2017) found prevalence of IBD to be highest in individuals aged 20-29 years, though
other studies have found the median age of diagnosis for UC to range from 28-34.9 years
(Long et al., 2012; Shivashankar et al., 2017). Diagnoses of UC among men and women
have been found to have a relatively equal distribution (Shivashankar et al., 2017;
Sonnenberg et al., 2017).
2.1.2 Potential Etiology of Ulcerative Colitis
The cause of UC is unknown. Current frameworks suggest the development and
progression of UC is a complex combination of environmental factors, abnormal immune
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response, gut microbiota, and genetic predisposition (Porter et al., 2020). Environmental
factors may include lifestyle behaviors such as smoking, sleep, stress, diet, and
breastfeeding, ecological factors such as pollution, and pharmacologic agents such as
antibiotics or vaccinations (Abegunde et al., 2016).
Some researchers parallel rapidly rising rates of UC with the adoption of the
westernized diet and culture in Eastern countries (Kaplan & Windsor, 2021; Rizzello et
al., 2019; Windsor & Kaplan, 2019). Processed foods, refined sugars, dairy, and less
plant-based fiber consumption has been linked with rising incidence rates in newly
industrialized nations (Jairath & Feagan, 2020; Windsor & Kaplan, 2019), giving rise to
increased attention to the impact of diet and various lifestyle health behaviors on the UC
disease course.
Stress is widely recognized to influence risk for digestive illnesses, and
commonly believed by UC patients to be a precursor for disease flares. Prolonged stress
can elicit numerous physiological reactions that contribute to immune dysfunction and
increased inflammation (Glaser & Kiecolt-Glaser, 2005). Living with UC is, in itself, a
chronic stressor. The burden of illness associated with UC contributes to the ongoing
nature of the illness by adding prolonged stress and, therefore, systemic inflammation and
a reduced immune system (Fedosiejew et al., 2016). Prolonged stress also contributes to
imbalances in the microbiome and natural gut flora, shown to be associated with UC
(Aleksandrova et al., 2017; Lane et al., 2017).
2.2 Burden of Illness Associated with Ulcerative Colitis
Living with UC often gives rise to a considerable personal burden of illness,
compounded by the unpredictable fluctuations between periods of remission and disease
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exacerbation. Periods of active disease, or flares, present exacerbations of gastrointestinal
symptoms and carry the greatest burden on daily functioning, yet disease activity often
fluctuates in symptom severity over the disease course and much of the extraintestinal
and psychosocial burden continues throughout periods of remission as well.
2.2.1 Gastrointestinal Symptoms
The most prominent localized physical symptoms reported among individuals
with UC include rectal bleeding, abdominal pain, bowel urgency, bowel frequency and
diarrhea (Fourie et al., 2018; Hall et al., 2005; Matini & Ogden, 2016; McMullan et al.,
2017; Wickman et al., 2016; Wolfe & Sirois, 2008). Such symptoms require proximity to
a restroom and challenge one’s ability to run errands, go shopping, travel, or attend social
events. Patients often refer to episodes of exacerbations of disease symptoms as ‘flares’
and periods of little to no gastrointestinal symptoms as ‘remission’, with varying
descriptions of symptom severity between such states (Devlen et al., 2014). Flares have
been referred to by individuals living with UC as ranging from ‘mild’ or ‘the beginnings
of a flare’ to having a ‘bad’ or ‘gigantic’ flare (Devlen et al., 2014).
2.2.2 Pain and Extraintestinal Manifestations
Between 50 and 70% of patients with IBD experience pain over the disease
course, with 20% of patients experiencing pain during periods of remission (Fedosiejew
et al., 2016). Physical pain often accompanies the symptoms of UC, yet sometimes
manifests despite remission of active GI symptoms. Pain is often reported locally in the
abdomen region, as well as manifesting extra-intestinally as arthropathy (i.e., joint pain).
In a study with over 2,500 participants diagnosed with UC, 47.2% of patients reported
painful joints (Long, 2012). Other extraintestinal manifestations of illness, such as eye
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inflammation, mouth ulcerations, or various skin conditions have also been reported
(Long, 2012; Wolfe & Sirois, 2008).
2.2.3 Fatigue
Fatigue is a predominant burden of illness and can be worse when UC activity is
in remission (Keefer et al., 2022; Matini & Ogden, 2016; McMullan et al., 2017).
Physical symptoms leave UC patients feeling drained with little to no energy. Systemic
inflammation and use of immunosuppressant medications also contribute to chronic
fatigue that is often reported by patients as different than typical tiredness (Keefer et al.,
2022; Lacourt et al., 2018; Villoria et al., 2017). Reports of tiredness and lack of energy
may be compounded by difficulty sleeping reported by patients (Wickman et al., 2016).
As a result, patients must prioritize where to allocate their limited energy and often feel
restricted in their daily activities (Matini & Ogden, 2016). Patients have expressed the
burden of cognitive fatigue as well, given the continual need to attend to symptoms,
spend cognitive energy on disease management and prevention of worsening symptoms,
and worry about future flares and cancer risks (Fedosiejew et al., 2016; Hall et al., 2005;
Wolfe & Sirois, 2008). Patient reported ‘brain fog’ is also believed to limit cognitive
productivity and memory (Keefer et al., 2022).
2.2.4 Mental Health and Emotional Distress
High rates of psychiatric disorders are prevalent among individuals with UC.
Among patients with UC, research estimates an incidence rate ratio of 1.58 (95%
CI:1.41-1.76) for depression and 1.39 (95%CI: 1.26-1.53) for anxiety compared to the
general population (Bernstein et al., 2019; Engel et al., 2021). Regardless of active
disease, symptoms of anxiety persist for many individuals throughout the disease course
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(Faust et al., 2012). The nature of a chronic illness, the implications of UC on daily life,
and the disease symptoms that accompany UC each contribute to depression, anxiety, and
emotional distress. The majority of individuals with UC report varying levels of
emotional distress, as making sense of a chronic illness with an unknown cause and no
available cure can weigh heavily a patient’s emotional well-being (Fourie et al., 2018;
Hall et al., 2005; Matini & Ogden, 2016; McMullan et al., 2017; Wickman et al., 2016;
Wolfe & Sirois, 2008). Patients with UC report that the stressors of diagnostic
procedures, uncomfortable or embarrassing symptoms, and limitations on daily activities
are compounded by fear and anxiety toward the overarching uncertainty surrounding
treatment efficacy and the future course of illness (Devlen et al., 2014; Fedosiejew et al.,
2016; López-Sanromán et al., 2017; Matini & Ogden, 2016). In addition, the chronic
nature of UC and the distressing implications can have a significant impact on an
individual’s perception of life’s goals, meaning, and purpose, with feelings of loss
revisited with each exacerbation of disease activity (Fedosiejew et al., 2016; Pereira,
1984).
UC has been described as an ‘invisible’ illness, where many patients feel that
others, including health professionals, do not recognize, understand, or validate the
gravity of their illness experience (Fourie et al., 2018; Hall et al., 2005; Wolfe & Sirois,
2008). Many patients express feelings of loneliness and difficulty sharing their feelings
about UC with others and letting others into their illness experience (Wickman et al.,
2016). Such social and emotional isolation contributes to depression and depressive
symptoms. UC is often accompanied with diminished self-concept, guilt, anger,
frustration, and self-blame (Fedosiejew et al., 2016; López-Sanromán et al., 2017).
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Additionally, participants experience poor sleep, strained relationships, and significant
social anxieties around symptom management, which heightens overall emotional
distress.
2.2.5 Economic Burden
A report on the economic implications of IBD in the US estimated direct and
indirect costs to range between at least $14.6 and $31.6 billion annually (Mehta, 2016).
The direct and indirect costs of IBD, driven by medical therapies, hospitalizations,
surgeries, lost work time, etc., generate a substantial economic burden on patients and
health care systems with costs specifically for UC totaling nearly $15 billion annually
(Beard et al., 2020). In the US, patients may be burdened with substantial direct costs for
medications, physician appointments, diagnostic procedures, surgeries, and other
associated hospital tests and treatments. A 2010 review estimated annual per-patient
direct medical costs for UC patients to range from $6,217 to $11,477 in the US (Cohen et
al., 2010). Multiple costly new medications, such as injection and infusion treatments,
have been incorporated into patient care since these estimates were calculated. In 2015, a
systematic review estimated annual per-patient indirect costs to range from $2,424.01 to
$9,622.15 (Kawalec, 2016). Indirect costs are incurred by work absenteeism, decreased
productivity, limited work capacity and professional development, as well as time spent
attending to the disease. Psychological treatment and care and other complementary and
alternative therapies can be very costly as well. Health insurance is pivotal for access to
medical treatments and care. Reliance on supplemental coverage programs to reduce out
of pocket costs is high among patients receiving injections, infusions, and other recently
released pharmaceutical treatment options.

16

2.2.6 Impact on Daily Life
Due to the physical and emotional burden of UC, the majority of individuals with
UC report decreased productivity at work and home, social isolation, and negative body
image (Fourie et al., 2018). Many patients feel like a burden or disappointment to their
family and friends, while others feel restricted from developing close relationships due to
their illness (Fedosiejew et al., 2016; Fourie et al., 2018; Wolfe & Sirois, 2008). UC
often restricts choices regarding employment status, career development, family
planning, and social engagement (Devlen et al., 2014; Fedosiejew et al., 2016; Fourie et
al., 2018; Matini & Ogden, 2016; McMullan et al., 2017). Despite best efforts to manage
their chronic health condition, many patients report significant difficulty committing to
social events or making plans for the future, due to the unpredictable nature of UC
(Devlen et al., 2014; Matini & Ogden, 2016).
2.2.7 Quality of Life
Quality of Life (QoL) encompasses an individual’s perception of their position in
life in relation to their values, goals, expectations, and standards (World Health
Organization, 2022). IBD is associated with a decreased QoL, with patients
experiencing a lower QoL than healthy individuals (Knowles et al., 2018). QoL among
individuals with IBD is often described by physical, emotional, systemic, and social
domains (Irvine, 1996). Health related quality of life (HRQoL) encompasses one’s
physical and mental health impact on the ability to live a fulfilling life (Carr et al., 2001).
Wolfe & Sirois (2008) identified patient-reported dimensions of HRQoL affected by IBD
to include 1) physical, 2) emotional, 3) social, 4) cognitive 5) self-regulatory (feelings of
control), and 6) practical (economic). Studies have shown a significant inverse

17

relationship between disease activity and HRQoL among the UC population (Faust et al.,
2012). The burden of illness associated with UC, including GI symptoms, pain, fatigue,
financial costs, emotional distress, etc., influences all dimensions of HRQOL. High
anxiety and depression symptoms have been shown to significantly reduce HRQoL
among patients with UC (Faust et al., 2012). The magnitude of UC’s burden on daily life
and overall QoL is influenced by perceptions of control, coping skills, and social support
(Wolfe & Sirois, 2008). In general, individuals with a chronic illness who can rely on
family members or a support group tend to experience a higher QoL (Fedosiejew et al.,
2016).
2.3 Treatment
Although there is currently no cure for UC, multiple methods exist to manage
disease symptoms and reduce the burden of illness on every-day life. The main goal of
medical treatments for UC is to reduce GI symptoms and induce a state of remission by
regulating the immune system with pharmaceutical therapies (Crohn’s & Colitis
Foundation, 2021; Falvo & Holland, 2018; Wickman et al., 2016). For the majority of
individuals with UC, pharmacotherapy is insufficient to regain and maintain a ‘normal’
lifestyle (Fourie et al., 2018; Matini & Ogden, 2016; McMullan et al., 2017).
Medications for UC can be very costly and bring a range of side effects (e.g., weight
gain, fatigue, nausea, skin rashes, and musculoskeletal pain).
Many of those diagnosed with UC seek out a combination of medical,
complimentary, and/or alternative treatment methods, as well as undertake social and
lifestyle adaptations to self-manage disease symptoms, reduce dependence upon
pharmaceuticals, and respond to the challenges of living with chronic illness.
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Manipulations to diet intake, adjustments in physical activity, chiropractic treatment,
probiotic use, and stress reduction techniques have been reported (Fourie et al., 2018;
Hall et al., 2005; Matini & Ogden, 2016; McMullan et al., 2017; Wickman et al., 2016;
Wolfe & Sirois, 2008). Seeking out new and personal preference-based self-management
options for treatment of UC has been associated with a high QoL and successful selfmanagement (Wickman et al., 2016).
2.3.1 Pharmacologic Treatment
The most common approach for treatment and management of UC symptoms is
physician-prescribed pharmaceutical therapies. Pharmacological management of UC can
include aminosalicylates, corticosteroids, immunomodulators, biologic or biosimilar
therapies, and target synthetic small molecules (or Janus Kinase (JAK) Inhibitors)
(Crohn’s & Colitis Foundation, 2021). Aminosalicylates contain 5-aminosalicylic acid
(5-ASA) and target the surface lining of the colon to decrease inflammation.
Corticosteroids suppress the entire immune response and are often used in response to
disease flares, though rarely used as long-term maintenance medication.
Immunomodulators suppress the entire immune system and can increase the effectiveness
of other UC medications, such as biologics. Biologics are protein-based antibodies that
block inflammation-causing proteins in the body. JAK inhibitors target specific parts of
the immune system to reduce inflammation. (Crohn’s & Colitis Foundation, 2021) Some
medications are ingested in pill form, while others are administered through injections or
infusions.
Medications for UC are prescribed in reaction to disease activity with the goal of
decreasing GI symptoms, regulating the immune system, and moving toward healing the
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inflamed mucosal lining of the colon. While pharmaceutical treatments provide
beneficial improvements to disease activity, patients report pharmaceuticals overall as
insufficient treatment (Matini & Ogden, 2016; McMullan et al., 2017; Wickman et al.,
2016; Wolfe & Sirois, 2008). The use of multiple concurrent medications is not
uncommon in attempts to control symptoms (Falvo & Holland, 2018; McMullan et al.,
2017). Continuous medication use is accompanied by various side effects (e.g., weight
gain, fatigue, nausea, skin rashes, and musculoskeletal pain) that may add to the burden
of illness. Many medications used for treatment of UC suppress the immune system and
can lead to additional health challenges. The majority of pharmaceutical treatments,
particularly biologic therapies, are known to lose effectiveness over time, or when
administered after the use of a similar biological agent (Cleveland et al., 2022). This loss
of response to medication leads to disease relapse, emotional distress, and progressive use
of stronger and more costly medications.
2.3.2 Surgery
Some patients with UC choose to undergo colectomy surgery to remove diseased
portions of the colon. In cases when patients become unresponsive to available
treatments or dangerously ill, surgery may be recommended or required (Crohn’s &
Colitis Foundation, 2021). In many cases surgery provides relief to patients and
improves HRQOL (Brown et al., 2015). For an ileostomy, a surgeon will create a small
hole in the abdominal wall and invert a piece of the small intestine to expel waste into an
ostomy pouch worn outside of the abdomen. More commonly today, patients choose a
proctocolectomy ileal pouch-anal anastomosis. Typically performed in 3 stages of
surgery, the colon and rectum are removed and the small intestine is attached to the anus
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with an internal pouch (J-pouch) created from the small intestine. This procedure still
allows patients to have bowel movements and use the bathroom (Crohn’s & Colitis
Foundation, 2021).
2.3.3 Diet and Ulcerative Colitis
Despite limited evidence to support consistent dietary recommendations for the
management of UC, dietary change is a popular self-management method among UC
patients (Rizzello et al., 2019). Clinical evidence is lacking on the impact of diet on
disease activity, leaving physicians unable to provide dietary recommendations for their
patients (Cohen et al., 2013; Sáez-González et al., 2019). Individuals with UC believe
that their diets play a role in managing disease symptoms and have reported diet
manipulation as a strategy for managing GI symptoms for quite some time (Hall et al.,
2005). At the same time, research examining diet as a behavioral treatment and
management method for mitigating disease activity is relatively new (Celiberto et al.,
2018; Torres et al., 2019; Wark et al., 2021). Patients with severe cases of disease often
rely on parenteral nutrition administered through a feeding tube in order to eliminate the
passage of food substance through the intestines. Such a change in ‘normalcy’ is often
associated with depression (Fedosiejew et al., 2016).
With varying success, many patients attempt to identify and avoid foods that seem to
trigger GI symptoms or adopt highly restrictive diets (Cohen et al., 2014; Jowett et al.,
2004). Many patients attribute symptom exacerbations to particular foods and adopt selfdictated exclusionary diet practices. Others struggle to identify beneficial dietary
changes through exclusionary trial and error. Some patient-reported foods that are
perceived to worsen symptoms (e.g., dairy, ice cream, soda, sugar, high-fiber foods, leafy
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and non-leafy vegetables, gluten, fatty foods, corn, red meat, chocolate, nuts, fruits)
overlap with foods also reported by other patients to improve symptoms (e.g., milk,
cheese, cereal, whole grains, leafy and non-leafy vegetables, potatoes, rice, fruit) (Cohen
et al., 2013). Patients have also reported that despite doing everything ‘right’ (i.e., food
selection, managing symptoms), many still experience flares with significant
accompanying discouragement and frustration (Devlen et al., 2014).
Popular diets currently recommended for UC, such as the Specific Carbohydrate
Diet (SCD) (Cohen et al., 2014), Low-FODMAP diet (Carlson et al., 2015), and lowfiber recommendations, have received the most attention among the UC community and
aim to reduce irritable bowel (note: irritable bowel vs inflammatory bowel) symptoms
such as gassiness or diarrhea. Scientific studies have explored the influence of dietary
manipulations on disease activity among UC patients with varying outcomes. Diet has
been shown to improve outcomes associated with UC, but specific dietary
recommendations continue to remain inconsistent across the field (Raman & Ghosh,
2019; Sáez-González et al., 2019; Wark et al., 2021).
The SCD diet excludes complex carbohydrates, sugar, and dairy products
believed to contribute to intestinal inflammation and allows limited types of nuts and
vegetables, fresh poultry and fish, and fermented yogurts (Cohen et al., 2014; Parrish &
Rdn, 2019; Wark et al., 2021). Interventions among IBD patients tend to include samples
with higher inclusion of Crohn’s Disease patients than UC patients (Kakodkar et al.,
2015), and patients are guided by dieticians for optimal adherence and nutrient intake
(Wark et al., 2021). Research on the SCD diet has been retrospective and lacking
objective measures of disease activity, although a few small case series among IBD
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patients have shown evidence of improved stool inflammatory markers (Wark et al.,
2021).
Non-digestible short-chain carbohydrates are collectively known as FODMAPs.
Low-FODMAP diets have generated evidence of reduced GI symptoms among patients
with IBD, but lack evidence of change in inflammatory markers (Wark et al., 2021). A 6week trial with 22 UC patients found improved disease activity scores and decreased
median calprotectin scores after following a low-FODMAP diet (Bodini et al., 2019), but
not all studies have found similar results (Cox et al., 2020). Research has found
improvement to HRQoL after following a low FODMAP diet in patients with IBD, yet
dietary studies are lacking large sample sizes of UC patients (Cox et al., 2020).
These exclusion-focused diets can help ease the burden of UC to an extent, yet are
often reported as difficult to maintain (Nazarenkov et al., 2019). Exclusionary diet
practices can result in healthier dietary intake, but also can result in malnutrition,
disengagement from social activities, excessive cognitive energy spent on food choices,
frustration with the desire for excluded foods, and significant distress after straying from
dietary exclusion goals (Nazarenkov et al., 2019). Low-fiber diets are often suggested to
help ease the roughage passing through an inflamed colon during UC flares. Indeed, lowfiber and exclusion diets tend to be strongly pro-inflammatory (Khayyatzadeh et al.,
2017; Krishnamurthy et al., 2012; Y. Ma et al., 2008). So, this prescription could tend to
exacerbate the problem and amplify symptoms when adopted for an extended period of
time. There is very limited evidence in the effectiveness of these recommended
exclusion diets in healing the inflamed and ulcerated mucosal lining of the colon.
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A promising approach to food choice among individuals with UC may be the
adoption of an anti-inflammatory dietary lifestyle to manage the burden of living with
UC. Research suggests that a focus on removing ‘pro-inflammatory’ foods, such as
refined carbohydrates and processed foods should guide exclusion diets among patients
with UC (Marsh et al., 2022). Among the general population, an anti-inflammatory
dietary intake has been shown to decrease anxiety, depression, and risk of colon cancer,
among other health outcomes (Shivappa et al., 2017; Shivappa, et al., 2016b). This
method of dietary intake expands food choices by incorporating aromatic spices, blends
of colorful foods, and plentiful intake of fruits, vegetables, and healthy fats. Olendzki
and colleagues (2021) developed the IBD Anti-Inflammatory Diet (IBD-AID) as a
protocol built from the SCD diet that incorporates anti-inflammatory components to
rebuild bacterial gut flora and mitigate disease activity
(https://www.umassmed.edu/nutrition/ibd/ibdaid/). An associated study screened
medical records for 10 IBD patients who followed the IBD-AID and found improvements
in GI symptoms, yet the sample included only three cases of UC (Olendzki et al., 2014).
Recent evidence indicates an association between the adoption of the IBD-AID and
beneficial changes in the microbiome of IBD patients (Olendzki et al., 2022).
Outside of the development of the IBD-AID protocol and subsequent examination
of its interaction with the microbiome, the adoption of an anti-inflammatory dietary
lifestyle has not been otherwise examined as a complementary treatment approach and
self-management method for UC. Though there is abundant evidence on the relationship
between diet-associated inflammation and diseases of the gastro-intestinal tract, and
suggestive links from work using the Dietary Inflammatory Index (DII®) (Marx et al.,
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2021; Mirmiran et al., 2019; Phillips et al., 2019; Shivappa, et al., 2016a), additional
carefully designed, ideally prospective studies need to be conducted in order to provide
sufficient scientific evidence to support clear dietary recommendations for the
management of UC.
2.3.4 Complementary and Alternative Therapies/ Lifestyle Change
Patients have reported the use of complementary and alternative therapies to
manage their UC that either contribute to or replace treatment regimens recommended by
their healthcare providers (McMullan et al., 2017; Wickman et al., 2016). Probiotic use
has been promoted for improved gut health, yet no evidence currently exists to support
this method in mitigating disease activity (Torres et al., 2019). Cannabis and other herbal
therapies have been tried among the IBD population, but little evidence exists to show
positive results (Torres et al., 2019). Vitamins and minerals are often used to supplement
deficiencies, yet evidence to suggest the treatment effects of supplement use on disease
activity is insufficient (Torres et al., 2019).
Many patients report stress reduction techniques to manage the burden of illness.
Mindfulness, yoga, relaxation courses, and exercise has been reported by patients to be
beneficial (McMullan et al., 2017). Relaxation and mindfulness techniques help patients
overcome negative experiences and stimuli (Fedosiejew et al., 2016; Torres et al., 2019).
Cognitive behavioural therapy has been found to improve short term QoL in adults with
IBD, and some patients report using this type of psychotherapy, by trying to find a
positive outlook in a challenging condition, as a way to cope with the burden of illness
(Fedosiejew et al., 2016; Torres et al., 2019). Additional lifestyle changes for stress
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management have also been reported by patients, such as increasing sleep and decreasing
work hours (Wickman et al., 2016).
2.3.5 Physical Activity and Ulcerative Colitis
Physical activity (PA) is another behavioral method UC patients look to for
reduction and management of the physical and psychosocial burden of illness. PA is
widely known to reduce stress and depression, regulate systemic inflammation, reduce
the risk of co-morbidities, improve social relationships, and demonstrate QoL benefits
among the general population. PA is highly likely to contribute to a reduced burden of
illness among individuals with UC, yet few studies have examined PA among this
population. Existing studies on PA and UC suggest that although patients struggle with
motivation to exercise during periods of active disease, engagement in PA or structured
exercise is associated with improvements in QoL, fatigue, and mental health (Eckert et
al., 2019; Lamers et al., 2021; Raman et al., 2021; Wiestler et al., 2019). Physical
activity, for the majority of patients, has not been shown to worsen symptoms and is
suggested as safe among the IBD population (Engles et al., 2018; Nathan et al., 2013).
Some research suggests that exercise may serve as a protective factor against
disease activity (Jones et al., 2015), and reviews of evidence suggests that PA may be an
effective modifier in the disease course of UC (Eckert et al., 2019; Engles et al., 2018),
but studies on physical activity’s impact on disease activity are limited (Engles et al.,
2018). Although patients with UC tend to report benefits of physical activity on wellbeing, participation in exercise is often difficult, given barriers associated with GI
symptoms (Engles, 2018). Recommendations for PA and maintenance of health among
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the UC population do not currently exist. Research is needed to determine the magnitude
of effect physical activity has on decreasing the burden of illness associated with UC.
Conceptual Framework
This work is anchored in a biopsychosocial lens examining the illness experience
associated with UC. The biopsychosocial model is a clinical and practical guide for
understanding how suffering and illness is affected by an interaction between biological,
psychological, and social influences (Borell-Carrió et al., 2004; Engel, 1977). The cause
of UC is unknown, yet the combination of one’s genetics, environment, microbiome, and
immune system are believed to play a prominent influential role in the development of
UC. Patients with UC experience a significant physical, psychological, and social burden
of illness. Due to the biopsychosocial nature of UC, this research is guided by a
conceptual framework to understand the illness experience in whole and examine how
treatment and management methods may play a role in reducing the biopsychosocial
burden of illness (see Figure 2.1 Conceptual Framework).
UC is experienced in degrees of disease severity and extent with fluctuating
degrees of disease activity, and characterized by localized inflammation evident in the
colon and systemic inflammation throughout the body. As UC is associated with
increased levels of localized and systemic inflammation, changes in localized and
systemic inflammation can increase or decrease UC severity and activity. Increases and
decreases in localized and systemic inflammation are mainly affected by the environment
and the immune system.
The burden of illness is a cumulative biopsychosocial experience of physical
gastrointestinal symptoms, extraintestinal manifestations of illness, pain, physical and
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mental fatigue, stress and emotional distress, anxiety and depression, insufficient sleep,
medication use and accompanying side effects, and the costs of health care. All of these
experiences impact one another. The burden of illness impacts social, mental healthrelated, and biological aspects of daily life. Aspects of daily life effected by the burden
associated with UC include work capacity and productivity, participation in social and
leisure activities, isolation, relationships, self-image and risks for cancer and other
comorbidities. These interrelated aspects of daily life often feed back into the burden of
illness. For example, isolation from activities once enjoyed may increase feelings of
depression, but new supportive relationships can decrease stress. Inflammation has a bidirectional relationship with aspects of the burden of illness.
Treatment and management methods may impact the overall experience of living
with UC. Methods such as medication, diet change, physical activity, stress
management, lifestyle changes, and other complementary and alternative treatments can
have an impact on the magnitude of burden and the impact of such burden on everyday
life. Treatment and management methods may also have direct impacts on inflammation.
Treatment and management methods may also influence the immune system,
microbiome, and environmental factors that influence disease severity and activity.
Recent evidence suggests that many types of therapies may also change gene expression
(Buric et al., 2017). Decisions to use various treatment and management methods are
shaped by internal and external factors such as personal suffering, patient-provider
relationships, knowledge and familiarity, perceptions/beliefs and attitudes, resources and
barriers, social support and messages, and values and faith. Each of these factors
influence one another as well.
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Figure 2.1. Conceptual Framework

Significance
This dissertation draws attention to health behaviors as lifestyle methods that aid
in managing the burden of illness associated with UC, as well as the potential of these
methods to contribute to achieving reduced disease activity, disease remission, and
healing of the colon’s mucosal lining. While existing research has indicated the use of
various treatment and management methods among individuals with UC, current
literature is lacking sufficient description of how and why individuals use treatment and
management methods as they face the burden of illness in daily life and over the disease
course, as well as examination of the perspectives, resources, and motivations that guide
decisions regarding the use of various methods (Crooks et al., 2021).
Diet and physical activity are health behaviors commonly understood to improve
overall health, and although dietary change is a predominant health behavior used by
patients to self-manage their experience with UC, research on the impact of diet and
physical activity on the disease course is limited and insufficient to support clear dietary
and physical activity recommendations. In fact, no tailored recommendations for
physical activity among the UC population currently exist. Research is needed to
determine the magnitude of effect physical activity has on decreasing the burden of
illness associated with UC. Additionally, recent reviews call for data on the intensity and
frequency of exercise that would generate the greatest benefit among individuals with UC
in order to determine exercise recommendations for this population (Eckert et al., 2019;
Engles et al., 2018; Nathan et al., 2013; Raman et al., 2021). This study provides a
unique examination of the associations between engagement of physical activity at
varying intensities and UC related health outcomes.
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This research is the first, to our knowledge, to examine how patients use treatment
and management methods to manage the burden of illness and the factors that guide
patient decision making in the use of such methods throughout the disease course. This is
also the first work, to our knowledge, that examines the relationships between disease
outcomes relevant to UC, dietary inflammatory potential, and physical activity. More
specifically, this is the first study to use the DII to examine dietary inflammatory
potential and UC-related physical and psychosocial health outcomes among a large
cohort of UC patients.
Outside of the development of the IBD-AID protocol and subsequent examination
of its interaction with the microbiome, the adoption of an anti-inflammatory dietary
lifestyle has not been otherwise examined as a complementary treatment approach and
self-management method for UC. An anti-inflammatory diet may play a significant role
in self-managing the localized and systemic inflammation associated with UC and
therefore may decrease disease activity and associated extraintestinal manifestations of
illness.
Results of this study may provide additional insights to physicians and patients
regarding diet and PA as complimentary self-management methods to mitigate disease
activity and manage the burden of UC, as well as insights on patient perspectives and
experiences that influence patient decision making and support improved patient-provider
communication. Collaborative care between patients and providers helps patients feel a
sense of control over their illness verses their illness controlling them, which, in turn,
improves self-management overall (Plevinsky et al., 2016). This research can aid in
framing patient education and contribute to the development of evidence-based
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behavioral interventions that assist patients in adopting and sustaining self-management
behaviors to reduce and prevent disease activity. This research can also inform
evidence-based dietary and physical activity recommendations for the UC population.
This work may assist providers in understanding complementary treatment methods that
may be acceptable and desired by patients, which could also be incorporated into
standard care. Seeking out personal preference-based management options for treatment
of UC has been associated with a high QoL and successful self-management among the
UC population (Wickman et al., 2016).
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CHAPTER 3
RESEARCH DESIGN AND METHODS
Overall Dissertation Design
This dissertation follows a mixed-methods design that aimed to utilize both
qualitative and quantitative approaches to understand the effect of treatment and
management methods on the daily burden of UC. To achieve the aims of this dissertation
two separate studies were conducted. Study 1 was a qualitative study that aimed to
examine the perspectives of individuals with UC regarding the use of various treatment
and management methods to reduce the burden of illness and the factors that guide
decision making in the use of such methods. Study 2 was a secondary data analysis that
aimed to analyze associations between diet and physical activity as self-management
methods and disease outcomes relevant to the burden of illness among a large population.
Study 1
1.1 Research Design- Study 1
As patients cope with the burdens of living with UC, various treatment and
management methods are often used to manage the impact of UC on daily life. Study 1
sought to understand how and why treatment and management methods are used to
influence the burden of living with UC. Study 1 utilized a qualitative design to obtain
rich, in-depth data reflecting the experiences and perspectives of participants. Data was
obtained through individual semi-structured interviews (Creswell, 2007; Patton, 2015)
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with patients diagnosed with UC. Each interview was scheduled and conducted by the
researcher. Interviews were audio-recorded, transcribed verbatim, and uploaded into
Nvivo software. Interviews were coded and organized into meaningful themes and subthemes relevant to the study aims.
1.2 Setting- Study 1
Patient recruitment and data collection for Study 1 initially occurred in
collaboration with the Greenville Health System/Prisma Health (GHS) Gastroenterology
department in Greenville, South Carolina. Patients receiving care for UC at GHS were
identified by a GHS gastroenterologist, Anjani Jammula, MD and invited to participate in
this study. Patient recruitment was expanded through the South Carolina Center for
Integrative Medicine (SCCIM), the Carolina’s Crohn’s and Colitis Foundation support
group, and through posting study fliers in two Facebook support groups. In-depth, semistructured interviews were conducted in person at the participant’s home, a private room
on site at GHS, a private room at the local library, over a secure web-based platform
(Skype), or over the phone according to participant preference. Data collection occurred
outside of the clinical flow on site at GHS such that it did not disrupt clinical activities.
1.3 Sample- Study 1
This study included individuals with UC receiving care from either
gastroenterologists at GHS or providers at SCCIM, along with individuals who engage
with the Carolina’s Crohn’s and Colitis Foundation support group, or Facebook support
groups. Participants met the following criteria to be eligible to participate in this study:
1) diagnosed with UC, 2) duration of illness ≥5 years, 3) experienced a minimum of one
disease flare during the illness trajectory, and 4) speak English. Participants who were
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referred to the study through GHS were screened for eligibility criteria through clinical
records. All other participants met the eligibility criteria based on self-report.
Purposeful sampling was used to ensure variation in the final sample across race,
ethnicity, gender, and current medication use (i.e., to represent mild, moderate, and
severe cases of UC) in order to obtain variation in participant experiences (Creswell,
2007; Morse, 1998, 1999; Patton, 2015).
1.4 Recruitment- Study 1
Patient recruitment for Study 1 began in collaboration with the GHS
Gastroenterology department in Greenville, South Carolina. Patients receiving care for
UC at GHS were identified by a GHS gastroenterologist, Anjani Jammula, MD and
invited to participate in this study. Two methods of recruitment occurred simultaneously:
1.) An invitation letter (see Appendix A) was mailed from GHS to each eligible
patient to inform the patient of the study and invite them to participate. GHS
identified 105 patients with UC in their records. Invitation letters were mailed to 44
patients, as the remaining 61 subjects did not meet the eligibility requirement of
duration of UC >5 years, or subjects had been lost to follow up at GHS. Patients
interested in participating were instructed to contact the researcher directly by phone
or email. GHS staff mailed a 2nd copy of the invitation letter to 42 existing or newly
identified eligible subjects two months later.
2.) Recruitment flyers (see Appendix B) were posted in the GHS patient waiting
room, in patient care rooms, and near check-in and check-out areas. Additional
copies of the flyer were available with office receptionists for distribution to
interested patients. The flyer directed interested patients to contact the researcher by
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phone or email. The GHS physician encouraged eligible patients to participate in the
study and provided additional copies of the flyers and invitation letters to eligible
patients during patient care.
Seven subjects responded to the mailed invitation letter after the first distribution.
Four additional subjects responded to the invitation letter after the second distribution, for
a total of 11 respondents (10 of which completed an interview). Patient recruitment was
expanded to collaborated with the South Carolina Center for Integrative Medicine
(SCCIM) and the Carolina’s Crohn’s and Colitis Foundation support group. The
researcher contacted each organization through email to describe the research study and
invite each organization to refer eligible subjects. The recruitment flyer was attached to
each email. The SCCIM referred one eligible subject. Carolina’s Crohn’s and Colitis
Foundation referred two eligible subjects. These three subjects each complete an
interview. At the same time, the researcher joined two UC support groups on Facebook
(Ulcerative Colitis, and Ulcerative Colitis Support Group) and posted the recruitment
flyer and a request for participation on each Facebook newsfeed. Of those who
responded, eight eligible subjects from the Ulcerative Colitis group, and one eligible
subject from the Ulcerative Colitis Support Group completed an interview.
Upon phone or email/messaging contact from an interested patient, the researcher
followed a scripted protocol (see Appendix C) to inform patients about the study, screen
for eligibility (see Appendix D), obtain verbal consent, and schedule an interview
appointment. Additional snowball sampling was attempted to recruit participants, as the
researcher encouraged patients to share the study information with any acquaintances
who may be eligible and interested. A $25 cash gift card was offered to each participant
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as a gesture of gratitude for their time. Participant gift cards were funded by an Olga I.
Ogoussan Doctoral Research Award from the University of South Carolina. Recruitment
continued until saturation in the data was achieved (Morse, 1998, 2000).
1.5 Data Collection Procedures- Study 1
Data was obtained through in-depth individual semi-structured interviews
(Creswell, 2007; Patton, 2015). Each interview was scheduled and conducted by the
researcher. Interviews were conducted in person (n=10), over a secure web-based
platform (n=4) (Skype), or over the phone (n=7) according to participant preference
(Creswell, 2007). Interviews lasted approximately 60 minutes and followed a semistructured interview guide (see Appendix E).
Interviews addressed the participant’s retrospective course of illness, the impact
of UC on daily life, experiences with medical and complementary treatment methods
used to control disease symptoms, methods for self-managing the impact of UC on daily
living, and the processes of making decisions regarding treatment and management of
UC over the course of illness. A brief survey to obtain demographic information (eg.
age, gender, race, ethnicity, education, duration of illness) was also administered at the
end of each interview (see Appendix E). Participants shared their experiences using
treatment and self-management methods and described factors that contributed to their
decisions to use such methods.
To facilitate a collaborative environment with the participant, the researcher
consistently framed the interview experience as an opportunity to learn from the
participant about the participant’s experiences. To establish a comfortable rapport with
the participant, the researcher introduced herself as a student from the University of
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South Carolina. She also expressed that she has a longstanding history with UC herself,
and, knowing that she is not the only one who has struggled to manage the burden of
illness, wants to hear the participant’s story. (See introduction of interview guide,
Appendix E)
Upon data collection, the researcher was mindfully aware that the experiences of
others would be different from her own and aimed to uphold an objective stance in the
interview. The researcher maintained an understanding that some UC patients do not
have a desire to make lifestyle improvements or seek complementary treatments to
decrease the burden of illness, and that many patients would express experiences or
opinions contrary to the researcher’s personal beliefs and experiences. The researcher
attempted to the best of her ability to suspend her own biases and experiences in order to
allow the participant to lead the conversation and feel comfortable and confident in
voicing their own experiences and opinions.
Interviews were audio-recorded and transcribed verbatim by a professional
transcription service (Rev.com) and then reviewed for accuracy by the primary
researcher. Transcription costs were funded by a SPARC grant awarded to the researcher
by the University of South Carolina. All identifying information was removed from
transcriptions. Interview transcripts were uploaded into Nvivo 12 qualitative analysis
software (QSR International, 2020).
Transcription and data analysis co-occurred with data collection. Memos were
written throughout the data collection and analysis process to document insights and
observations related to the research aims (Creswell, 2007; Miles & Huberman, 1994).
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1.6 Data Analysis- Study 1
Data was analyzed using QRS International NVivo 12 software (QSR
International, 2020) by researchers with training and experience conducting qualitative
studies. Thematic analysis was conducted using a constant comparative approach. The
primary coder (KD) led the analysis with input from a secondary coder (CB) throughout
the process. KD coded passages of text relevant to the study’s aim to reflect the content
and meaning of each passage. Content and meaning of passages were discussed and
clarified in biweekly meetings with KD and CB to verify the analysis to ensure accurate
representation of the data (Creswell, 2007; Miles & Huberman, 1994).
Multiple steps were taken to strengthen the integrity of the findings: 1.)
Transcriptions were first read in whole to capture the overall context of passages (KD);
2.) An initial codebook was developed from analysis of the first five interviews using an
emergent inductive approach and guided the coding of subsequent transcripts, allowing
for additional codes to be added as they emerged in the data (Creswell, 2007; Miles &
Huberman, 2013; Patton, 2015); 3.) The rest of the interviews were coded, identifying
themes addressing the burden of illness, treatment and management methods, attributions
of UC and disease activity, decision making process, motivating factors, sources of
information, the impact of methods on daily life experiences and disease activity, and the
disease course; 4.) Codes were iteratively organized into meaningful themes and subthemes across all interviews to capture key elements of the participants’ experiences
(Miles & Huberman, 1994, 2013); 5.) Themes on treatment and self-management
methods used by participants were assessed and categorized as medical, lifestyle, or
complementary/alternative methods; 6.) Memos were written to capture additional
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insights and observations throughout data analysis; 7.) Disease trajectories were
delineated for approximately 1/3 of the participants in attempt to explore potential
patterns of disease flares among life events and treatment and management methods; 8.)
Queries were created to explore patterns of dietary behaviors among participants; 9.)
Contextual relationships were considered between treatment and management methods,
decision making approaches, sources of information, and motivating factors.
Study 2
2.1 Research Design- Study 2
This work is motivated by the underlying hypothesis that an anti-inflammatory
diet and physical activity can improve immune system functioning and overall health.
Choosing to consume foods with anti-inflammatory properties, while decreasing
consumption of pro-inflammatory foods may affect symptoms of UC. Dietary
inflammatory intake may have a direct impact on the localized and systemic
inflammation associated with UC. Such an impact could have direct and indirect effects
on disease activity, components of the burden of illness (e.g. fatigue, emotional distress)
and overall quality of life. PA may also be of particular benefit to individuals with UC,
given established associations with improved immune functioning, decreased fatigue, and
improvements in mental health, social functioning, and QoL. This research hypothesized
that an anti-inflammatory diet is associated with improved health outcomes associated
with UC. In addition, we hypothesized that PA is also associated with improved health
outcomes.
To test the associations between dietary inflammatory intake, physical activity,
and UC related health outcomes, data from the IBD Partners e-cohort was analyzed using
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a cross-sectional design. Outcomes of interest included disease activity, IBD-related
QoL, and Patient Reported Outcome (PRO) domains of fatigue, anxiety, depression,
satisfaction with social role, and sleep disturbance. Disease activity was measured using
the Simple Clinical Colitis Activity Index (SCCAI). IBD-related quality of life was
measured using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). Fatigue,
anxiety, depression, satisfaction with social role, and sleep disturbance were measured
using the Patient Reported Outcome Measurement Information System (PROMIS).
Associations were tested using multivariate regression models. Predictor
variables included dietary inflammatory intake and physical activity. Given the
established association between body mass index (BMI) and disease activity, BMI was
calculated using data on weight and height and included in the statistical model.
Additional confounders included age, sex, race, level of education, smoking status,
disease duration, and medication class. Dietary data were collected using a National
Cancer Food Frequency Questionnaire and converted into a Dietary Inflammatory Index
Score (DII®). Physical activity data were collected using the Godin-Shephard Leisure
Time Activity Index.
2.2 Data Set- Study 2
IBD Partners, previously named the Crohn’s and Colitis Foundation of America
(CCFA) Partners, is a longitudinal Internet-based cohort of patients with IBD. This
cohort was developed in response to needed patient reported data that is lacking in
administrative and clinical data from the IBD patient population, such as dietary patterns,
exercise, quality of life, and other important patient-reported outcomes (PROs) (Long et
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al., 2012). IBD Partners serves as a facilitator for research studies using a large, diverse
population and as a platform for additional disease related studies (Long et al., 2012).
The initial CCFA Partners cohort included 7,819 individuals with self-reported
IBD who joined through August 2011. A total of 96.4% of cohort members were from
within the US, and 72.3% were female. Distribution of disease was as follows: Crohn’s
Disease n=4933 (63.1%), Ulcerative Colitis n=2675 (34.2%), Indeterminate colitis/IBD
unspecified n=211 (2.7%). Patients were recruited through the Crohn’s and Colitis
Foundation of America email roster, social media, CCFA website promotion, word of
mouth, and promotion at CCFA events. Eligible participants were required to be over the
age of 18 years with self-reported IBD (Crohn’s Disease, Ulcerative Colitis, or
indeterminate colitis) and access to the internet.
All initial participants received Module 1, providing information on
demographics, disease phenotype, disease activity, and medication use, among others.
Participants were randomized to complete their 2nd module, either Module 2 or Module
3. Participants were then given an option to complete a 3rd module, which was the
Module 2 or Module 3 they had not yet completed (Long et al., 2012). Module 2
assessed diet and exercise. Module 3 consisted of patient-reported outcomes (PROs),
which are health data provided by the patient regarding their feelings as they deal with
chronic conditions (Long et al., 2012). Additionally, Module 3 included the Short IBD
Questionnaire (SIBDQ) to collect data on IBD-specific QoL.
2.3 Population of Interest- Study 2
This research included patients over 18 years of age who self-reported UC and
completed modules 1, 2, and 3 (as described above in 2.2 Data Set-Study 2). Patients

42

who had undergone UC-related intestinal surgery were excluded. Studies have shown
that patients who receive surgical treatment to remove portions of their diseased colon
have significantly reduced disease severity and activity, and experience challenges
separate from the scope of this research.
2.4 Variables and Measures- Study 2
The following variables were abstracted from validated measures administered within
the IBD Partners surveys.
2.4.1 Outcome Variables
Disease Activity
Disease activity was measured using the Simple Clinical Colitis Activity Index
(SCCAI) (Long et al., 2012; Walmsley et al., 1998). This measure assesses five clinical
criteria and general wellbeing to generate a summed activity index score. Strong
psychometric validity and performance validity was found for the SCCAI in a repeated
measures longitudinal study of patients with UC (Higgins et al., 2007). The SCCAI has
been validated for use as a self-report measure (Jowett et al., 2003).
Patients are asked to rate 1) bowel frequency during the day 2) bowel frequency at
night 3) urgency of defecation 4) blood in stool, 5) general well-being and 6) extracolonic
manifestations (see Appendix F). Items 1-5 are scored individually using Likert-scale
type response options, then summed into a disease activity score. An additional 1 point
per extracolonic manifestation is added to the total SCCAI score. Scores range from 015+ points. Remission in UC is associated with a SCCAI score <2; clinical relapse is
defined by a SCCAI score ≥5 (Jowett et al., 2003; Turner et al., 2009).
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Disease-related Quality of Life
The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a 10-item
questionnaire used to assesses disease related quality of life among individuals with IBD
(Irvine et al., 1996). The SIBDQ assesses four domains, including bowel symptoms,
emotional health, systemic systems, and social function, to generate a summed quality of
life score relative to the two weeks prior to self-report. The SIBDQ correlates to disease
activity in patients with UC and demonstrates good test-retest reliability (Irvine et al.,
1996). The 10-item questionnaire is highly correlated with the full 32-item Inflammatory
Bowel Disease Questionnaire (IBDQ) (Irvine et al., 1996).
Individuals are asked to answer questions relative to how they have felt in the last
two weeks. Questions address 1) feelings of fatigue or being worn out, 2) canceling a
social engagement because of bowel disease, 3) difficulty doing desired leisure or sports
activities, 4) pain in the abdomen, 5) feeling depressed or discouraged, 6) passing gas, 7)
maintaining or gaining weight, 8) feeling relaxed and free of tension, 9) a feeling of
having to go to the bathroom even though bowels were empty, and 10) feelings of anger
as a result of illness. (see Appendix G)
Seven response options were provided as follows: All of the time, most of the
time, a good bit of time, some of the time, a little of the time, hardly any of the time, none
of the time. Each item is scored by a 7-point scale, from 1 being a severe problem to 7
indicating no problem at all. An absolute score ranges from 10 to 70, with 70 indicating
optimum HRQOL. Scores can be averaged by dividing each absolute score by the
number of items (10) so that all scores range from 1 to 7, with 1 indicating poor HRQOL
and 7 indicating optimum HRQOL.
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Patient Reported Outcomes
The National Institutes of Health Patient Reported Outcome Measurement
Information System (PROMIS) is a system of precise measures of patient-reported
physical, mental and social wellbeing with high reliability (Cella et al., 2007, 2010).
Various domains of well-being can be measured using validated item banks, or groupings
of questionnaire items that reflect the construct of interest. PROMIS items have been
validated among the general population, with recently recognized construct validity in the
IBD population (Cella et al., 2010; Kappelman et al., 2014).
IBD Partners selected short form PROMIS item banks to measure individual
constructs of health-related quality of life particularly relevant to IBD. Selected domains
included anxiety, depression, fatigue, sleep disturbance, and satisfaction with social role.
Each item bank consisted of 4 items. One item was also included to assess self-perceived
general health. All PROMIS items included in the IBD Partners data set are included in
Appendix H.
The majority of PROMIS items use a five-option response scale ranging in value
from one to five (eg. 1=Not at all, 2=A little bit, 3=Somewhat, 4=Quite a bit, 5=Very
much) (Cella et al., 2010). Raw scores are summed when all questions have been
answered. If a participant does not complete each item, a HealthMeasures Scoring
Service provided through PROMIS is available to generate a reliable final score. The
total raw score will range from 4 to 20 for each domain. Item scores are calibrated using
a T-score metric which scales the raw score to a standardized score with a mean of 50
and a standard deviation of 10. A score of 50 is the average for the US general
population for most PROMIS instruments. Score conversion tables to translate the total
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raw score into a T-score for each participant are available through
www.healthmeasures.net. Higher scores represent more of the measured domain. High
scores for fatigue, anxiety, depression, and sleep disturbance represent poor health while
high scores for social function and perceived general health represent good health
(Kappelman et al., 2014).
2.4.2 Predictor Variables
Dietary Inflammatory Index (DII®) Score
IBD Partners administered a National Health and Nutrition Examination Survey
(NHANES) Dietary Screener Questionnaire (DSQ) to e-cohort participants to collect data
on average daily consumption in the prior month for various foods (Cohen et al., 2013;
National Cancer Institute, 2021c). The DSQ collects data on intake frequency for fruits
and vegetables, red meats and processed meats, cheese, milk, sweetened beverages,
desserts, popcorn, beans, and rice, among others (see 2.6.1 NHANES DSQ).
The DSQ data was used as a basis to compute both a DII score and an EnergyAdjusted DII Score (E-DIITM) for this study (Hébert et al., 2019; Shivappa et al., 2014a) .
The DII was developed based on an extensive literature search to quantify the effect of
diet on inflammation using an algorithm that takes into account up to 45 food parameters
identified in the search, including a combination of nutrients and food intake (Shivappa et
al., 2014a). Due to unique differences observed in the relationship between total energy
intake (a determinant of the DII) and nutrient intake, the energy-adjusted DII score (EDII) was also developed. DII scores can range from a theoretically minimum -8.87,
indicating a strongly anti-inflammatory intake, to a theoretically maximum +7.98,
indicating a strongly pro-inflammatory intake (Shivappa et al., 2014a). At least 41
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studies have demonstrated construct validity of the DII or E-DII against inflammatory
biomarkers in different populations under varying conditions (Gialluisi et al., 2021; Li et
al., 2021; Malcomson et al., 2021; Marx et al., 2021; Phillips et al., 2019; Saghafi-Asl et
al., 2021; Skoczek-Rubińska et al., 2021; Zamora-Ros et al., 2015). Both the DII and EDII scores were computed for each participant and analyzed against outcome variables
(See 2.6 Converting DSQ Dietary Data to DII & E-DII Scores-Study 2).
Physical Activity
Physical Activity Data were collected using the Godin-Shephard Leisure Time
Exercise Index (Godin, 2011; Godin & Shephard, 1985). This questionnaire was
developed to measure leisure time physical activity and classify activity levels among
healthy adults. The Leisure Time Activity Index has been validated to assess exercise
behavior in different populations (Gionet & Godin, 1989). Concurrent validity was
determined by assessing two main determinants of physical fitness, maximal aerobic
capacity (VO2max) and percentage of body fat, and their correlation with the scores from
the leisure time physical activity questionnaire (Godin, 2011; Godin & Shephard, 1985).
Significant correlation was found between the questionnaire and VO2max (r=0.24, p,
0.001), as well as percentage of body fat (r=0.13, p , 0.01) (Godin, 2011). Godin’s
Leisure Time Exercise Index was also tested against a physical activity electronic motion
sensor and confirmed to be a valid measure to assess physical activity(Miller et al.,
1994).
The four-item questionnaire asks participants to indicate the number of times
during a 7-day period that the participant engages in mild (minimal effort – e.g., easy
walking, fishing), moderate (not exhausting – e.g., fast walking, tennis), and strenuous
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(heart beats rapidly – e.g., running, basketball) physical activity for at least 15 minutes
(Amireault & Godin, 2015; Godin, 2011; Godin & Shephard, 1985). (See Appendix I)
Total Leisure-Time Activity scores are calculated by multiplying reported weekly
frequencies of mild, moderate, and strenuous activities by corresponding Metabolic
Equivalent of Task (MET) values, which indicate energy expenditure, of three, five and
nine respectively, then summing the products of each intensity level (Godin, 2011; Godin
& Shephard, 1985). In addition to Total Leisure Time Activity, frequency of engagement
in PA at each intensity was assessed in this study as continuous variables of PA intensitymild, moderate, and strenuous.
Covariates
Additional variables included age, sex, body mass index (BMI), race, education,
smoking status, disease duration, medication class, and presence of conditions limiting
participation in PA. Age was indicated by entering a numeric value. Sex was reported as
either male or female. BMI (kg/m2) was calculated from participant-reported height and
weight. Given that 84% of the participants indicated race as ‘White’, a dummy variable
for race was created for this analysis as either ‘white’ White’ or ‘not White’. Education
was indicated as ‘high school or less’ (combining survey response items of ‘12th grade’
and ‘less than 12th grade’), ‘some college’, ‘college’, and ‘graduate school’. Participants
indicated smoking status as ‘never’, ‘ever’, or ‘current’. Disease duration was selfreported by entering a numeric value of years since first IBD diagnosis.
Participants reported on currently used medications by indicating ‘yes’ or ‘no’ to
various listed medications and treatment methods. For this study, seven “medication
classes” were grouped as follows: Corticosteroids included ‘oral corticosteroids’,
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‘budesonide’, and ‘steroids, rectal’ questionnaire items; Aminosalicylates included
‘mesalamines oral’, ‘mesalamines rectal’, and ‘Azulfidine (sulfasalazine)’;
Immunomodulators included ‘Azathioprine/6MP’ and ‘Oral MTX’ (methotrexate);
Biologics included ‘infliximab’ and ‘adalimumab’; Antibiotics included ‘ciprofloxacin’,
‘metronidazole’, and ‘other antibiotics’, Complementary/Alternative included
‘probiotics’, ‘Other complementary or alternative therapy’, and ‘calcium’; Opioids
included ‘opioids’. (Crohn’s & Colitis Foundation, 2021). Participants also reported the
presence of other unrelated to IBD conditions that limit participation in physical activity,
such as injury, by indicating ‘yes’ or ‘no’.
2.5 Data Analysis- Study 2
Data were analyzed using Stata 16 (StataCorp, College Station, TX). Descriptive
statistics were generated for all variables of interest. Predictor variables were added
individually as models were tested, watching for increases in R2 to indicate the added
variables are contributing to the explanatory power of model. All models were assessed
for multicollinearity using a Variance Inflation Factor (VIF).
2.5.1 Hypothesis 1
To address hypothesis 1, associations between DII scores and health outcomes
were tested with multivariable regression models using ordinary least squares. Disease
activity, quality of life, and PROs were each predicted by a set of covariates and DII
score. For all outcomes, control variables included: age, sex, BMI, race, education,
smoking status, disease duration, medication class, and PA). Age, BMI, disease duration,
and PA (Total Leisure Time Activity score) were included as continuous variables. Sex,
race, education, smoking status, and medication class were included as categorical
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variables. Dummy variables were created for race, education, and medication class (see
categories used to create dummy variables in 2.4.2 Predictor Variables, Covariates).
Missing responses were taken into account and included as a dummy variable (indicated
by _9 in Stata variable names) for each categorical variable to ensure confidence in
results.
Statistical models to address hypothesis 1 are as follows:
Y(disease activity)= X1(DII)+X2(physical activity)+X3(BMI)+ adjust for additional
confounders+ε
Y(IBD-QOL)= X1(DII)+X2(physical activity)+X3(BMI)+adjust for additional
confounders+ε
Y(anxiety)= X1(DII)+X2(physical activity)+X3(BMI)+adjust for additional
confounders+ε
Y(depression)= X1(DII)+X2(physical activity)+X3(BMI)+adjust for additional
confounders+ε
Y(fatigue)= X1(DII)+X2(physical activity)+X3(BMI)+adjust for additional
confounders+ε
Y(satisfaction with social role)= X1(DII)+X2(physical activity)+X3(BMI)+adjust for
additional confounders+ε
An example of the Stata commands for analysis is as follows:
regress SCCAI_score DII LeisureActivityScore BMI age sex race_white race_9
ed_somecollege ed_college ed_gradschool ed_9 smokernever smokercurrent
corticosteroids corticosteroids_9 aminosalicylates aminosalicylates_9 immunomodulator
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immunomodulator_9 biologics biologics_9 antibiotics antibiotics_9 complimentary_alt
complimentary_alt_9 opioids opioid_9 disease_duration if anysurgeries ==0
To test for robustness with regards to explanatory power (R2), models were run
using the E-DII variable score in place of DII scores. The E-DII score was selected for
final analysis given the variable’s greater explanatory ability, as well as lower skewness
and other distributional characteristics in comparing among scores. DII and E-DII scores
were analyzed as continuous variables. E-DII scores were subsequently analyzed as
quartiles to test for linear trends across quartiles (Quartile 1=-4.13 to -1.46, Quartile 2= 1.46 to -0.35, Quartile 3= -0.35 to 0.96, Quartile 4= 0.96 to 4.47).
2.5.2 Hypothesis 2
To address hypothesis 2, associations between physical activity and health
outcomes were tested with multivariable regression models using ordinary least squares.
Physical activity was assessed as a Total Leisure Time Activity score, analyzed as a
continuous variable. Disease activity, quality of life, and PROs were each predicted by a
set of covariates and Total Leisure Time Activity scores. For all outcomes, control
variables (with the use of dummy variables described previously) included: age, sex,
BMI, race, education, smoking status, disease duration, medication class, E-DII score,
and presence of conditions limiting participation in PA. Age, BMI, disease duration, and
E-DII score were included as continuous variables. Sex, race, education, smoking status,
medication class, and presence of conditions limiting participation in PA were included
as categorical variables.
Statistical models to address hypothesis 2 are as follows:
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Y(disease activity)= X1(Leisure Time Physical Activity)+X2(E-DII)+X3(BMI)+ adjust
for additional confounders+ε
Y(IBD-QOL)= X1(Leisure Time Physical Activity)+X2(E-DII)+X3(BMI)+adjust for
additional confounders+ε
Y(anxiety)= X1(Leisure Time Physical Activity)+X2(E-DII)+X3(BMI)+adjust for
additional confounders+ε
Y(depression)= X1(Leisure Time Physical Activity)+X2(E-DII)+X3(BMI)+adjust for
additional confounders+ε
Y(fatigue)= X1(Leisure Time Physical Activity)+X2(E-DII)+X3(BMI)+adjust for
additional confounders+ε
Y(satisfaction with social role)= X1(Leisure Time Physical Activity)+X2(EDII)+X3(BMI)+adjust for additional confounders+ε
An example of the Stata commands for analysis is as follows:
regress SCCAI_score LeisureActivityScore EDII BMI age sex race_white race_9
ed_somecollege ed_college ed_gradschool ed_9 smokernever smokercurrent
corticosteroids corticosteroids_9 aminosalicylates aminosalicylates_9 immunomodulator
immunomodulator_9 biologics biologics_9 antibiotics antibiotics_9 complimentary_alt
complimentary_alt_9 opioids opioid_9 other_conditionyes other_condition9
disease_duration if anysurgeries ==0
To address hypothesis 2a, physical activity was analyzed as total frequencies of
engagement in PA at each level of intensity (mild, moderate, strenuous) to explore the
differences in associations between differing exercise intensities and UC related health
outcomes. Disease activity, quality of life, and PROs were each predicted by a set of
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covariates, frequency of moderate intensity, and frequency of strenuous intensity.
Frequency of mild intensity was excluded from the model as the reference comparator.
Each intensity was assessed as a continuous variable.
Statistical models are as follows:
Y(disease activity)= X1(moderate intensity)+X2(strenuous intensity)+X3(EDII)+X4(BMI)+ adjust for additional confounders+ε
Y(IBD-QOL)= X1(moderate intensity)+X2(strenuous intensity)+X3(E-DII)+X4(BMI)+
adjust for additional confounders+ε
Y(anxiety)= X1(moderate intensity)+X2(strenuous intensity)+X3(E-DII)+X4(BMI)+
adjust for additional confounders+ε
Y(depression)= X1(moderate intensity)+X2(strenuous intensity)+X3(E-DII)+X4(BMI)+
adjust for additional confounders+ε
Y(fatigue)= X1(moderate intensity)+X2(strenuous intensity)+X3(E-DII)+X4(BMI)+
adjust for additional confounders+ε
Y(satisfaction with social role)= X1(moderate intensity)+X2(strenuous intensity)+X3(EDII)+X4(BMI)+ adjust for additional confounders+ε
An example of the Stata commands is as follows:
regress SCCAI_score PAstrenuous PAmoderate PAmild_9 age sex BMI race_white
race_9 ed_somecollege ed_college ed_gradschool ed_9 smokernever smokercurrent
corticosteroids corticosteroids_9 aminosalicylates aminosalicylates_9 immunomodulator
immunomodulator_9 biologics biologics_9 antibiotics antibiotics_9 complimentary_alt
complimentary_alt_9 opioids opioid_9 other_conditionyes other_condition9
disease_duration EDII if anysurgeries ==0
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2.5.3 Hypothesis 3
This work’s third hypothesis explores the interaction effects between dietary
inflammatory intake and physical activity on health outcomes in UC. To address
hypothesis 3, data was analyzed with multivariate regression models using ordinary least
squares including interaction terms. For all health outcomes, interactions were first tested
between DII scores and Total Leisure Time Activity scores, and then tested again using
E-DII in place of DII. For all outcomes, control variables (with the use of dummy
variables described previously) included: age, sex, BMI, race, education, smoking status,
disease duration, medication class, E-DII score, and presence of conditions limiting
participation in PA.
Statistical models to address Hypothesis 3 are as follows:
Y(disease activity)= X1(E-DII)+X2(Total Leisure Time Activity)+
X1*X2(DII*PA)+X3(BMI)+adjust for additional confounders+ε
Y(IBD-QOL)= X1(E-DII)+X2(Total Leisure Time Activity)+ X1*X2(EDII*PA)+X3(BMI)+adjust for additional confounders+ε
Y(anxiety)= X1(E-DII)+X2(Total Leisure Time Activity)+ X1*X2(EDII*PA)+X3(BMI)+adjust for additional confounders+ε
Y(depression)= X1(E-DII)+X2(Total Leisure Time Activity)+ X1*X2(EDII*PA)+X3(BMI)+adjust for additional confounders+ε
Y(fatigue)= X1(E-DII)+X2(Total Leisure Time Activity)+ X1*X2(EDII*PA)+X3(BMI)+adjust for additional confounders+ε
Y(satisfaction with social role)= X1(E-DII)+X2(Total Leisure Time Activity)+ X1*X2(EDII*PA)+X3(BMI)+adjust for additional confounders+ε
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Y(perceived general health)= X1(E-DII)+X2(Total Leisure Time Activity)+ X1*X2(EDII*PA)+X3(BMI)+adjust for additional confounders+ε
Additionally, interactions were also tested between frequency of exercise at each
intensity and E-DII quartiles. Quartile 1 and mild intensity were excluded from the
model as reference comparators. The statistical model used is as follows:
Y= X1(E-DII Quartile2)+X2(moderate intensity)+ X1*X2(E-DII Quartile2*moderate
intensity)+X3(E-DII Quartile3)+X3*X2(E-DII Quartile3*moderate intensity)+X4(EDII Quartile4)+X4*X2(E-DII Quartile4*moderate intensity)+ X5(strenuous
intensity)+ X1*X5(E-DII Quartile2* strenuous intensity)+X3*X5(E-DII Quartile3*
strenuous intensity)+X4*X5(E-DII Quartile4* strenuous) (BMI)+adjust for
additional confounders+ε
2.6 Converting DSQ Dietary Data to DII & E-DII Scores-Study 2
Data collected from an NHANES DSQ was used as a basis to compute both a DII
score and an Energy-Adjusted DII Score (E-DIITM) used as independent variables in this
study (Hébert et al., 2019; Shivappa et al., 2014a).
2.6.1 NHANES DSQ
Dietary data was collected through a National Health and Nutrition Examination
Survey (NHANES) Dietary Screener Questionnaire administered to participants in the
IBD Partners’ e-cohort (National Cancer Institute, 2021c). DSQ data provided frequency
of consumption data for 25 various Food Items: 1. “hot or cold cereals”, 2. “milk”, 3.
“regular soda or pop”, 4. “100% pure fruit juice”, 5. “coffee or tea that had sugar or
honey added”, 6. “sweetened fruit drinks, sports or energy drinks”, 7. “fruit”, 8. “green
leafy or lettuce salad”, 9. “fried potatoes”, 10. “other kind of potatoes”, 11. “refried
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beans, baked beans, beans in soup, pork and beans or other cooked dried beans”, 12.
“brown rice”, 13. “other vegetables” 14. “salsa”, 15. “pizza”, 16. “tomato sauces”, 17.
“cheese”, 18. “red meat”, 19. “processed meat”, 20. “whole grain bread”, 21. “chocolate
or any other types of candy”, 22. “doughnuts” 23. “cookies, cake, pie, or brownies”, 24.
“ice cream or other frozen desserts”, 25. “popcorn”.
Participants responded to two DSQ questions for each Food Item: 1. During the
past month, did you eat (or drink) any [food item]? Response options were ‘yes’ or ‘no’.
2a. During the past month, how often did you eat (or drink) [food item]? Response
option was an open numerical entry (rate). 2b. Participants were also asked to indicate
their reported frequency as per day, per week, or per month, or ‘don’t know’. In addition,
participants were asked: What kind of cereal did you usually eat? Participants were able
to select one cereal from a list of 328 cereal names, including ‘other’ as a selection
option. Participants were then asked: During the past month, what second kind of cereal
did you usually eat? Participants were again able to select a cereal from the list of 328
cereal names, including ‘other’ as a selection option. Participants we also asked: During
the past month, what kind of milk did you usually drink? Response options included: 1.
whole or regular 2. 2% fat or reduced-fat 3. 1%, ½%, or low-fat 4. Fat free, skim, or
nonfat 5. Soy 6. Other.
2.6.2 Overview of Procedures
Using DSQ data, daily intake frequency for each food item was calculated in Excel.
As portion-sizes of food intake was not included in the IBD Partners data set, data on
average portion size or serving size was extracted from other sources (see 2.6.4
Identifying Average Portion Size or Serving Size). Daily intake frequency was multiplied
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by the respective average portion size to calculate total intake equivalents for each of the
25 food items. Representative foods were identified for each of the 25 food items (See
2.6.6 Collecting Nutrient Data). Nutrient data for up to 19 food parameters were
collected for each representative food and organized in Excel. Total nutrient profiles for
each parameter were calculated for each participant and used to calculate a composite DII
and E-DII score.
2.6.3 Calculating Daily Intake Frequency
Daily intake frequency for each food item was calculated in Excel. If a
participant answered ‘yes’ to the DSQ question “During the past month, did you eat/drink
any [food item]?”, daily frequency was calculated as the reported frequency rate divided
by unit of time. When the unit of time was ‘day’, daily frequency was kept as reported.
When the unit of time was ‘week’, daily frequency was calculated as reported frequency
divided by 7. When the unit of time was ‘month’, daily frequency was calculated as
reported frequency divided by 30 (National Cancer Institute, 2021a).
Missing frequency data:
In the instance participants indicated ‘yes’ to eating or drinking a food item, yet
no frequency rate was reported and ‘don’t know’ was selected as the unit, daily frequency
was calculated as zero. If a rate was reported, but ‘don’t know’ was selected as the unit
of time, daily frequency was calculated using a ‘monthly’ unit of time. This assumption
allowed for participant data to be included while calculating a frequency that most
closely reflects a participant intake that leaned towards an lower assumed daily frequency
in comparison to assuming a ‘weekly’ or ‘daily’ unit of time. This occurred 50 times
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among participants across all 25 food items, equaling an average of two participant
frequency adjustments per each food item.
Winsorized frequency data:
Data was sorted in excel to identify extreme values of reported consumption rates.
To reduce potential influence of extreme outlier frequency values, some data was
winsorized as follows:
Coffee: Total daily frequency was winsorized at a maximum of 7 times per day.
Only two participants reported a daily intake greater than 7. (Extreme values were 9 and
10 times per day.) A maximum of seven was selected, as a daily frequency of 7 was
repeated within the data set multiple times.
Milk: Total daily frequency was winsorized at a maximum of 7 times per day.
Only two participants reported a daily intake greater than seven. (Extreme values were 8
and 10 times a day.) A maximum of seven was selected, as a daily frequency of 7 was
repeated within the data set multiple times.
Cereal: Total daily frequency was winsorized at a maximum total of four. Ten
participants reported they ate cereal more than 4 times a day. (These ten participants
reported eating cereal 5, 6, 7, or 30 times a day.) A maximum of four was selected to
account for potentially eating cereal for three typical meals plus one snack.
Winsorizing coffee intake would decrease the inflammatory potential (improve
the DII score) of their measured intake, as caffeine is a pro-inflammatory parameter.
Winsorizing milk frequencies would potentially decrease the inflammatory potential
(improve the DII score) as CHO and saturated fat are pro-inflammatory. The effect of
winsorizing cereal on overall DII scores would be dependent on the type of cereal
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indicated by each participant. Sugary cereals would act as pro-inflammatory, but fiberrich fortified whole grain cereals may contribute to an anti-inflammatory effect.
2.6.4 Identifying Average Portion Size or Serving Size
Data on portion-sizes of food intake was not included in the reported DSQ data.
Data indicating average portion sizes, which was needed for calculating participants’ total
dietary intake, were collected as follows:
A NHANES DSQ scoring procedure uses mean sex-age specific portion size
equivalents of food groups defined in the Dietary Guidelines for Americans, 2015
(National Cancer Institute, 2019, 2021b; Thompson et al., 2017; U.S. Department of
Agriculture & U.S. Department of Health and Human Services, 2010). Mean sex-age
specific portion size equivalents for adults were obtained from the NHANES DSQ
scoring procedures for the following food items: Fruit, 100% pure fruit juices, Refried
beans, baked beans, beans in soup, cooked dried beans, whole grain bread, brown rice or
other cooked whole grains, milk, cheese, green leafy or lettuce salad, fried potatoes, other
kinds of potatoes, other vegetables, tomato sauces, salsa.
This study was unable to use the provided DSQ scoring sex-age specific portion
size equivalents for the following food items: 1. Pizza, 2. Cookies, cake, pie, brownies 3.
Doughnuts 4. Candy/chocolate 5. Fruit drinks/sports drinks 6. Soda 7. Frozen desserts 8.
Coffee or tea 9. Popcorn 10. Cereals. Inability to use the provided mean portion sizes are
due to the following: Mean portion size equivalents of pizza were presented to reflect
fruit and vegetable equivalents verses mean portion size of the whole food. Mean portion
size equivalents of popcorn and cereals were presented to reflect whole grain equivalents
verses mean portion size of the whole food. Mean portion size equivalents of cereals,
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cookies, doughnuts, chocolate/candy, sweetened fruit drinks/sports drinks, soda, ice
cream or other frozen desserts, and coffee or tea were each presented to reflect teaspoon
equivalents of added sugars verses the mean portion size of the whole food. (Multiple
efforts to locate data on the initial 24-h NHANES dietary recall portion size data of
whole foods used to calculate the portions sizes of added sugars or whole grains indicated
by the DSQ scoring procedures proved unsuccessful.) For these food items, mean
portion size estimates were obtained from the USDA as FDA Reference Amounts
Customarily Consumed (U.S. Food & Drug Administration, 2022). Reference amounts
of one serving size were presented as one value for all age groups and sex combined.
Suggested portion sizes for cereals were based on cereal density. Suggested serving size
for red meat and processed meat were obtained from American Heart Association. (See
Appendix J)
2.6.5 Determining Total Daily Intake of Each Food Item
Daily intake frequency was multiplied by the respective average portion size,
based on age and sex when applicable, to calculate total intake of each food item in cup,
ounce, or gram equivalents for each participant.
2.6.6 Collecting Nutrient Data
Dietary nutrient profiles, consisting of at least 19 of nutrient parameters, are
required to calculate a DII score. To obtain nutrient profiles to accompany the DSQ’s
frequency of dietary intake data, representative foods were selected for each of the 25
food items (See Appendix K). Data for the following 25 available nutrient parameters,
needed to calculate at DII/E-DII score for each participant, were collected for each
representative food item using the USDA Food Data Central database: Energy (kcal),
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Protein (g), Total Fat (g), Carbohydrate (g), Fiber (g), Iron (mg), Magnesium (mg), Zinc
(mg), Selenium (ug), Vitamin C (mg), Thiamin (mg), Riboflavin (mg), Niacin (mg),
Vitamin B6 (mg), Folic Acid+Folate (µg), Vitamin B12 (µg), Vitamin A (RAE) (µg),
Beta-Carotene (µg), Vitamin E (mg), Vitamin D (D2+D3) (µg), Saturated Fat (g),
Monounsaturated Fat (g), Polyunsaturated Fat (g), Cholesterol (mg), and Caffeine (mg).
Selecting Representative Foods
Representative foods were chosen to reflect the top consumed foods for each food
item category of the DSQ. Representative foods selected for fruit, 100% pure fruit juices,
beans, cheese, other vegetables were based on the 2019-2020 USDA data report for LossAdjusted per capita food availability, as “the data serve as proxies for actual consumption
at the national level” (USDA Economic Research Service, 2021). The USDA notes that
“Loss-adjusted food availability data (LAFA) are derived from food availability data by
adjusting for food spoilage, plate waste, and other losses to more closely approximate
actual consumption.” (USDA Economic Research Service, 2021). USDA data was
reported in lbs/year, oz/day, and g/day, and organized by year dating from 1970 to 2018.
For this study, data used to identify top consumed foods for each food item category was
gathered from 2011 reports, given that the IBD Partners data was also collected in 2011.
The seven highest reported ‘consumed’ fruits, based on their 2011 per capita
availability adjusted for loss data, were selected as representative foods for Fruit.
Multiple fruits were selected for a representative fruit intake in efforts to generate a wellrounded, proportioned nutrient profile to best represent potential fruit intake among
participants. The same approach was used to select representative vegetables for the
‘other vegetables’ food item. Potatoes, tomatoes, and lettuce were reported among the
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top consumed vegetables, yet intake of these vegetables is reflected in other DSQ food
items measured. The subsequent 5 highest reported consumed vegetables were selected
for as representative foods for Other Vegetables. Per-capita food availability data for the
two top fruit juices were reported at a noticeably higher consumption than all other
juices, therefore the top two reported fruit juices were selected to represent consumption
of 100% Pure Fruit Juices. In a similar fashion, the two top reported cheeses were
selected to represent consumption of Cheese. The three top reported beans were selected
in the same fashion as representative foods for the Refried Beans, Baked Beans, Beans in
Soups, Cooked Dried Beans food item category. (See Appendix K)
Zeng et al. (2019), examined trends in red meat and processed meat consumption
in the United States through 1999-2016, finding consistent consumption patterns of
processed meat among adults over the 18 year trajectory. Zeng, et al (2019) identified
the top five processed meats that accounted for 87% of total processed meat
consumption: as luncheon meat (39.3%), sausage (24.4%), hot dog (9.4%), ham (9.4%),
and bacon (4.6%). These five processed meats were used as representative foods for the
Processed Meat Food Item.
For the Fruit, 100% Pure Fruit Juices, Beans, Cheese, Other Vegetables, and
Processed Meat Food Items, multiple representative foods were selected to provide a
well-balanced representative intake for each given food item. In cases where multiple
representative foods were selected for one food item, intake of representative foods was
proportioned based on reported consumption rates (See “Proportioning Combinations of
Representative Foods for One Food Item” below).
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Using words from the DSQ food item descriptions (National Cancer Institute,
2021c), the researcher searched USDA Data Central to select the representative food or
foods that best matched the following remaining food item categories: Whole grain
Bread, Brown Rice or Other Cooked Whole Grains, Red Meat, Pizza, Sweetened Fruit
Drinks Sports Drinks or Energy Drinks, Soda, Coffee or Tea with Added Sugar,
Chocolate or Other Types of Candy, Donuts, etc., Cookies Cakes Pie or Brownies, Ice
Cream or other Frozen Desserts, Popcorn. (Selected representative foods for all 25 DSQ
Food Items are shown in Appendix K.)
Two food items did not require use of representative foods. Participants indicated
the type of milk they consumed by choosing from the following options: whole or
regular; 2% fat or reduced-fat; 1%, ½%, or low-fat; fat-free, skim, or nonfat; soy; and
other. If ‘other’ was selected, participants were able to specify their choice of alternative
dairy by manual entry. Alternative entries included almond milk, lactose free milk,
goat’s milk, rice milk, buttermilk, and cream/half & half. Cereal did not require
representative foods, as participants were asked to select from a list of 328 specified
cereals. 187 or the 328 specified cereals were indicated as consumed by participants (See
Appendix L). For milk and cereal, DSQ response options were used in this study to
obtain nutrient profiles for DII calculation.
Proportioning Combinations of Representative Foods for One Food Item
When multiple representative foods were used for one DSQ food item, nutrient
data for representative foods were proportioned relative to most consumed, according to
USDA data report for Loss-Adjusted per capita food availability (USDA Economic
Research Service, 2021). (See Appendix K) Data used to identify top consumed foods for
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each food item category was collected from 2011 reports, given that the IBD Partners
data was also collected in 2011. Proportions were determined by selecting the number of
representative foods (7 fruits), then totaling the per capita availability adjusted for loss in
g/day respective to each representative food. The per capita availability adjusted for loss
in g/day for each representative food was then divided by the totaled g/day to equate the
percentage of contribution each representative food would provide to the proportioned
nutrient profile.
When participants were asked to select the type of cereal they eat, they were
allowed to select up to two types of cereals. In cases where participants identified two
cereals, nutrient data for each cereal was proportioned at 50%.
Gathering Nutrient Data for Representative Foods
Nutrient data for each representative foods, as well as each of the 185 specified
cereals and reported milks were found using USDA Food Data Central. Cereals that
were unavailable on USDA Food Data Central were treated as a similar cereal that best
matched the participant’s initial reported selection (See Appendix L) and had typically
been discontinued from the market.
USDA Food Data Central provides nutrient data using information from five
distinct data types: Food and Nutrient Database for Dietary Studies 2017-2018 (FNDDS),
National Nutrient Database for Standard Reference Legacy Release (SR Legacy), USDA
Global Branded Food Products Database (Branded), Foundation Foods, and Experimental
Foods. This study gleaned nutrient data primarily from the FNDDS, as this database
typically provided a more comprehensive nutrient profile relative to the purposes of this
study. When FNDDS data was not available for a specific food, most often in the case
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for cereals, SR Legacy or Branded data was collected. All nutrient data was organized
and stored in Excel.
USDA Food Data Central databases provided nutrient data for a select number of
portion sizes or measured amounts (eg. grams, slices, cups, teaspoons). When possible,
the measurement amount was selected to match the cup, gram, or ounce equivalent
determined as the typical portion size for use in this study. (See 2.6.4 Identifying
Average Portion Size or Serving Size). When an equivalent measurement amount was
not available, nutrient data was recorded for the provided measurement amount and then
multiplied by the appropriate percentage of the provided measured amount to result in
nutrient values that reflected the portion sizes used for this study (See Appendix J and
Appendix L).
Nutrient values for up to 25 parameters were gleaned for each food. These 25
parameters included: Energy (kcal), Protein (g), Total Fat (g), Carbohydrate (g), Fiber
(g), Iron (mg), Magnesium (mg), Zinc (mg), Selenium (ug), Vitamin C (mg), Thiamin
(mg), Riboflavin (mg), Niacin (mg), Vitamin B6 (mg), Folic Acid+Folate (µg), Vitamin
B12 (µg), Vitamin A (RAE) (µg), Beta-Carotene (µg), Vitamin E (mg), Vitamin D
(D2+D3) (µg), Saturated Fat (g), Monounsaturated Fat (g), Polyunsaturated Fat (g),
Cholesterol (mg), and Caffeine (mg).
2.6.7 Calculating total nutrient profile for each participant
For every participant, a total nutrient profile was calculated. Values for each of
the 25 nutrient parameters were totaled across all foods in order to obtain a single daily
intake value per nutrient parameter for each participant. Nutrient profile calculations
were performed in Excel.
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Calculating Nutrient Parameter Values
For each of the 25 DSQ food items/categories, each participant’s total values for
each of the 25 nutrient parameters were calculated. If a participant indicated ‘yes’ to
eating a food item on the DSQ, the reported daily frequency of eating that item was
multiplied by the representative food’s nutrient parameter value, with available age and
sex specific portion sizes taken into account. For each participant, this was done for each
of the individual 25 nutrient parameters, across all of the 25 DSQ food items and
categories. Extensive if/then equations were written and applied in Excel to calculate all
values (based on age and sex when age/sex specific portion sizes were applicable to the
food item- see 2.6.4 Identifying Average Portion Size or Serving Size), described as
follows:
When one representative food was used for a food item:
If ‘yes’ to eating food item, and (sex), within (a specified age group), then age/sex
specific portion size (daily frequency*parameter value of representative food)
When multiple representative foods were to be proportioned:
If ‘yes’ to eating food item, and (sex), within (a specified age group), then age/sex
specific portion size * [daily frequency*((proportion % of representative food
1*parameter value of representative food 1)+(proportion % of representative food
2*parameter value of representative food 2)+(proportion % of representative food 3*
parameter value of representative food 3))]
An example of an excel command written to calculate each individual
participant’s single parameter intake from three proportioned representative foods in one
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food item category is as follows and includes commands that take into account sex, each
age group, and each age/sex specific portion size:
=IF(AND(D10=1,B10=1,C10>=18,C10<=25),(0.65*(G10*((0.47*$I$6)+(0.29*
$I$7)+(0.24*$I$8)))),IF(AND(D10=1,B10=2,C10>=18,C10<=25),(0.48*(G10*((0.47*
$I$6)+(0.29*$I$7)+(0.24*$I$8)))),IF(AND(D10=1,B10=1,C10>=26,C10<=35),(0.56*(
G10*((0.47*$I$6)+(0.29*$I$7)+(0.24*$I$8)))),IF(AND(D10=1,B10=2,C10>=26,C10<
=35),(0.495*(G10*((0.47*$I$6)+(0.29*$I$7)+(0.24*$I$8)))),IF(AND(D10=1,B10=1,C
10>=36,C10<=45),(0.72*(G10*((0.47*$I$6)+(0.29*$I$7)+(0.24*$I$8)))),IF(AND(D10
=1,B10=2,C10>=36,C10<=45),(0.43*(G10*((0.47*$I$6)+(0.29*$I$7)+(0.24*$I$8)))),I
F(AND(D10=1,B10=1,C10>=46,C10<=60),(0.63*(G10*((0.47*$I$6)+(0.29*$I$7)+(0.
24*$I$8)))),IF(AND(D10=1,B10=2,C10>=46,C10<=60),(0.47*(G10*((0.47*$I$6)+(0.
29*$I$7)+(0.24*$I$8)))),IF(AND(D10=1,B10=1,C10>=61,C10<=69),(0.655*(G10*((0
.47*$I$6)+(0.29*$I$7)+(0.24*$I$8)))),IF(AND(D10=1,B10=2,C10>=61,C10<=69),(0.
34*(G10*((0.47*$I$6)+(0.29*$I$7)+(0.24*$I$8)))),IF(AND(D10=1,B10=1,C10>=70),(
0.635*(G10*((0.47*$I$6)+(0.29*$I$7)+(0.24*$I$8)))),IF(AND(D10=1,B10=2,C10>=7
0),(0.37*(G10*((0.47*$I$6)+(0.29*$I$7)+(0.24*$I$8)))),0))))))))))))
Similar equations were written for each of the 25 DSQ food items and
individually adjusted for application to each of the 25 food parameters’ data.
Calculating Nutrient Parameter Totals
Total parameter values for each of the nutrient parameters across all
representative foods were calculated for each participant. Using an excel spreadsheet,
parameter values were summed for each participant, resulting in one total value for every
nutrient parameter, which reflected the combined representative nutrient intake for that
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particular parameter across all 25 DSQ food items and categories. Nutrient parameter
values were organized by DSQ food items/categories using multiple Excel spreadsheets
within one file. An example of one Excel equation used to calculate one parameter’s
total value across all foods for one participant is as follows:
=SUM('ProcessedMeat'!J9+'RedMeat'!J9+Cookies!J9+Cereals!O9+'TomatoSauces'!J9
+Milk!L9+Salsa!J9+'OtherVegetables'!J9+'OtherPotatoes'!J9+'FriedPotatoes'!J9+'Gre
enLeafy'!J9+'BrownRice'!J9+'W.G.Bread'!J9+Beans!J9+Fruit!J9+Cheese!J9+'100%Fr
uitJuice'!J9+'IceCream'!J9+Pizza!J9+'FruitSportsDrinks'!J9+CoffeeTea!J9+Soda!J9+
Chocolate_Candy!J9+'Donuts,etc'!J9+Popcorn!J9)
All nutrient parameter totals were calculated for each participant. Each
participant’s total nutrient profile consisted of total parameter values for each of the 25
nutrient parameters.
2.6.8 Generating a Dietary Inflammatory Index Score
For this study, total nutrient profiles for each participant were submitted to James
Hébert, PhD at the University of South Carolina, Department of Epidemiology, who
calculated DII and E-DII scores from the provided representative nutrient data. A
number of steps are taken to calculate a DII score. From a participant’s reported intake
amount of a parameter (e.g., 6 g of fiber/day), an indexed ‘standard mean’ intake for that
parameter is subtracted. The resulting value is divided by an indexed standard deviation.
The value is then converted to a percentile. The percentage is doubled, from which 1 is
then subtracted. This generates a centered percentile value, which is then multiplied by
an overall food-parameter specific inflammatory effect score (Shivappa et al., 2014a).
The resulting value is the food parameter-specific DII score (for one parameter). This
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calculation is performed for each parameter and reported intakes separately for
parameter-specific DII scores. DII scores for each parameter are then summed to
calculate the participant’s total overall DII score.
Summary
This chapter outlined the mixed methods research design using two separate
studies to address the specific aims guiding this dissertation. Chapter 4 presents the
results of Study 1 and Study 2 in two separate manuscripts.
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CHAPTER 4
RESULTS
4.1 Manuscript 1
“Preventing a flare would be to continue living as if you are in a flare even when you’re
not, and I’m not good at that.”- The Use of Treatment and Self-Management Methods
Among Patients with Ulcerative Colitis

Authors: DuBois, K., Blake, C.E., Rudisill, C., Harrison, S.E., Hebert, J.R.
To be submitted to Patient Education & Counseling
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Abstract
Objective: This study examines how treatment and management methods are used by
individuals with Ulcerative Colitis (UC) and how patients make decisions regarding the
use of these methods throughout the disease course.
Methods: Qualitative data were collected using individual semi-structured interviews
and analyzed using thematic analysis in Nvivo12.
Results: Decisions are shaped by a patient’s approach towards disease management,
personal experiences, sources of information and individual motivating factors. Patients
are willing to try new methods of management and overlook long-term implications in
order to reduce suffering and be able to ‘function’ in the present day. Suffering may
motivate long term behavior change, but the majority of participants tend to utilize most
treatment and management methods as responses to flares and UC suffering instead of as
preventative health behaviors.
Conclusion: This study offers added insight into how and why treatment and
management methods are used to reduce the physical and psychosocial burden of illness
associated with UC.
Practice Implications: Study findings can aid in framing patient education and
behavioral interventions that assist patients with UC in adopting and sustaining selfmanagement behaviors to reduce and prevent disease activity.
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Introduction
Ulcerative Colitis (UC) is an inflammatory bowel disease (IBD) defined by
inflammation and ulcerations of the mucosal lining of the colon and an unclear
pathogenesis. Current frameworks suggest the development and progression of UC is a
complex combination of environmental factors, abnormal immune response, gut
microbiota, and genetic predisposition (Porter et al., 2020). The direct and indirect costs
of IBD generate a substantial economic burden on patients and health care systems driven
by factors such as medical therapies, hospitalizations, surgeries, lost work time with costs
for UC totaling nearly $15 billion annually (Beard et al., 2020). UC is characterized by
unpredictable fluctuations between periods of disease activity and remission. Periods of
active disease, or flares, present exacerbations of disease symptoms and the greatest
burden on daily functioning, yet disease activity often fluctuates in symptom severity
over the disease course and much of the extraintestinal burden continues throughout
periods of remission as well.
Patients with UC experience a range of gastrointestinal and extraintestinal
symptoms that generate a significant burden on daily life. Prominent localized physical
symptoms include rectal bleeding, bowel urgency, bowel frequency, diarrhea, and
significant abdominal pain. Patients also report considerable physical and cognitive
fatigue, isolation, reduced productivity, ‘brain fog’, diminished self-concept, anxiety,
depression, strained relationships, as well as strained physical, emotional, and social
functioning (Devlen et al., 2014; Fedosiejew et al., 2016; Fourie et al., 2018; LópezSanromán et al., 2017; Matini & Ogden, 2016; Yarlas et al., 2018). The most common
approach for treatment and management of UC symptoms is physician- prescribed
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pharmaceutical therapies. The primary goal of medical treatments for UC is to reduce
symptoms and induce a state of remission by regulating the immune system with
medication (Crohn’s and Colitis Foundation, 2022; Falvo & Holland, 2018). For many
individuals with UC, pharmacotherapy is often reported as insufficient to maintain a
‘normal’ lifestyle. Moreover, the use of multiple concurrent medications is not
uncommon in attempts to control symptoms (Falvo & Holland, 2018; Fourie et al., 2018;
Matini & Ogden, 2016; McMullan et al., 2017).
Many of those diagnosed with UC seek out a combination of medical, lifestyle,
and/or alternative treatment and management methods in efforts to mitigate disease
symptoms, reduce dependence upon pharmaceuticals, and respond to the challenges of
living with chronic illness. While existing research has indicated the use of various
treatment and management methods among individuals with UC, current literature is
lacking sufficient description of how individuals use treatment and management methods
on a daily basis and over the disease course, as well as examination of the perspectives,
resources, and motivations supporting utilization of various methods (Crooks et al.,
2021).
Seeking out personal preference-based management options for treatment of UC
has been associated with a high quality of life and successful self-management (Wickman
et al., 2016). Greater understanding of patient perspectives and experiences influencing
treatment and management decisions may inform evidence-based programs to promote
self-management and contribute to improved patient care within the UC population. The
purpose of this study is to examine how treatment and management methods are used by
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individuals with UC and how patients make decisions regarding the use of these
treatment and management methods throughout the disease course.
Methods
Qualitative data were collected using individual semi-structured interviews (n=21)
to obtain in-depth data reflecting the perspectives and experiences of individuals with
UC. Eligibility criteria included: 1) diagnosis of UC; 2) duration of illness ≥5 years; 3) a
minimum of one disease flare during the illness trajectory; and 4) English speaking.
Patients were recruited in collaboration with a large gastroenterology clinic in
South Carolina (n=9), a support group for individuals experiencing Crohn’s and UC
(n=2), an integrative medicine clinic in South Carolina, (n=1), and through posting study
fliers in two UC-focused Facebook support groups (n=9). A purposive sampling strategy
was used in recruitment collaborations with these entities for at least 20 participants. At
the gastroenterology clinic, patients who met eligibility criteria were identified by clinic
staff and mailed an invitation to participate in the study. Staff members of the support
group and integrative medicine clinic identified qualifying individuals and shared study
recruitment fliers. This study was approved by the University of South Carolina’s
Institutional Review Board.
Interviews were conducted by KD in person (n=10), over a secure web-based
platform (n=4), or over the phone (n=7) according to participant preference. Interviews
lasted approximately one hour and addressed the participant’s retrospective illness
trajectory, the impact of UC on daily life, experiences with medical and complementary
or alternative treatment methods used to control disease activity, methods for selfmanaging the impact of UC on daily living, and processes of making decisions regarding
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treatment and management of UC of the course of illness. (See Appendix E for full
interview guide.) Participants shared their experiences using treatment and selfmanagement methods and described factors that contributed to their decisions to use such
methods.
Interviews were audio recorded, transcribed verbatim, and reviewed for accuracy.
Thematic analysis was conducted using QSR International NVivo 12 software (QSR
International, 2020). A primary coder (KD) led the analysis with input from a secondary
coder (CB) throughout the process. Transcriptions were first read in whole to capture the
overall context of passages (KD). An initial codebook was developed from analysis of
the first five interviews using an emergent inductive approach, and guided the coding of
subsequent transcripts, allowing for additional codes to be added as they emerged in the
data (Creswell, 2007; Miles & Huberman, 2013; Patton, 2015). KD coded passages of
text relevant to the study’s aim to reflect the content and meaning of each passage.
Content and meaning of passages was discussed and clarified in biweekly meetings with
KD and CB to verify the data analysis to ensure accurate representation of the data.
(Creswell, 2007; Miles & Huberman, 1994). Codes were organized into meaningful
themes and sub-themes across all interviews to capture key elements of the participants’
experiences (Miles & Huberman, 1994, 2013). Themes on treatment and selfmanagement methods used by participants were iteratively assessed and categorized as
medical, lifestyle, or complementary/alternative methods.
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Results
Study Participants
Of the 21 participants, 14 were female and 7 were male. The mean age was 46.9
years (range: 26-67 years). The mean number of years since diagnosis was 19.2 years
(range: 5-47 years). A total of 3 participants had previously undergone bowel surgery to
remove diseased portions of their colon. The vast majority of the sample (90%) were
white. Eleven participants resided in South Carolina, two in North Carolina, and one in
each of the following states: Wisconsin, Florida, New Jersey, Ohio, California,
Connecticut, Georgia, and New York.

Treatment and Self-Management Methods Used Over the Disease Trajectory
Medical
Participants identified medication, surgery, and self-advocacy as predominant
biomedical methods for treatment and management of UC. All participants reported
involvement with a gastroenterologist for disease management and were advised by their
physician to use medication as a primary treatment approach. Medications, primarily
including aminosalicylates, biologics, immunomodulators, and corticosteroids, were used
as the primary treatment approach to manage gastrointestinal symptoms of UC. Most
participants used medication as continual maintenance therapy, while a few relied on
medications only as a short-term response to observed increases in disease activity. The
majority of participants reported declined responsiveness to medications over the course
of their illness and reported needing new ‘stronger’ medications as their illness
progressed. Prescription medication was used among some participants to manage
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depression and anxiety post-diagnosis. A few also mentioned occasional use of
medications to manage pain and sleep quality.
Three participants had undergone bowel surgery to remove diseased portions of
their colon. Participants expressed that they had expected their UC trajectory to be
eliminated after surgery, yet they continued to need self-management of GI symptoms,
experience fatigue, and have other complications (e.g. J-pouch twists and blockages).
These patients experienced bowel frequency, abdominal pain, stress of ostomy
management, and psychosocial challenges that extended the burden of living with UC
beyond surgery treatment. One woman who experienced blockages, pain, and
extraintestinal manifestations of illness post-surgery explained:
“…it’s not a cure all…you had an auto immune [disease]…you’re never going to
be normal” (8)
Some participants identified self-advocacy within the medical environment as a
key method of self-management, emphasizing the value of being their own advocate and
effectively communicating needs to their physician to “get the best treatment that you
can” (17). One young woman described:
“…you really have to advocate for yourself…It’s like a job that, you have to pay
attention” (16)
Some patients learned over time to be proactive in their medical treatment. Staying
informed, advocating for treatment changes, and keeping ahead of their disease
management was important for self-management. One man shared:
“…when I would go to the doctor early on, it was just like okay, a last resort type
thing. I’m not getting any better, I need to schedule an appointment…over the
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years I’ve learned…I need to stay ahead of my appointments, stay up with my lab
work, get ahead of everything.” (17)
A handful of participants reported making significant efforts to research and study
the disease and various treatment options to educate themselves and become an active
participant in decision making over the course of their illness. A few participants also
reported taking personal action to seek out support groups or professional therapy to help
manage the emotional burden associated with UC.

Lifestyle Choices
Participants employed multiple lifestyle methods in efforts to mitigate the burden
of UC in daily life. Manipulating dietary intake, reducing stress, engaging in physical
activity, and obtaining sufficient rest each played a role in managing UC for the large
majority of participants.
Most participants believed at some point, at least, during their disease trajectory
that diet played a role in managing burden of UC. Among those participants, a spectrum
of approaches and attitudes towards diet were evident. Most participants described an
enduring effort to identify dietary triggers responsible for UC symptoms. A common
management strategy among many participants was to skip or delay meals to avoid GI
symptoms. One woman tried to avoid any potential public embarrassment by not eating
before venturing out of her home, saying:
“If I want to go somewhere, what I have to do is by five o’clock I cut myself off
from eatin’ if I want to do something the next day.” (6)
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Reducing stress was frequently acknowledged as an essential method to selfmanage and prevent flares. To cope with or reduce stress, many participants changed
employment or reduced their daily workloads, including dropping out of school and
seeking disability benefits. Additionally, participants limited their professional and social
commitments, avoided stressful situations, engaged in exercise, spent time outdoors,
found enjoyment in various hobbies, made conscious efforts to reframe thoughts and
mindsets, enjoyed the companionship of a pet, and relied on faith and prayer. One
participant enjoyed moments of heated relaxation to help her self-manage her UC:
“I have one of those blankets that you plug in…oh, that helps tremendously. I just
lock the door, put the seat back, and curl up…heat helps…it relaxes me, and I
think the fact that I’m relaxed relieves some of the UC.” (10)
Another woman described her efforts to alleviate stress, particularly when experiencing
flares:
“I would not make plans with people at all because I knew every ounce of energy
had to be given to doing my work, so I just wouldn’t plan things. It was horrible.
…Trying to get rid of things, not adding anything to your plate, saying no to
people more, or not taking more things on that you could, just trying to simplify
your life as much as possible.” (15)
Although GI symptoms often limited high levels of physical activity, many
participants used exercise as a method to reduce stress, reduce joint pain, increase energy,
improve sleep, and improve overall health. Spending time walking outside was reported
by one man to help improve his health, reduce stress, and mentally re-frame the burden of
UC on daily life. He explained:
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“I walk and jog at times. As far as the stress and just on it’s own, I think it helps.
I’ll go for a walk around the block, and I’ll look at the houses… just gets my mind
to a different place…putting it in perspective of- I’m in my house having these
digestive issues, I have colitis, but yet, outside of my world,…there’s a million
other things going on… that have nothing to do with what my perceived huge
troubles are.” (13)
Many participants reported sufficient sleep and rest as essential to prevent and
recover from flares. Rest was a predominant method for managing daily life with UC as
participants not only felt deeply fatigued during flares and periods of remission, but also
as a method to reduce stress and inflammation in efforts to mitigate disease activity. One
woman shared:
“I need to make sure I sleep. It sounds kind of lame, but I just lay around and try
to heal…if you don’t get rest, it gets worse.” (16)

Complementary/Alternative Treatments
Participants reported little use of complementary or alternative methods to
manage their UC symptoms. A few participants were taking or had tried taking
probiotics as an effort to improve overall general health. A few participants reported
taking Vitamin D supplements to offset deficiencies associated with UC. One woman
followed a regimen of natural remedies suggested by her chiropractor and naturopathic
primary care physician (ex. “high doses of fish oil and very specific probiotics…” (22))
but was unable to maintain such a regimen due primarily to cost. She also made her own
aloe enemas and homemade suppositories with coconut oil and essential oils.
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Participants mentioned short term experimentation with growing mint for tea, nicotine
patches, psyllium seed husks, and peppermint oil. Although no participants reported use
of non-prescription drug use, a few expressed curiosity towards trying such methods.
Massage therapy was occasionally used to reduce stress and manage pain, since, as one
woman explained, “I felt it was more natural than taking pain medicine.” (9)

Table 4.1. Treatment and Management Categories with Predominant Methods Used

Medical

Lifestyle

Complementary/
Alternative

• Medication
• Surgery
• Self-Advocacy
o Patient-provider communication
o Stay informed
o Keeping ahead of disease management
o Seek out professional therapy
• Dietary Change
o Identify trigger foods
o Skip or delay meals
• Stress Reduction
o Change employment/Reduce Workload
o Limit professional or social commitments
o Exercise
o Hobbies
o Reframe mindsets
o Faith/Prayer
• Physical Activity
• Sleep/Rest
• Probiotics
• Vitamins
• Naturopathic supplements
• Massage Therapy

Decision-making on Treatments and Self-management Methods
Sources of Information
Although all participants were under physician care to some degree, few
participants reported that conversations with their physician provided a sufficient amount
of information about treatment and management methods overall. Participants noted
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personal research and reading about treatment methods as playing a strong role in selfadvocacy. Many described doing research on the Internet, particularly for information
about medication and diet. One man explained that the information online is simply
more accessible than doctors, and added:
“The internet’s there 24/7. Your doctor isn’t.” (13)
While nearly all participants reported not personally knowing anyone else with
UC, most participants gleaned information through word of mouth, as participants
considered perspectives from their extended social circle or from individuals on social
media sharing experiences with various methods. Shared information would sometimes
inspire willingness to try new things, generate confusion after receiving mixed messages,
or ignite fear and aversion towards various treatment methods, specifically surgery and
certain medications. One woman described the value in learning from other UC patients
through online support groups by saying:
“I utilize the Facebook pages a lot because it’s other people that actually have
what I have…I know that even though doctors are there with all this information,
they’re not experiencing it themselves, So, people that actually have what I have, I
feel like they’re the best sources of information because they have personal
experience.” (18)
A few participants read various books providing dietary guidance (e.g., blood type
diets, gluten-free, night shade vegetables, eliminating toxins). Books were often
recommended by a friend who was diagnosed with cancer or another autoimmune
disease.
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Decision Making Approach
Participants described various approaches to making decisions surrounding the
use of treatment and management methods. Participants often relied on physician
recommendations for medical therapies. Some participants described taking ownership
of the illness experience by utilizing individual decision-making skills and an attitude of
self-advocacy. A great deal of trial and error also directed the use of treatment and
management methods, particularly prescription medications and dietary change.
A majority of participants resorted to following physician recommendations for
UC treatment, trusting that their provider was more knowledgeable on best practices. A
few of those participants described shared decision making based on physician’s analysis
of blood and stool test data, some trusted physician recommendations “because they
haven’t steered me wrong” (14), and many followed physician guidance blindly. For
example, one woman described her treatment regimen by saying:
“Right now, [medication] and the [medication] pills too. I don’t even know if
that does anything, really, but my doctor said to take it. So, I don’t know…but I’ll
just keep taking it...My doctor just said ‘if it’s working don’t stop it’…like, don’t
mess with it.” (16)
Despite potential side effects, long term repercussions, and even desire for more
‘natural’ treatment methods, most participants often resigned to “keep doing what I’m
doing for now” (8) and maintain treatment options that seemed to be keeping disease
activity at bay. One woman explained her willingness to receive treatment despite her
fears of the future by saying:
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“I’m scared that the infusions one day are going to cause another problem, which
is really scary, cause it’s like a really serious strong drug that I’m taking…but
I’m okay with it cause it helps me right now.” (5)
Another woman echoed:
“they say a lot of [specific medication] can cause liver cancer…I can’t worry
about that later on. I have to be able to function today” (3)
There was difference between taking ownership for the health condition (i.e.,
attributing the disease and disease course to personal health behaviors) versus taking
ownership of the illness experience (i.e., belief that individual choices and behaviors can
modify the lived experience). Few participants felt that they were responsible for the
course of illness, as UC is unpredictable, but some participants felt that they could control
how they would handle their experiences with UC. Some participants described taking
ownership of their illness experience and making their own decisions regarding how and
when to use treatment and management methods. Some of these participants felt free to
self-assess and make minor adjustments to their medication dosing. For example, one
man described how he adjusted doses of his daily maintenance medication based on
symptom activity, saying:
“I actually take one in the morning unless I have some sort of flaring going on, in
which case I'll take three.” (19)
Many of those who took ownership of their illness experience often worked through
making changes in their own daily health behaviors in attempts to mitigate disease
activity before reaching out for additional medical treatment. In response to a flare, many
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participants described trying to reduce stress, adjust dietary intake, and/or rest. One
woman shared:
“Despite the fact that I despise Prednisone with every fiber of my being, it does
work. I only take it when I've done everything else on my own. I go through the
process on my own first. I know when I need to ask for help.” (14)
Participants who took ownership of their illness experience used self-advocacy to
manage their illness experience, often searching for greater satisfaction with treatment
options and patient-provider communication. In regards to her experience with
physicians who did not provide appropriate care, one woman emphasized:
“You need to find somebody else [physician] that listens to you…but you have to
be informed and ask them the questions that…they’re not a mind reader. You’re
wasting your time in there if you go in there and just go, ‘I don’t know, I just
stopped feeling good.’” (3)
Most participants described extensive trial and error within treatment and selfmanagement methods. As many insurance companies require a progressive treatment
approach to the prescription of medications approved for UC, participants commonly
experienced a pre-determined trial and error approach to finding a medication that could
induce and maintain remission. Additionally, some participants preferred taking time to
try all other available treatment options before resorting to certain medications or UC
surgery. One woman felt overwhelmed by the impact the multi-step J-pouch surgery
would have on her life and explained:
“And I decided at that point I just needed to take some time off and just try every
possible approach that I could before I do surgery. (9)
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Trial and error predominantly guided participant’s perspectives on diet as a selfmanagement method. Some participants reported trying diet as a treatment method and
observed no perceived success, and consequently disregarded diet as a treatment and
management method. For example, one woman felt that the efforts she made to change
her diet were ineffective, and concluded the following:
“I tried fixing my diet of going gluten free…that didn’t do anything…I started
doing dairy free. That didn’t do anything. So for me, diet hasn’t made me any
better.” (18)
Others identified dietary changes that seemed to alter their entire experience with UC,
and therefore adopted new dietary behaviors long term. Many participants made
associations between specific foods and disease activity based on immediate observed
gastrointestinal symptoms. For example, one woman described how she identified
packaged lunch meat as a food that ‘triggered’ UC symptoms using trial and error
observations:
“As long as I buy deli meat, like, fresh sliced deli meat, it doesn’t bother me, but
if I buy packaged, like off the shelf, yeah, it kicks my tail…packaged meat and I’m
like ‘whew’, you know? Two or three times I’ll go to the bathroom after that.
And for the longest time I couldn’t figure out what it was….I had a sandwich,
why’d it bother me today? It’s a sandwich. But then I got putting two and two
together that it was deli meat and that was, so, I don’t know.” (4)
Another man described his observations over time as he sought to identify patterns
between diet intake and UC symptoms:
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“You learn food that sort of will trigger things. The pepperoni pizza…four hours
later I’ll be spending some time in the bathroom. You know, I mean, you avoid
certain things. I won’t eat very spicy foods, they will just go through me. And
there’s other times I can have chicken soup and I’ll be in the bathroom three or
four times after that. So, it’s hard, you know, inflammatory bowel disease is a
strange auto-immune type of disorder.” (21)

Motivating Factors for Treatment & Management Decisions
Overall, participants used treatment and management methods to reduce the
physical and psychosocial burden of living with a chronic illness. Participants aimed to
reduce gastrointestinal symptoms, overcome and recover from fatigue, cope with the fear
and anxieties of an unpredictable illness, avoid embarrassment, cope with physical and
emotional isolation, and avoid pain and suffering. Participants described various
individual goals such as wanting to keep up with demands of daily life, raise a family, be
productive, and have peace of mind.
Participants frequently reported that a strong motivator for change and method
use across all treatment and management methods was the suffering associated with UC
symptoms. Patients reported feeling ‘miserable.’ Suffering motivated a willingness to
embrace new treatment recommendations and action towards adopting behavior change.
Participants experienced flares and were subsequently willing to add additional or new
prescriptions to their treatment regimen. One particular young woman felt hesitant to
begin taking a biologic therapy, but explained how she weighed her decision:
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“So, I can either not function, or lose my colon or whatever, or I can just bite the
bullet and get this done.” (15)
Another participant avoided physician treatment until her suffering was too much to bear:
“I remember because I thought maybe it [flare] would just go away by itself. It
would kind of ease off and it would get worse, and finally…I said, you guys got to
do something. I’m going to die, this thing is killing me. And so they [physician’s
office] gave me a month’s worth of Prednisone.” (20)
Ineffective treatment, and the associated suffering, often motivated participants to try
new treatment modalities. One woman sought out homeopathic treatment when she felt
other options were not working, saying “I just went to him kind of out of desperation”
(22). Later, after a pregnancy and flare, she felt resigned to return to pharmaceutical
therapies, explaining:
“what we were doing, just wasn’t…I was going downhill so fast that I ended up
on, you know, Remicade” (22)
Suffering motivated a few participants to make significant lifestyle changes. For
example, one young man explained how his initial experience with UC motivated him to
increase his physical activity in order to live a healthy life:
“I used to like just sit around all day. Now I bike, I run, I walk everywhere.
…Probably like a month after I started getting symptoms,…like I was having
symptoms and I was trying to be active…I wanted to be healthier in general. Just,
I knew I had to change.” (11)
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Another man reported making long term changes to his dietary patterns in addition to
staying loyal to his maintenance medication to avoid living with active disease
symptoms, saying:
“I’d eat a big bowl of bread pudding with a pint of ice cream…I cut that out and
things improved. …We used to eat a lot of red meat…switched over to fish and
chicken. I pretty much quit eatin’ a lot of stuff too because I didn’t want to go to
the bathroom so much……I switched over to eating brown rice every day instead
of French fries, and…deep fried Okra…if I bake them, they won’t irritate my
tummy. …I don’t want to go back to the old days again” (2).
Participants reported adopting the majority of treatment and management methods
in reaction to flares with hopes to reduce UC symptoms and suffering. Outside of
maintenance medications and efforts to reduce stress, participants rarely described the use
of treatment and management methods as preventative measures against disease activity
and disease progression. Preventative self-management was often perceived as
challenging to maintain, given the common belief that:
“…preventing a flare would be to continue [living as if] you are in a flare even
when you’re not, and I’m not good at that.” (15)
Discussion
Over the illness trajectory, patients with UC experience fluctuating levels of
suffering associated with disease activity, with no clear or consistent patterns of treatment
and management methods across patient experiences evident to yield optimal UC
outcomes or justify disease flares. From the patient perspective, fluctuations in disease
activity are attributed to stress, diminished medication effectiveness, or dietary triggers.
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Decision making surrounding the use of various treatment and management methods is
shaped by a patient’s approach towards disease management, personal experiences,
sources of information and individual motivating factors.
In this study, the leading reported motivating factor for the use of treatment and
management methods was personal suffering. Living with UC is accompanied by
physical symptoms and psychosocial challenges that causes significant suffering and
disruption in patients’ lives. Especially during times of active disease, patients are
willing to try new methods of management and overlook long-term implications in order
to reduce suffering and be able to ‘function’ in the present day. For a few patients,
suffering has motivated long term health behavior change. Although suffering motivates
the use of treatment and management methods, this study found that the majority of
participants tend to use treatment and management methods in reaction to suffering and
disease activity.
Patients identify some medications and overall stress reduction as important
methods to avoid UC flares, yet treatment and management methods are predominantly
employed as efforts to recover from flares and reduce existing symptoms. Recent
research is recognizing UC as a progressive illness with a growing need for preventative
action against progressive damage and impairment (Cleveland et al., 2022). A need is
evident for patients to shift away from reactive treatment and management approaches
and adopt preventative behaviors. Work is needed to support and empower patients with
UC to take action around disease activity, and to increase understanding on how
behavioral management methods influence the disease course (Conley & Redeker, 2016;
Rozich et al., 2020). Research is needed to design and evaluate methods to shift
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treatment and management approaches away from reactive measures and promote
preventative self-management behaviors.
Participants in this study typically rely on physician recommendations for the use
of pharmaceutical therapies. At the same time, many patients reported that physicians
did not provide sufficient information regarding treatment and management methods. A
recent study interviewed 10 patients with UC about the drivers of decision-making
regarding pharmaceutical treatments versus colorectal surgery, finding that patientprovider communication was a key driver of decision making, decision satisfaction, and
adherence (Lai et al., 2019). Findings from this study suggest that many patients seek out
and collect the majority of advice and information regarding forms of treatment and
management methods from peers and the Internet. Additionally, the majority of
treatment and management methods are adopted through a trial-and-error approach.
Given that UC has no known cause or cure at this time, the use of medical therapies and
lifestyle methods are guided by trial and assessment of effectiveness.
Findings from this study highlighted a difference between taking ownership for
the health condition (i.e., attributing the disease and disease course to personal health
behaviors) versus taking ownership of the illness experience (i.e., belief that individual
choices and behaviors can modify the lived experience). Few participants feel that they
are responsible for the unpredictable course of illness, but some believe that they can
control, to varying degrees, how they manage their experiences with UC. A few patients
in this study take an active approach to managing their illness experience through
individual-based decision-making, health behavior change, and self-advocacy towards
greater satisfaction with treatment options and patient-provider communication.
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Overall, participants use an individualized mix of treatment and self-management
methods to overcome the challenges of living with UC in daily life. Daily life with UC
carries a significant physical, emotional, mental, professional, and social burden.
Participants report unpredictable disease trajectories and adaptive approaches to
treatment and disease management over time. Treatment and management effectiveness
varies among participants, as does sustainability of method use. Medication, self
advocacy, dietary change, stress management, physical activity, and sleep improved
participants’ individual experiences overall, yet are often utilized as responses to flares
and UC suffering instead of as preventative health behaviors. Patients express reliance
on physicians for pharmaceutical treatment, yet identified diet restrictions and stress
management as a main approach for self-management of UC.
Diet is characterized in this study as a lifestyle method of treatment and
management due to the context of participant responses describing dietary practices as a
behavioral change to their normal or previous lifestyle. Individuals with UC have
reported diet manipulation as a strategy for managing gastrointestinal symptoms for quite
some time (Hall et al., 2005), yet research examining diet as a behavioral treatment and
management method for mitigating disease activity is relatively new (Celiberto et al.,
2018; Torres et al., 2019; Wark et al., 2021). This study found that dietary change as a
management method often evolves over time through extensive trial and error, during
which participants evaluate diet’s impact on disease activity based primarily on
immediate GI symptoms. A study on dietary practices and beliefs among patients with
UC also found that over 90% of patients’ beliefs regarding diet and disease activity were
based on the patient’s personal experiences (Crooks et al., 2021).
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Participants report strong beliefs regarding the negative impact of stress on
disease activity. Reducing stress is widely reported as a key management method for
preventing and recovering from flares. Prolonged stress can elicit numerous
physiological reactions that contribute to immune dysfunction and increased
inflammation (Glaser & Kiecolt-Glaser, 2005). Prolonged stress also contributes to
imbalances in the microbiome and natural gut flora, shown to be associated with IBD
(Aleksandrova et al., 2017; Lane et al., 2017). Living with UC is arguably, on its own, a
chronic stressor. Patients experience fatigue and reduced productivity, strained
relationships, marital disruption, reduced sexual activity, various misconceptions due to
the social stigma that accompanies an ‘invisible’ illness (Larsson et al., 2017; Rapport et
al., 2019; Taft et al., 2009). The burden of illness associated with UC contributes to the
ongoing nature of the illness by adding prolonged stress and, therefore, systemic
inflammation and a reduced immune system (Fedosiejew et al., 2016; Larsson et al.,
2017).
The use of complementary and alternative methods is low among participants in
this study. This may be due to the recruitment of a portion of the participant sample
through a gastroenterology clinic. Some participants expressed openness to
complementary and alternative methods, including supplements, chiropractic care,
acupuncture, and massage therapy as potential treatments, but high costs and limited
familiarity are strong barriers to use overall. Although various types of complementary
and alternative methods exist, research examining their effect on UC is limited (Torres et
al., 2019).
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This study depended on volunteer participants who were willing to share their
experiences with UC, which may skew the variability of the sample, yet the participant
sample provided perspectives and experiences from patients under the care of many
different health facilities. Although this study included recruitment through social media
and integrative health care clinics, all participants reported treatment under physician
care, which may have limited a broader collection of data on the use of alternative
therapies. Findings from this study are limited to patient perspectives and do not assess
the biopsychosocial effectiveness on reducing the burden of UC. At the same time, this
qualitative study provides deeper understanding of the perspectives and lived experiences
of patients with UC.
Recent research calls for an expanded view of self-management in IBD research;
to expand beyond symptom management and explore methods for improving emotional,
social, and psychological well-being among individuals with IBD (Peters & Brown,
2022). Most self-management interventions for people with UC target decision-making
skills and partnering with healthcare providers, but lack focus on symptom management,
employment, or other aspects of daily life affected by UC (Conley & Redeker, 2016).
This study offers added insight into the use of treatment and management methods to
manage the physical and psychosocial burden of illness on daily life.
Findings from this study can inform providers on factors that influence patient
decision making and support improved patient-provider communication. Collaborative
care between patients and providers helps patients feel a sense of control over their illness
verses their illness controlling them, which, in turn, improves self-management overall
(Plevinsky et al., 2016). Additionally, these findings can aid in framing patient education
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and behavioral interventions that assist patients in adopting and sustaining selfmanagement behaviors to reduce and prevent disease activity.
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Abstract
Background: Individuals with Ulcerative Colitis (UC) seek complementary lifestyle
methods, such as diet and physical activity (PA), to manage the challenges of living with
chronic illness. The Energy Adjusted Dietary Inflammatory Index (E-DIITM) measures
the inflammatory potential of food intake and has never been studied among the UC
population. This study tested the associations between E-DII scores, PA, and health
outcomes.
Methods: Data obtained from IBD Partners e-cohort participants with UC (n=2,052) were
analyzed using a cross-sectional, secondary data analysis. Dietary data were converted
into an E-DII score. PA data were collected using the Godin-Shephard Leisure Time
Activity Index. Outcome variables included the Simple Clinical Colitis Activity Index,
Short Inflammatory Bowel Disease Questionnaire, and psychosocial PROMIS domains.
Multivariable regression models controlled for age, sex, body mass index (BMI), race,
education, diet, PA, smoking status, medication class, and disease duration.
Findings: Pro-inflammatory dietary intake, indicated by E-DII score, was associated with
increased disease activity (β=0.166; p<0.001), anxiety (β=0.342; p=0.006), depression
(β=0.408; p=0.004), fatigue (β=0.386; p=0.005), sleep disturbance (β=0.339; p=0.003),
and decreased social satisfaction (β= -0.370; p=0.004) and QoL (β= -0.056; p<0.001).
PA was inversely associated with disease activity (β= -0.108; p<0.001), anxiety (β= 0.025; p=0.001), depression (β= -0.025; p=0.001), fatigue (β= -0.058; p<0.001), and
sleep disturbance (β= -0.019; p=0.008), while positively associated with social
satisfaction (β=0.063; p<0.001), and QoL (β=0.005; p<0.001). The benefit across

101

outcomes, excluding depression, was greater for strenuous PA intensity than for moderate
or mild. For all outcomes, interaction effects between E-DII and PA were not significant.
Interpretation: An anti-inflammatory diet and PA are associated with decreased disease
activity, anxiety, depression, and fatigue, and improved QoL, sleep, and social
satisfaction for patients with UC. Such modalities may aid in managing systemic and
localized inflammation associated with UC and reduce the burden of UC on daily living.
Funding: Crohn’s and Colitis Foundation Young Investigator Award.

Keywords: inflammatory bowel diseases; disease severity; ulcerative colitis; diet;
inflammation; dietary inflammatory index; physical activity
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Introduction
Ulcerative Colitis (UC) is a chronic illness under the umbrella of Inflammatory
Bowel Disease (IBD). UC is characterized by chronic inflammation and ulcerations in
the colon’s mucosal lining due to abnormal inflammatory and immune system responses
(Crohn’s and Colitis Foundation, 2022; Porter et al., 2020). The majority of cases are
currently diagnosed in Western societies, reflecting to some extent reporting/diagnosis
bias (Delgado-Rodríguez & Llorca, 2004; Jairath & Feagan, 2020; Solomon, 1992).
Despite the complexity of the condition and irregularities in reporting and data collection
(Mulder et al., 2014), IBD is becoming a global health issue as incidence rates are rising
throughout the world (Jairath & Feagan, 2020; Windsor & Kaplan, 2019). For example,
IBD is known to be grossly underreported in India (Amarapurkar et al., 2018; Banarjee et
al., 2020; Jain & Venkataraman, 2021; Maroo et al., 1974; Olfatifar et al., 2021; Patel et
al., 2013) where it has been determined to be a “sleeping giant”(Juyal et al., 2018). Some
researchers parallel rapidly rising rates with the adoption of the Westernized diet and
culture in Eastern countries (Kaplan & Windsor, 2021; Rizzello et al., 2019; Windsor &
Kaplan, 2019).
Individuals with UC experience lifelong unpredictable fluctuations between
periods of disease remission and exacerbations of disease activity (Falvo & Holland,
2018). Disease severity ranges from mild to moderate or severe (Peyrin-Biroulet et al.,
2016). Disease activity generates physical symptoms such as abdominal pain, rectal
bleeding, bowel urgency, bowel frequency, diarrhea, and fatigue, along with various
extra-intestinal manifestations of disease, which interfere with maintaining normal daily
activities (Fourie et al., 2018; Hall et al., 2005; Matini & Ogden, 2016; McMullan et al.,
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2017; Wickman et al., 2016; Wolfe & Sirois, 2008). Regardless of whether or not
disease is active, the majority of individuals with UC report decreased work productivity,
anxiety and depression, isolation, strained relationships, ‘brain fog’, poor sleep quality,
and negative body image (Falvo & Holland, 2018; Fedosiejew et al., 2016; LópezSanromán et al., 2017; McMullan et al., 2017). UC has been found to influence
individuals’ choices surrounding their employment status, career planning and
development, family planning, and social engagement (Fourie et al., 2018; Hall et al.,
2005; Matini & Ogden, 2016; McMullan et al., 2017; Wickman et al., 2016; Wolfe &
Sirois, 2008)
Medical treatments for UC aim to reduce symptoms and induce a state of
remission through reducing inflammation using pharmaceutical therapies. While certain
drugs can lead to improvements in reducing disease activity, many patients report that
pharmaceuticals, overall, provide insufficient treatment to induce or maintain remission
and overcome the burden of UC in everyday life (Matini & Ogden, 2016; McMullan et
al., 2017; Wickman et al., 2016; Wolfe & Sirois, 2008). Additionally, the cost of
medication is a key driver of healthcare spending on UC (Beard et al., 2020), which has
implications for patient affordability of and access to new medicines. Many individuals
living with UC seek information on lifestyle methods (e.g., diet, physical activity) as
complementary treatments to reduce symptoms, avoid medication side effects, achieve
disease remission, reduce the burden of illness on the activities of every-day life and
improve overall quality of life (Fourie et al., 2018; le Berre et al., 2020; McCormick et
al., 2012; McMullan et al., 2017; Wolfe & Sirois, 2008).
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Despite limited evidence to support consistent dietary recommendations for the
management of UC, dietary change is a popular self-management method among UC
patients (Rizzello et al., 2019). With varying success, many patients attempt to identify
and avoid foods that seem to trigger gastrointestinal symptoms or adopt highly restrictive
diets in response to a disease flare (Cohen et al., 2014; Jowett et al., 2004). Popular diets
currently recommended for UC, such as the Specific Carbohydrate Diet (Cohen et al.,
2014), Low-FODMAP diet (Carlson et al., 2015), and low-fiber diets, have received
increasing attention among the IBD community and aim to reduce irritable bowel (note:
irritable bowel vs inflammatory bowel) symptoms such as gassiness or diarrhea. These
exclusion-focused diets can help ease the burden of UC to an extent, yet are often
reported as difficult to maintain (Nazarenkov et al., 2019). Exclusionary diet practices
can result in healthier dietary intake, but also can result in malnutrition, disengagement
from social activities, excessive cognitive energy spent on food choices, frustration with
the desire for excluded foods, and significant distress after straying from dietary
exclusion goals (Nazarenkov et al., 2019). Low-fiber diets are often suggested to help
ease the roughage passing through an inflamed colon during UC flares. Indeed, low-fiber
and exclusion diets tend to be strongly pro-inflammatory (Khayyatzadeh et al., 2017;
Krishnamurthy et al., 2012; Y. Ma et al., 2008). So, this prescription could tend to
exacerbate the problem and amplify symptoms when adopted for an extended period of
time. There is very limited evidence about the effectiveness of these recommended
exclusion diets in healing the inflamed and ulcerated mucosal lining of the colon.
A successful approach to food choice among individuals with UC may be the
adoption of an anti-inflammatory dietary lifestyle to manage the burden of living with
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UC. Outside of the development of the IBD Anti-Inflammatory Diet (IBD-AID) protocol
and subsequent examination of its interaction with the microbiome (Olendzki et al., 2022;
Olendzki et al., 2014), the adoption of an anti-inflammatory dietary lifestyle has not been
otherwise examined as a complementary treatment approach and self-management
method for UC. An anti-inflammatory diet may play a significant role in self-managing
the localized and systemic inflammation associated with UC and therefore may decrease
disease activity and associated extraintestinal manifestations of illness. Among the
general population, an anti-inflammatory dietary intake has been shown to decrease
anxiety, depression, and risk of colon cancer, among other health outcomes (Shivappa et
al., 2017; Shivappa, et al., 2016b). This method of dietary intake expands food choices
by incorporating aromatic spices, blends of colorful foods, and plentiful intake of fruits,
vegetables, and healthy fats.
Olendzki and colleagues developed the IBD-AID as a protocol built from the
SCD diet that incorporates anti-inflammatory components to rebuild bacterial gut flora
and mitigate disease activity (https://www.umassmed.edu/nutrition/ibd/ibdaid/) (Olendzki
et al., 2014). An associated study screened medical records for 10 IBD patients who
followed an IBD-Anti Inflammatory Diet and found improvements in gastrointestinal
symptoms, yet the sample included only three cases of UC (Olendzki et al., 2014).
Recent evidence indicates an association between the adoption of the IBD-AID and
beneficial changes in the microbiome of IBD patients (Olendzki et al., 2022). Though
there is abundant evidence on the relationship between diet-associated inflammation and
diseases of the gastro-intestinal tract, and suggestive links from work using the Dietary
Inflammatory Index (DII®) (Marx et al., 2021; Mirmiran et al., 2019; Phillips et al.,
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2019; Shivappa et al., 2016a), additional carefully designed, ideally prospective, studies
need to be conducted in order to provide sufficient scientific evidence to support clear
dietary recommendations for the management of UC.
The DII is a literature-derived dietary index developed to measure the
inflammatory potential of one’s food intake (Shivappa et al., 2014a). Outside of a study
showing that a pro-inflammatory diet was a risk factor for developing UC (Shivappa,
2016a) and another one producing suggestive results (Mirmiran et al., 2019), the DII has
never been studied among the UC population.
In addition to diet, physical activity (PA) is another behavioral method UC
patients use for reduction and management of the physical and psychosocial burden of
illness. PA is widely known to reduce stress and depression, regulate systemic
inflammation, reduce the risk of co-morbidities, improve social relationships, and
demonstrate quality of life benefits among the general population. Physical activity is
highly likely to contribute to a reduced burden of illness among individuals with UC, yet
few studies have examined PA among this population. Existing studies on PA and IBD
suggest that although patients struggle with motivation to exercise during periods of
active disease, engagement in PA or structured exercise is associated with improvements
in quality of life, fatigue, and mental health (Eckert et al., 2019; Lamers et al., 2021;
Raman et al., 2021; Wiestler et al., 2019). Additionally, evidence suggests that physical
activity also may be an effective modifier in the disease course of UC (Eckert et al.,
2019; Engles et al., 2018). However, recommendations for PA and maintenance of
health among the UC population do not currently exist. Research is needed to determine
the magnitude of effect physical activity has on decreasing the burden of illness
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associated with UC. Additionally, recent reviews call for data on the intensity and
frequency of exercise that would generate the greatest benefit among individuals with UC
in order to determine exercise recommendations for this population (Eckert et al., 2019;
Engles et al., 2018; Nathan et al., 2013; Raman et al., 2021).
This research examines associations between diet-related inflammation, as
indicated by the DII, physical activity at varying intensities, and both physical and
psychosocial health outcomes associated with the burden of living with UC. To our
knowledge, this is the first study to use the DII to examine dietary inflammatory potential
and UC-related physical and psychosocial health outcomes. Results of this study may
provide additional insights to physicians and patients regarding diet and PA as
complimentary self-management methods to mitigate disease activity and manage the
burden of UC. Such insights are needed to develop and provide evidence-based dietary
and physical activity recommendations for the UC population.

Methods
The IBD Partners e-cohort provides the basis for analyses conducted to test the
associations between diet-associated inflammation (using the DII), physical activity, and
ulcerative colitis. IBD Partners, previously named the Crohn’s and Colitis Foundation of
America (CCFA) Partners, is a longitudinal Internet-based cohort that aims to follow IBD
patients and serve as a resource for education and research. Data obtained from
participants in the IBD Partners e-cohort were analyzed using a cross-sectional,
secondary data analysis design to examine associations between the inflammatory
capacity of individuals’ diets, physical activity, and UC-related health outcomes.
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Participants provided information on demographics, disease phenotype, disease activity,
and medication use, among others, and completed self-report surveys regarding dietary
patterns, physical activity, disease activity, IBD-specific quality of life, and various
patient-reported outcomes (PROs) reflecting psychosocial elements relating to chronic
illness. For this study, survey data were included from those participants over 18 years of
age who self-reported a diagnosis of UC. Respondents who had undergone UC-related
surgery were excluded.

Variables of Interest
The following variables were abstracted from validated measures administered within the
IBD Partners survey. Dependent variables are the following:
Disease Activity
Disease activity was reported using the Simple Clinical Colitis Activity Index
(SCCAI) (Long et al., 2012; Walmsley et al., 1998). The SCCAI is a validated selfreport measure, with strong psychometric and performance validity for use among
patients with UC (Higgins et al., 2007; Jowett et al., 2003). Patients are asked to rate
bowel frequency during day and night, bowel urgency, rectal bleeding, general wellbeing, and extracolonic manifestations. Items are scored individually using Likert-scale
type response options, then summed into a total disease activity score, with an additional
point added per extracolonic manifestation. Scores range from 0-15+ points. Remission
in UC is associated with a SCCAI score <2; clinical relapse is defined by a SCCAI score
≥5 (Jowett et al., 2003; Turner et al., 2009).
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Disease-related Quality of Life
The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a 10-item
questionnaire used to assess disease-related quality of life among individuals with IBD
(Irvine et al., 1996). The SIBDQ assesses four domains, including bowel, emotional,
systemic, and social for a summed quality of life score relative to the two weeks prior to
self-report. The SIBDQ is highly correlated with the full 32-item Inflammatory Bowel
Disease Questionnaire (IBDQ), correlates to disease activity in patients with UC, and
demonstrates good test-retest reliability (Irvine et al., 1996). Items are individually
scored by a 7-point scale, totaled, and averaged for a total SIBDQ score, with 1 indicating
poor HRQOL and 7 indicating optimum HRQOL.
Patient-Reported Outcome Domains
The National Institutes of Health Patient Reported Outcome Measurement
Information System (PROMIS) is a system of precise measures of patient-reported
physical, mental, and social wellbeing with high reliability (Cella et al., 2007, 2010).
Various domains of well-being can be measured using validated item banks, or groupings
of questionnaire items that reflect the construct of interest. PROMIS items have been
validated among the general population, with recently recognized construct validity in the
IBD population (Cella et al., 2010; Kappelman et al., 2014). IBD Partners administered
short form PROMIS item banks to measure five individual constructs of health-related
quality of life particularly relevant to IBD: anxiety, depression, fatigue, sleep disturbance,
and satisfaction with social role. Each domain’s item bank consisted of 4 items, using a
5-option response scale ranging in value from 1 to 5. Item scores are calibrated using a
T-score metric which scales the raw score to a standardized score with a mean of 50 and
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a standard deviation of 10. A score of 50 is the mean for the United States general
population for most PROMIS instruments. High scores for fatigue, anxiety, depression,
and sleep disturbance represent poor health while high scores for social function
represent good health (Kappelman et al., 2014).

The study’s independent variables are the following:
Dietary Inflammatory Index (DII®) Score
Dietary data were collected using a National Health and Nutrition Examination
Survey (NHANES) Dietary Screener Questionnaire (National Cancer Institute, 2021c)
that was used as a basis to compute both a DII score and an Energy-Adjusted DII Score
(E-DIITM) for this study (Hébert et al., 2019; Shivappa et al., 2014a). The DII was
developed based on an extensive literature search to quantify the effect of diet on
inflammation using an algorithm that takes into account up to 45 food parameters
identified in the search, including a combination of nutrients and food intake (Shivappa et
al., 2014a). Due to unique differences observed in the relationship between total energy
intake (a determinant of the DII) and nutrient intake, the E-DII also was developed
(Hébert et al., 2019). DII scores can range from a theoretically minimum -8.87,
indicating a strongly anti-inflammatory intake, to a theoretically maximum +7.98,
indicating a strongly pro-inflammatory intake (Shivappa et al., 2014a). At least 41
studies have demonstrated construct validity of the DII or E-DII against inflammatory
biomarkers in different populations under varying conditions (Gialluisi et al., 2021; Li et
al., 2021; Malcomson et al., 2021; Marx et al., 2021; Phillips et al., 2019; Saghafi-Asl et
al., 2021; Skoczek-Rubińska et al., 2021; Zamora-Ros et al., 2015).
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Physical Activity
Physical activity data were collected using the Godin-Shephard Leisure Time
Physical Activity Questionnaire (Godin, 2011; Godin & Shephard, 1985). This
questionnaire was developed to measure leisure-time physical activity among healthy
adults and has been validated to assess exercise behavior in different (populations, with
significant correlation to VO2max, and percentage of body fat (Amireault & Godin, 2015;
Gionet & Godin, 1989; Godin, 2011; Miller et al., 1994).
The 4-item questionnaire asks participants to indicate the number of times during
a 7-day period that the participant engages in mild (minimal effort – e.g., easy walking,
fishing), moderate (not exhausting- e.g., fast walking, tennis), and strenuous (heart beats
rapidly- e.g. running, basketball) physical activity for at least 15 minutes (Amireault &
Godin, 2015; Godin, 2011; Godin & Shephard, 1985). Total Leisure-Time Activity
scores are calculated by multiplying reported weekly frequencies of mild, moderate, and
strenuous activities by corresponding Metabolic Equivalent of Task (MET) values, which
indicate energy expenditure, of three, five and nine respectively, then summing the
products of each intensity level (Godin, 2011; Godin & Shephard, 1985). In addition to
Total Leisure Time Activity, frequency of engagement in PA at each intensity was
assessed in this study as continuous variables of PA intensity- mild, moderate, and
strenuous.
Covariates
Additional variables included age, sex, body mass index (BMI), race, education,
smoking status, disease duration, and medication class. Age was indicated by entering a
numeric value. Sex was identified as either male or female. BMI (kg/m2) was calculated
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from participant-reported height and weight. Given that 84% of the participants indicated
race as ‘White’, a dummy variable for race was created (‘White’ or ‘not White’).
Education was indicated as ‘high school or less’ (combining survey response items of
‘12th grade’ and ‘less than 12th grade’), ‘some college’, ‘college’, and ‘graduate school’.
Smoking status was denoted as ‘never’, ‘ever’, or ‘current’. Disease duration was selfreported by number of years since first IBD diagnosis. Participants reported on currently
used medications by indicating ‘yes’ or ‘no’ to various listed medications and treatment
methods. Seven “medication classes” were grouped as follows: Corticosteroids included
‘oral corticosteroids’, ‘budesonide’, and ‘steroids, rectal’ questionnaire items;
Aminosalicylates included ‘mesalamines oral’, ‘mesalamines rectal’, and ‘Azulfidine
(sulfasalazine)’; Immunomodulators included ‘Azathioprine/6MP’ and ‘Oral MTX’
(methotrexate); Biologics included ‘infliximab’ and ‘adalimumab’; Antibiotics included
‘ciprofloxacin’, ‘metronidazole’, and ‘other antibiotics’, Complementary/Alternative
included ‘probiotics’, ‘Other complementary or alternative therapy’, and ‘calcium’;
Opioids included ‘opioids’. (Crohn’s & Colitis Foundation, 2021) Participants also
reported the presence of other conditions unrelated to IBD that limit participation in PA,
such as injury, by indicating ‘yes’ or ‘no’.
Statistical Analysis
Associations between DII/E-DII scores and health outcomes were tested using
multivariable regressions. Disease activity, quality of life, and PROs were each predicted
by a vector of covariates (age, sex, BMI), race, education, smoking status, disease
duration, medication class, and PA) and DII score. Models were assessed for
multicollinearity using Variance Inflation Factors (VIF) and tested for explanatory power
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robustness (R2 ) when using the E-DII variable score versus DII scores. The E-DII score
was selected for preferred specifications given the variable’s greater explanatory ability,
as well as lower skewness and other distributional characteristics in comparing scores. EDII scores were analyzed as a continuous variable, with subsequent analysis to test linear
trends across quartiles
Associations between physical activity and health outcomes also were tested
using multivariable regressions. Again, disease activity, quality of life, and PROs were
each predicted by a set of controls (age, sex, BMI, race, education, smoking status,
medication class, disease duration, E-DII score, and presence of conditions limiting
participation in PA), and physical activity. Physical activity was analyzed against each
health outcome (Y). Physical activity modeled in two ways – First, as a Total LeisureTime Activity Score (X2), and second as intensity levels (where X2 is moderate intensity,
and X3 is strenuous intensity). The full model appears as follows:
Y=B0+B1X1+B2X2+B3X3+ ε, where X1 is a vector of controls and ε is a random error
term.
Interaction effects between E-DII scores expressed continuously and as quartiles
with PA intensity were also tested.

Results
Participant Characteristics
A total of 2,368 patients with UC completed the surveys of interest to this study.
After excluding patients who had undergone UC-related surgery, data from 2,052
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respondents were included. Participant characteristics are described in Table 4.2, along
with mean scores for each independent and dependent variable.
Dietary Inflammatory Intake
DII scores ranged from -2.94 to 4.48. E-DII scores ranged from -4.13 to 4.47
(mean=-0.25, median=-0.41). An increase of one point in E-DII score (indicating
increased pro-inflammatory dietary intake potential) was significantly associated with
increased SCCAI scores (p<0.001, t=4.71, [95%CI=0.97-0.24]), anxiety (p=0.006,
t=2.73, [95%CI=0.096-0.59]), depression (p=0.001, t=3.32, [95%CI=0.17-0.65]), fatigue
(p=0.005, t=2.82, [95%CI=0.12-0.66]) and sleep disturbance (p=0.003, t=2.99,
[95%CI=0.12-0.56]), and decreased satisfaction with social role (p=0.004, t=-2.92,
[95%CI=-0.62- -0.12]) and SIBDQ scores (p<0.001, t=-3.87, [95%CI=-0.08- -0.03]).
(See Table 4.3) Quartile analysis indicated a robust distribution and linear trends across
quartiles. (See Table 4.4)
Physical Activity
Total leisure time activity was inversely associated with disease activity (p<0.001,
t=-4.71, [95%CI=-0.15- -0.01]), anxiety (p=0.001, t=-3.29, [95%CI=-0.04- -0.01]),
depression (p=0.001, t=-3.23, [95%CI=-0.04- -0.01]), fatigue (p<0.001, t=-6.74,
[95%CI=-0.08- -0.04]), and sleep disturbance (p=0.008, t=-2.67, [95%CI=-0.03- -0.01]),
while positively associated with IBD-related quality of life (p<0.001, t=5.33,
[95%CI=0.003-0.01]) and satisfaction with social role (p<0.001, t=7.94, [95%CI=0.070.08]).

When comparing frequency of PA at mild, moderate, and strenuous intensity

levels, the strongest associations existed between strenuous intensities of PA and each
health outcome (though insignificant for depression). (See Table 4.5)
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Interaction Effects
No significant interaction was observed between diet and physical activity across
any of the outcomes. While diet and physical activity are understood to be correlated and
have the potential to interact in their effect on health, the way they statistically impact
UC-related health outcomes appears to be independent of each other in the context of this
analysis.
Discussion
These findings suggest that an anti-inflammatory diet and increased physical
activity is each likely to contribute to a lower burden of illness associated with UC.
Significant associations were found between increases in E-DII scores (indicating proinflammatory dietary potential) and increases in disease activity, anxiety, depression,
fatigue, and sleep disturbance, along with decreases in satisfaction with social role and
health-related quality of life. As a corollary, these results suggest that an antiinflammatory dietary intake may decrease disease activity, anxiety, depression, and
fatigue, as well as improve disease-related quality of life, sleep, and satisfaction with
social role.
For disease activity, a one point change in SCCAI score is considered clinically
significant in the medial field. According to this study, where a one point E-DII score is
significantly associated with a 0.17 point increase in SCCAI score, a patient with UC
would need to change his or her E-DII score by about 6 points for a clinical difference in
disease activity. DII scores range from a maximally pro-inflammatory diet score of
+7.98 to a maximally anti-inflammatory diet score of -8.87, indicating a range of 16.85
points (Shivappa et al., 2014b). Within this range, a 6 point change in E-DII score would
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require a legitimate, yet feasible change from a pro-inflammatory dietary intake to an
anti-inflammatory dietary lifestyle.
Increases in total leisure time physical activity were associated with increases in
IBD-related quality of life and satisfaction with social role, along with decreases in
disease activity, anxiety, depression, fatigue, and sleep disturbance. Results suggest that
increasing engagement in physical activity may reduce disease activity, anxiety,
depression, fatigue, and sleep disturbance while improving IBD-related quality of life and
satisfaction with social role. Increases in the frequency of strenuous activity indicated
stronger associations with improved disease outcomes than increases in moderate or mild
intensity activities. Findings suggest that increased engagement in physical activity at a
strenuous intensity (i.e., heart beats rapidly) may yield greater improvements in disease
outcomes in comparison to increases in moderate or mild PA. While each of these
lifestyle-related factors appears to be associated with important UC outcomes, there was
no indication of an interaction between these 2 important risk factors.
According to the results of this study, the adoption of an anti-inflammatory diet
may be an effective approach to mitigating disease activity. This dietary approach
differs from current recommended diets, which tend to focus solely on easing the GI
symptoms associated with UC, such as diarrhea, bloating, and gassiness, and reducing
roughage that passes through the colon by restricting various types of fruits, vegetables,
and processed foods. Attention to the inflammatory potential of diet broadens the
understood influence of diet beyond just the colonic symptoms, to improve immune
system functioning and health of the whole body.
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A common weakness of current diets suggested for UC is the lack of evidence
that these diets decrease inflammation, which is essential for mucosal healing within the
colon. The DII is a literature-derived index developed to measure the inflammatory
potential of one’s food intake and found to be predictive of multiple inflammatory
biomarkers, such as C-reactive protein, Interleukin-4,6,8, and 10, TNF-a, and
calprotectin, among others (Gialluisi et al., 2021; Li et al., 2021; Malcomson et al., 2021;
Saghafi-Asl et al., 2021; Shivappa et al., 2014a; Shivappa et al., 2014b; SkoczekRubińska et al., 2021; Wirth et al., 2014; Zamora-Ros et al., 2015). Given the established
associations between the DII and inflammatory biomarkers (now in over 40 construct
validation studies), along with the results of this study, there is suggestive evidence that
an anti-inflammatory dietary intake may aid in managing systemic and localized, chronic
“simmering” (Hofseth & Hebert JR, 2022) inflammation associated with UC and reduce
the burden of UC on daily living. Results of this study support existing findings, which
indicate that anti-inflammatory dietary intake is associated with decreased anxiety,
depression, and risk of colon cancer, among other health outcomes (Marx et al., 2021;
Phillips et al., 2019; Shivappa et al., 2017; Shivappa et al., 2016b). This research may
advance the development of dietary recommendations for disease management and
influence the food choices among UC patients seeking to manage the burden of illness
associated with UC. Additional research is needed to examine the clinical impact of antiinflammatory dietary intake on the course of UC.
Physical activity is known to regulate inflammation among healthy individuals.
The medicinal benefits of PA are not fully understood among the IBD population, though
existing studies tend to show improvements in gastrointestinal symptoms, quality of life,
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and psychosocial outcomes, as well as a protective role in maintaining remission (Davis
et al., 2022; Eckert et al., 2019; Raman et al., 2021). Our findings support the limited
existing literature, indicating an association between increased engagement in PA and
improved health outcomes among the UC population. Prior studies suggest that rates of
exercise are inversely associated with disease activity (Eckert et al., 2019; Engles et al.,
2018; Shephard, 2016). Although PA has not been shown to worsen symptoms and is
recognized as safe among the majority of the IBD population (Engles et al., 2018; Nathan
et al., 2013), motivation is low among patients with active disease due to fatigue, bowel
urgency, and pain, among other symptoms (Davis et al., 2022; Lamers et al., 2021).
During periods of remission, patients with IBD are more receptive to engaging in PA and
report improved health-related quality of life and self-image (Lamers et al., 2021; Taylor
et al., 2018; Wiestler et al., 2019).
A significant gap in the literature calls for greater understanding of the frequency,
intensity, and type of PA best suited for optimal health outcomes among the UC
population. This study adds to the literature by examining the changes in association
with UC health outcomes by intensities of PA. Our findings support results of existing
studies. A recent Japanese study also examined total PA and PA intensities against
clinical outcomes, finding that strenuous activity and increased total PA were each
independently associated with improved mucosal healing in patients with UC (Watanabe
et al., 2021). A study by Taylor et al., (2018), found health-related quality of life benefits
(HRQoL) associated with all exercise intensities. Not only were high volumes of
moderate and vigorous exercise associated with physical health-related quality of life, but
high volumes of mild exercise (walking) also were associated with both physical and

119

mental HRQoL. Overall, studies argue that the employment of PA and structured
exercise could potentially help mitigate and protect against active disease (Davis et al.,
2022; Engles et al., 2018; Jones et al., 2015; Lamers et al., 2021). Additional research is
needed to develop evidence-based physical activity recommendations for individuals
with UC, with attention to exercise frequencies and intensities that may best reduce the
daily burden of living with UC (Raman et al., 2021).
This study did not find interaction effects between dietary inflammatory intake
and physical activity. Numerous studies have indicated the coupled benefits of diet and
physical activity on health, energy, vitality, overall well-being among the general
population (Stavsky & Maitra, 2019). Stavsky & Maitra (2019) examined the synergistic
influence of diet and physical activity in the management of UC, outlining theoretical
direct and indirect effects of diet and exercise on disease physiology, and proposed a
decrease in pro-inflammatory diet and increase in aerobic exercise for protective
influence against UC. While we did not see synergistic effect, it is also true that there was
no antagonistic effect. Therefore, there is no indication that both improving diet and
physical activity would result in a less favorable outcome than either one taken alone.
The cross-sectional design of this secondary data analysis limits causal inference.
For example, the association between total physical activity, particularly higher
frequency of strenuous physical activity, and decreased disease activity might be
explained by a patient’s capacity to engage in exercise. Although patients with UC tend
to recognize the benefits of physical activity on well-being, participation in exercise is
often difficult given barriers associated with disease activity (Engles et al., 2018).
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Research with longitudinal data is needed to better determine the mitigating influence of
physical activity on the disease course and other related outcomes.
The sample in this study is largely female and white. Stratified analyses by sex
were considered, yet given inconsistent findings on gender differences in UC outcomes
(Greuter et al., 2020), this gender distribution was accounted for as a control variable in
all models. While patients with UC often report feeling that their condition is not taken
seriously by family, peers, and physicians (Fourie et al., 2018), this injustice is often
compounded for African American women and other racial minorities in social
communities and health care systems (Belgrave & Abrams, 2016). Overall,
representation of racial minorities in research is a prominent limitation of health-related
research (Ma et al., 2021). This analysis is limited by the predominantly white sample.
Statistical models controlled for race as white and non-white to account for the skewed
representation of racial difference in the population.
Findings from this study also are limited by the nature of computing DII scores
from the NHANES DSQ. Additional studies using a comprehensive dietary assessment
are needed to explore the relationships between the DII/E-DII and UC related health
outcomes. As IBD Partners provides researchers with access to a large cohort of
individuals with UC, this research highlights the need for administration of
comprehensive dietary assessment measures among the IBD Partners cohort in order to
best assess the role of diet in IBD management.
All data were collected through self-reported measures, subjecting all results to
potential reporting bias. At the same time, no other study, to our knowledge, has
examined diet and physical activity’s associations with UC-related outcomes among such
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a large cohort. Very little research exists using the DII/E-DII among UC patients, and no
other research associated with IBD Partners has examined and compared the associations
between physical activity, particularly the frequencies of exercise intensities, and UC
related health outcomes. This study’s findings are also accompanied by high R2 values,
indicating strong explanatory power of our statistical models.
Study findings will aid future research that may expand models of patient care
and self-management programs to include anti-inflammatory dietary intake and PA as
complementary lifestyle methods that may reduce disease symptoms, maintain remission,
and improve psychosocial well-being among individuals with UC. More research in this
area will contribute to creating evidence-based health promotion programs for PA and
dietary change in UC.
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Table 4.2 Characteristics of Participants* with Ulcerative Colitis and mean scores for
independent and dependent variables from IBD Partner’s 2011 e-cohort data (n=2,052).
Mean (SD) or %
43.82(14.41)
71.39
84.35
11.75 (10.61)
25.56 (5.91)

Age (years)
sex- % female
Race - % White
Disease Duration (years)
BMI (kg/m2)
Education %
HS or Less
7.4
Some College
18.17
College
40.74
Graduate School
29.09
Never smokers, %
63.59
Current smokers, %
4.3
Prior smokers %
32.06
Conditions limiting PA %yes
9.9
Medication/Treatment Class**
Corticosteroids
17.1
Aminosalicylates
73.4
Immunomodulator
25.4
Biologics
17.3
Antibiotics
2.2
Complimentary/Alternative
30.5
Opioids
4.68
DII score
2.279 (1.28)
E-DII score
-0.251 (1.68)
Leisure Time Physical Activity
33.16 (26.98)
Strenuous***
1.39 (1.91)
Moderate
2.36 (2.79)
Mild
3.02 (3.24)
SCCAI
3.34 (2.77)
SIBDQ
4.96 (1.14)
Anxiety
53.39 (9.4)
Depression
51.37 (9.3)
Fatigue
53.89 (10.53)
Sleep Disturbance
51.35 (8.29)
Satisfaction with Social Role
49.05 (9.5)
* Respondents who had undergone UC-related surgery were excluded.
**Respondents were allowed to report current use of any or all medications/treatments.
Concurrent use of multiple medications is evident as total percent currently using
medication/treatments is 170.58%.
***Frequency scores indicate the number of times in the last 7 days an individual participated in
at least 15 minutes of physical activity at the associated intensity.

123

Table 4.3 Comparison between Dietary Inflammatory Index and Energy-Adjusted Dietary Inflammatory Index
scores’ associations with UC-Related Health Outcomes from IBD Partners 2011 e-cohort.
Associations between Dietary Inflammatory Index Scores and UC-Related Health Outcomes
Coef.

Std Err.

t

P>|t|

[95% CI]

R2

Adj. R2

SCCAI

0.15

0.05

3.23

0.001

[.06, .24]

0.195

0.183

SIBDQ

-0.05

0.02

-2.67

0.008

[-.09, -.01]

0.208

0.196

Anxiety

0.14

0.16

0.85

0.40

[-.18, .46]

0.092

0.079

Depression

0.16

0.16

0.97

0.33

[-.16, .47]

0.091

0.078

Fatigue

0.32

0.18

1.78

0.08

[-.03, .67]

0.148

0.136

Sleep Disturbance

0.35

0.15

2.36

0.02

[.058, .63]

0.082

0.068

Satisfaction w/Social Role

-0.39

0.16

-2.39

0.02

[-.71, -.07]

0.119

0.106
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Associations between Energy-Adjusted Dietary Inflammatory Index Scores and UC-Related Health Outcomes
SCCAI

0.17

0.04

4.71

p<0.001

[.097, .24]

0.200

0.188

SIBDQ

-0.06

0.01

-3.87

p<0.001

[-.08, -.03]

0.211

0.199

Anxiety

0.34

0.13

2.73

0.006

[.096, .59]

0.095

0.082

Depression

0.41

0.12

3.32

0.001

[.17, .65]

0.095

0.082

Fatigue

0.39

0.14

2.82

0.005

[.12, .66]

0.151

0.138

Sleep Disturbance

0.34

0.11

2.99

0.003

[.12, .56]

0.084

0.070

Satisfaction w/Social Role

-0.37

0.13

-2.92

0.004

[-.62, -.12]

0.120

0.107

Note: Specifications include age, sex, BMI, race, education, smoking status, medication class, disease duration, and physical activity.

Table 4.4 Associations between Energy-Adjusted Dietary Inflammatory Index (E-DII) Quartiles* and UC-Related
Health Outcomes from IBD Partners 2011 e-cohort.

SCCAI

SIBDQ

Anxiety
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Depression

Fatigue
Sleep
Disturbance
Satisfaction with
Social Role

Quartiles*
E-DII Quart2
E-DII Quart3
E-DII Quart4
E-DII Quart2
E-DII Quart3
E-DII Quart4
E-DII Quart2
E-DII Quart3
E-DII Quart4
E-DII Quart2
E-DII Quart3
E-DII Quart4
E-DII Quart2
E-DII Quart3
E-DII Quart4
E-DII Quart2
E-DII Quart3
E-DII Quart4
E-DII Quart2
E-DII Quart3
E-DII Quart4

Coef.
0.07
0.38
0.73
-0.02
-0.10
-0.26
-0.01
0.63
1.56
0.46
0.59
1.80
-0.22
0.27
1.54
-0.11
0.20
1.40
1.09
0.54
-1.25

Std Err.
0.16
0.16
0.17
0.07
0.07
0.07
0.57
0.58
0.59
0.56
0.57
0.58
0.62
0.64
0.65
0.51
0.52
0.54
0.57
0.59
0.60

t
0.46
2.32
4.35
-0.35
-1.49
-3.71
-0.02
1.09
2.63
0.82
1.03
3.09
-0.04
0.43
2.37
-0.02
0.39
2.61
1.91
0.92
-2.00

P>|t|
0.64
0.02
<0.001
0.73
0.14
<0.001
0.99
0.28
<0.01
0.41
0.30
<0.01
0.72
0.67
0.02
0.82
0.70
<0.01
0.06
0.36
0.05

[95% CI]
[-.24, .39]
[0.06, .70]
[.4, 1.06]
[-.15, .11]
[-.23, .03]
[-.39, -.12]
[-1.12, 1.1]
[-.51, 1.8]
[.398, 2.73]
[-.64, 1.55]
[-.53, 1.71]
[-.11, -.05]
[-1.44, .996]
[-.97, 1.52]
[.26, 2.81]
[-1.12, .89]
[-.82, 1.12]
[.35, 2.46]
[-.030, 2.21]
[-.61, 1.69]
[-2.38, -0.25]

R2

Adj. R2

0.201

0.189

0.211

0.199

0.096

0.082

0.095

0.081

0.151

0.137

0.084

0.070

0.124

0.110

Note: Specifications include age, sex, BMI, race, education, smoking status, medication class, disease duration, and physical activity.
*Energy-Adjusted Dietary Inflammatory Index Quartiles calculated from IBD Partners e-cohort 2011 dietary data. Values for E-DII
across quartiles - Quartile 1=-4.13 to -1.46, Quartile 2= -1.46 to -0.35, Quartile 3= -0.35 to 0.96, Quartile 4= 0.96 to 4.47.

Table 4.5 Associations between Total Leisure Time Exercise Activity, Frequencies of
Intensity, and UC-Related Health Outcomes from IBD Partners 2011 e-cohort.
Std
Err.
t
<0.01 -4.71
0.03 -4.19
0.03 -3.12

2

Adj.
R2
0.195
0.199
0.199

Coef.
P>|t|
[95% CI]
R
SCCAI
<0.001 [-.15, -.01] 0.208
Leisure Time Activity -0.01
-0.14
<0.001 [-.20, -.07] 0.212
Strenuous
-0.08
<0.01
[-.13, -.03] 0.212
Moderate
SIBDQ
0.01 <0.01 5.33 <0.001 [.003, .01] 0.221 0.209
Leisure Time Activity
0.06
0.01
4.3 <0.001
[.03, .08]
0.227 0.213
Strenuous
0.04
0.01 3.75 <0.001 [.018, .06] 0.227 0.213
Moderate
Anxiety
[-.04, -.01] 0.109 0.096
Leisure Time Activity -0.03 0.01 -3.29 <0.01
-0.39 0.12 -3.37 <0.01
[-.62, -.16] 0.112 0.097
Strenuous
-0.09 0.07 -1.25
0.21
[.24, .05]
0.112 0.097
Moderate
Depression
Leisure Time Activity -0.03 0.01 -3.23 <0.01 [-.040, -.01] 0.108 0.094
-0.20 0.11 -1.77
0.08
[-.43, -.02] 0.109 0.095
Strenuous
-0.16 0.07 -2.17
0.03
[-.30, -.02] 0.109 0.095
Moderate
Fatigue
Leisure Time Activity -0.06 0.01 -6.74 <0.001 [-.08, -.04] 0.166 0.153
-0.82 0.13 -6.48 <0.001 [-1.06, -.57] 0.173 0.160
Strenuous
-0.28 0.08 -3.41 <0.01
[-.44, -.12] 0.173 0.160
Moderate
Sleep Disturbance
[-.03, -.01] 0.090 0.075
Leisure Time Activity -0.02 0.01 -2.67 <0.01
-0.32 0.10 -3.02 <0.01
[-.52, -.11] 0.094 0.079
Strenuous
-0.06 0.08 -0.75
0.45
[-.22, .097] 0.094 0.079
Moderate
Satisfaction w/Social
Role
0.06
0.01 7.94 <0.001
[.07, .08]
0.134 0.120
Leisure Time Activity
0.73
0.12 6.29 <0.001
[.50, .96]
0.140 0.125
Strenuous
0.40
0.09 4.46 <0.001
[.23, .58]
0.140 0.125
Moderate
Note: Specifications include: age, sex, BMI, race, education, smoking status, medication class,
disease duration, E-DII score, and presence of conditions limiting participation in PA.
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CHAPTER 5
SUMMARY, IMPLICATIONS AND RECOMMENDATIONS
Summary of Major Findings
The purpose of this study was to understand the impact of treatment and
management methods on the daily burden of Ulcerative Colitis using a mixed-methods
design. Study one was a qualitative study involving semi-structured interviews with
patients diagnosed with UC from across the US. The research questions and interview
guide were guided by a literature review and conceptual framework. The specific aim of
this study was to examine how treatment and management methods are used by
individuals who have been living with UC for at least 5 years and how patients make
decisions regarding the use of these treatment and management methods.
Study 1
Findings from study one indicate that over the illness trajectory, patients with UC
experience fluctuating levels of suffering associated with disease activity, with no clear
or consistent patterns of treatment and management methods evident across patient
experiences to yield optimal UC outcomes or justify disease flares. From the patient
perspective, fluctuations in disease activity are attributed to stress, diminished medication
effectiveness, or dietary triggers. Decision making regarding the use of various treatment
and management methods is shaped by a patient’s approach towards disease
management, personal experiences, sources of information, and individual motivating
factors.
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In this study, the most predominant motivating factor for the use of treatment and
management methods is personal suffering. Living with UC is accompanied by physical
symptoms and psychosocial challenges that causes significant suffering and disruption in
patients’ lives. Especially during times of active disease, patients are willing to try new
methods of management and overlook long-term implications in order to reduce suffering
and be able to ‘function’ in the present day. For a few patients, suffering has motivated
long term health behavior change. Although suffering motivates the use of treatment and
management methods, this study found that the majority of participants tend to use
treatment and management methods in reaction to suffering and disease activity. Patients
identify some medications and overall stress reduction as important methods to avoid UC
flares, yet treatment and management methods are predominantly employed as efforts to
recover from flares and reduce existing symptoms. Recent research is recognizing UC as
a progressive illness with a growing need for preventative action against progressive
damage and impairment (Cleveland et al., 2022). A need is evident for patients to shift
away from reactive treatment and management approaches and adopt preventative
behaviors.
Participants in this study typically rely on physician recommendations for the use
of pharmaceutical therapies. At the same time, many patients do not rely on physicians
to provide sufficient information regarding treatment and management methods. A
recent study interviewed 10 patients with UC about the drivers of decision-making
regarding pharmaceutical treatments versus colorectal surgery, finding that patientprovider communication was a key driver of decision making, decision satisfaction, and
adherence (Lai et al., 2019). Findings from this study suggest that many patients seek out
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and collect the majority of advice and information regarding all forms of treatment and
management methods from peers and the internet. Additionally, the majority of
treatment and management methods are adopted through a trial-and-error approach.
Given that UC has no known cause or cure at this time, the use of medical therapies and
lifestyle methods are guided by trial and assessment of effectiveness.
Findings from this study highlighted a difference between taking ownership for
the health condition (i.e., attributing the disease and disease course to personal health
behaviors) verses taking ownership of the illness experience (i.e., belief that individual
choices and behaviors can modify the lived experience). Few participants feel that they
are responsible for the course of illness, as UC is unpredictable, but some believe that
they can control, to varying degrees, how they manage their experiences with UC. A few
patients in this study take an active approach to managing their illness experience through
individual-based decision-making, health behavior change, and self-advocacy towards
greater satisfaction with treatment options and patient-provider communication.
Overall, participants use an individualized mix of treatment and self-management
methods to overcome the challenges of living with UC in daily life. Daily life with UC
carries a significant physical, emotional, mental, professional, and social burden.
Participants report unpredictable disease trajectories and adaptive approaches to
treatment and disease management over time. Treatment and management effectiveness
varies among participants, as does sustainability of method use. Medication, selfadvocacy, dietary change, stress management, physical activity, and sleep improve
participants’ individual experiences overall, yet are often utilized as responses to flares
and UC suffering instead of as preventative health behaviors. Patients express reliance
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on physicians for pharmaceutical treatment, yet identify diet restrictions and stress
management as a main approach for self-management of UC.
Diet is characterized in this study as a lifestyle method of treatment and
management due to the context of participant responses describing dietary practices as a
behavioral change to their normal or previous lifestyle. Individuals with UC have
reported diet manipulation as a strategy for managing gastrointestinal symptoms for quite
some time (Hall et al., 2005), yet research examining diet as a behavioral treatment and
management method for mitigating disease activity is relatively new (Celiberto et al.,
2018; Torres et al., 2019; Wark et al., 2021). This study found that dietary change as a
management method often evolves over time through extensive trial and error, during
which participants associate diet’s impact on disease activity based primarily on their
personally-observed immediate GI symptoms. A study on dietary practices and beliefs
among patients with UC also found that over 90% of the leading information guiding
patients’ beliefs regarding diet and disease activity were based on the patient’s personal
experiences (Crooks et al., 2021).
Participants report strong beliefs regarding the negative impact of stress on
disease activity. Reducing stress is widely reported as a key management method for
preventing and recovering from flares. Prolonged stress can elicit numerous
physiological reactions that contribute to immune dysfunction and increased
inflammation (Glaser & Kiecolt-Glaser, 2005). Prolonged stress also contributes to
imbalances in the microbiome and natural gut flora, shown to be associated with UC
(Aleksandrova et al., 2017; Lane et al., 2017). Living with UC is arguably, on its own, a
chronic stressor. Patients experience fatigue and reduced productivity, strained
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relationships, marital disruption, reduced sexual activity, various misconceptions due to
the social stigma that accompanies an ‘invisible’ illness (Larsson et al., 2017; Rapport et
al., 2019; Taft et al., 2009). UC has been described as an ‘invisible’ illness, where many
patients feel that others, including health professionals, do not recognize, understand, or
validate the gravity of their illness experience (Fourie et al., 2018; Hall et al., 2005;
Wolfe & Sirois, 2008). The burden of illness associated with UC contributes to the
ongoing nature of the illness by adding prolonged stress and, therefore, systemic
inflammation and a reduced immune system (Fedosiejew et al., 2016; Larsson et al.,
2017).
The use of complementary and alternative methods is low among participants in
this study. This may be due to the recruitment of a portion of the participant sample
through a gastroenterology clinic. Some participants express openness to complementary
and alternative methods, including supplements, chiropractic care, acupuncture, and
massage therapy as potential treatments, but high costs and limited familiarity are strong
barriers to use overall. Although various types of complementary and alternative
methods exist, research examining their effect on UC is limited (Torres et al., 2019).
Study 2
Study two used a cross-sectional secondary data analysis design using data
obtained from participants in the IBD Partners e-cohort. The specific aim of this study
was to examine associations between dietary inflammatory potential, physical activity,
and health outcomes associated with the burden of living with UC. This research
examined associations between diet-related inflammation, as indicated by the DII,
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physical activity at varying intensities, and both physical and psychosocial health
outcomes associated with the burden of living with UC.
Findings from this quantitative study suggest, overall, that an anti-inflammatory
diet and increased physical activity are each likely to contribute to a lower burden of
illness associated with UC. Significant associations were found between increases in EDII scores (indicating pro-inflammatory dietary potential) and increases in disease
activity, anxiety, depression, fatigue, and sleep disturbance, along with decreases in
satisfaction with social role and health-related quality of life. As a corollary, these results
suggest that an anti-inflammatory diet may decrease disease activity, anxiety, depression,
and fatigue, while improving disease-related quality of life, sleep, and satisfaction with
social role.
Increases in total leisure time physical activity were associated with increases in
IBD-related quality of life and satisfaction with social role, along with decreases in
disease activity, anxiety, depression, fatigue, and sleep disturbance. Results suggest that
increasing engagement in PA may reduce disease activity, anxiety, depression, fatigue,
and sleep disturbance while improving IBD-related quality of life and satisfaction with
social role.
Increases in the frequency of strenuous activity indicated stronger associations
with improved disease outcomes than increases in moderate or mild intensity activities.
These findings suggest that increased engagement in PA at a strenuous intensity (heart
beats rapidly) may yield greater improvements in UC-related health outcomes in
comparison to increases in moderate or mild PA.
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While dietary inflammatory intake and PA are lifestyle-related factors that appear
to be associated with important UC outcomes, there was no indication of an interaction
between these 2 important risk factors. Numerous studies have indicated the coupled
benefits of diet and physical activity on health, energy, vitality, overall well-being among
the general population (Stavsky & Maitra, 2019). Stavsky & Maitra (2019) examined the
synergistic influence of diet and physical activity in the management of UC, outlining
theoretical direct and indirect effects of diet and exercise on disease physiology, and
proposed a decrease in pro-inflammatory diet and increase in aerobic exercise for
protective influence against UC. While we did not see synergistic effect in this analysis, it
is also true that there was no antagonistic effect. Therefore, there is no indication that
both improving diet and physical activity would result in a less favorable outcome than
either one taken alone.
According to the results of this study, the adoption of an anti-inflammatory diet
may be an effective approach to mitigating disease activity. This dietary approach
differs from current recommended diets, which tend to focus solely on easing the GI
symptoms associated with UC, such as diarrhea, bloating, and gassiness, and reducing
roughage that passes through the colon by restricting various types of fruits, vegetables,
and processed foods. Attention to the inflammatory potential of diet broadens the
understood influence of diet beyond just the colonic symptoms, to improve immune
system functioning and health of the whole body.
A common weakness of current diets suggested for UC is the lack of evidence
that these diets decrease inflammation, which is essential for mucosal healing within the
colon. The DII is a literature-derived index found to be predictive of multiple
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inflammatory biomarkers, such as C-reactive protein, Interleukin-4,6,8, and 10, TNF-a,
and calprotectin, among others (Gialluisi et al., 2021; Li et al., 2021; Malcomson et al.,
2021; Saghafi-Asl et al., 2021; Shivappa et al., 2014a; Shivappa, et al., 2014b; SkoczekRubińska et al., 2021; Wirth et al., 2014; Zamora-Ros et al., 2015). Given the established
associations between the DII and inflammatory biomarkers (now in over 40 construct
validation studies), along with the results of this study, there is suggestive evidence that
an anti-inflammatory dietary intake may aid in managing systemic and localized, chronic
“simmering” inflammation associated with UC and reduce the burden of UC on daily
living (Hofseth & Hebert, 2022). Results of this study support existing findings, which
indicate that anti-inflammatory dietary intake is associated with decreased anxiety,
depression, and risk of colon cancer, among other health outcomes (Marx et al., 2021;
Phillips et al., 2019; Shivappa et al., 2017; Shivappa, et al., 2016b). This research may
advance the development of dietary recommendations for disease management and
influence the food choices among UC patients seeking to manage the burden of illness
associated with UC. Additional research is needed to examine the clinical impact of antiinflammatory dietary intake on the course of UC.
This study analyzed both DII and E-DII scores for robust consideration of nutrient
density versus energy density. The E-DII score was selected for preferred specifications
given the variable’s greater explanatory ability, as well as lower skewness and other
distributional characteristics in comparing scores. Overall, the E-DII scores provided a
better range of participant scores. The E-DII may have fit the data better due to the
nature of the nature of the DSQ dietary data. The food groups assessed in the dietary
measure captured a nutrient dense profile, with many energy dense food items also
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represented. The E-DII may have fit the data better as this population tends to
preferentially adjust their dietary intake as well as delay or restrict eating.
Physical activity is known to regulate inflammation among healthy individuals.
The medicinal benefits of PA are not fully understood among the UC population, though
existing studies tend to show improvements in gastrointestinal symptoms, quality of life,
and psychosocial outcomes, as well as a protective role in maintaining remission (Davis
et al., 2022; Eckert et al., 2019; Raman et al., 2021). Our findings support the limited
existing literature, indicating an association between increased engagement in PA and
improved health outcomes among the UC population. Prior studies suggest that rates of
exercise are inversely associated with disease activity (Eckert et al., 2019; Engles et al.,
2018; Shephard, 2016). Although PA has not been shown to worsen symptoms and is
recognized as safe among the majority of the UC population (Engles et al., 2018; Nathan
et al., 2013), motivation is low among patients with active disease due to fatigue, bowel
urgency, and pain, among other symptoms (Davis et al., 2022; Lamers et al., 2021).
During periods of remission, patients with UC are more receptive to engaging in PA and
report improved health-related quality of life and self-image (Lamers et al., 2021; Taylor
et al., 2018; Wiestler et al., 2019).
A significant gap in the literature calls for greater understanding of the frequency,
intensity, and type of PA best suited for optimal health outcomes among the UC
population. This study adds to the literature by examining the changes in association
with UC health outcomes by intensities of PA. Our findings support results of existing
studies. A recent Japanese study also examined total PA and PA intensities against
clinical outcomes, finding that strenuous activity and increased total PA were each
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independently inversely associated with mucosal healing in patients with UC (Watanabe
et al., 2021). A study by Taylor et al., (2018), found HRQoL benefits associated with all
exercise intensities. Not only were high volumes of moderate and vigorous exercise
associated with physical HRQoL, but high volumes of mild exercise (walking) also were
associated with both physical and mental HRQoL. Overall, studies argue that the
employment of PA and structured exercise could potentially help mitigate and protect
against active disease (Davis et al., 2022; Engles et al., 2018; Jones et al., 2015; Lamers
et al., 2021). Additional research is needed to develop evidence-based physical activity
recommendations for individuals with UC, with attention to exercise frequencies and
intensities that may best reduce the daily burden of living with UC (Raman et al., 2021).
Strengths and Limitations
This research explored the impact of treatment and management methods on the
daily burden of Ulcerative Colitis using a mixed-methods design. Study one was a
qualitative study involving semi-structured interviews with patients diagnosed with UC
from multiple states throughout the US. This study depended on volunteer participants
who were willing to share their experiences with UC, which may skew the variability of
the sample, yet the participant sample provided perspectives and experiences from
patients under the care of many different health facilities. Although this study included
recruitment through social media and integrative health care clinics, all participants
reported treatment under physician care, which may have limited a broader collection of
data on the use of alternative therapies. Findings from this study are limited to patient
perspectives and do not assess the biopsychosocial effectiveness of treatment and
management methods on reducing the burden of UC. At the same time, this qualitative
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study provides deeper understanding of the perspectives and lived experiences of patients
with UC.
Study two utilized quantitative methods to analyze relationships between dietary
inflammatory intake, physical activity, and UC-related outcomes among over 2,000
patients with UC from the IBD Partners e-cohort. The cross-sectional design of this
secondary data analysis limits causal inference within our findings. For example, the
association between total physical activity, particularly higher frequency of strenuous
physical activity, and decreased disease activity might be explained by a patient’s
capacity to engage in exercise.
The sample in this study is largely female and white. Stratified analyses by sex
were considered, yet given inconsistent findings on gender differences in UC outcomes
(Greuter et al., 2020), this gender distribution was accounted for as a control variable in
all models. Representation of racial minorities in research is a prominent limitation of
health-related research (Ma et al., 2021). For this analysis, statistical models controlled
for race as white and non-white participants to account for the skewed representation of
racial difference in the study population.
All data were collected through self-reported measures, subjecting all results to
potential reporting bias. At the same time, no other study, to our knowledge, has
examined diet and physical activity’s associations with UC-related outcomes among such
a large cohort. Very little research exists using the DII/E-DII among the UC population,
and no other research associated with IBD Partners has examined and compared the
associations between physical activity, particularly the frequencies of exercise intensities,
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and UC related health outcomes. This study’s findings are also accompanied by high R2
values, indicating strong explanatory power of our statistical models.
Findings from this study also are limited by the nature of computing DII scores
from the NHANES DSQ. DSQ dietary data included frequency of consumption for 25
different food items. Data on portion sizes of food intake were not included, and nutrient
profiles for participant intake were collected and computed using representative foods.
For this study, DII scores are based on representative data and were not computed from
true dietary recall data. Multiple representative foods were selected and proportioned
within many DSQ food item categories to avoid inflated DII scores, account for
participant intake preferences not indicated within the data, and to reflect a broad range
of nutrient intake. Improved use of dietary assessment tools is needed among IBD
Partners cohort in order to better assess the role of diet in IBD management.
Conclusion and Implications for Future Research
Patients with UC are striving for clear understanding and guidance on how to
reduce the burden of living with UC and achieve increased ‘normalcy’ in daily life. From
this dissertation study, we have gained insights on why patients use various treatment and
management methods and how behavioral methods of diet and PA may impact the illness
experience. This work supports a need for increased attention to the role and impact of
health behaviors in managing disease activity and preventing disease progression.
From this research, we learned that an anti-inflammatory diet is likely to
contribute to a lower burden of illness associated with UC. Anti-inflammatory dietary
intake is associated with reduced disease activity, anxiety, depression, fatigue, and sleep
disturbance, along with improved satisfaction with social functioning and IBD-related
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quality of life. This research may advance the development of dietary and
recommendations for disease management and influence the food choices among UC
patients seeking to manage the burden of illness associated with UC. Though there is
abundant evidence on the relationship between diet-associated inflammation and diseases
of the gastro-intestinal tract, and suggestive links from work using the Dietary
Inflammatory Index (DII®) (Marx et al., 2021; Mirmiran et al., 2019; Phillips et al.,
2019; Shivappa, et al., 2016a), additional carefully designed, ideally prospective, studies
need to be conducted in order to provide sufficient scientific evidence to support clear
dietary recommendations for the management of UC.
This research used the DII to analyze diet in a large cohort of UC patients with a
limited dietary assessment measure. Studies using a comprehensive dietary assessment
are needed to explore the relationships between the DII/E-DII and UC related health
outcomes. As IBD Partners provides researchers with access to a large cohort of
individuals with UC, this research highlights the need for administration of
comprehensive dietary assessment measures among the IBD Partners cohort in order to
best assess the role of diet in IBD management.
The DII is a literature-derived index found to be predictive of multiple
inflammatory biomarkers of significant interest to the etiology of UC, such as C-reactive
protein, Interleukin-4,6,8, and 10, TNF-a, and calprotectin, among others (Gialluisi et al.,
2021; Li et al., 2021; Malcomson et al., 2021; Saghafi-Asl et al., 2021; Shivappa, et al.,
2014a; Shivappa, et al., 2014b; Skoczek-Rubińska et al., 2021; Wirth et al., 2014;
Zamora-Ros et al., 2015). Future studies should aim to examine DII/E-DII scores and
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inflammatory biomarkers among patients with UC to identify the clinical impact of an
anti-inflammatory diet on UC.
We also learned that engagement in PA, is likely to contribute to a lower burden
of illness. In particular, engagement in PA at higher levels of intensity have a stronger
association with positive health outcomes. A significant gap in the literature calls for
greater understanding of the frequency, intensity, and type of PA best suited for optimal
health outcomes among the UC population. This study adds to the literature by
examining the differences in association with UC health outcomes by intensities of PA.
Additional research is needed to develop evidence-based PA recommendations for
individuals with UC, with attention to exercise frequencies and intensities that may best
reduce the daily burden of living with UC (Raman et al., 2021). Future research with
longitudinal data is needed to better determine the mitigating influence of PA on the
disease course and other related outcomes. Future studies should also aim to develop PA
interventions among UC patients, tailored to account for the burden of illness
experienced in daily life.
From patient perspectives and experiences, we gained greater understanding of
the factors that play a role in the use of treatment and management methods. A driving
factor in decision making is personal suffering. Especially during times of active disease,
patients are willing to try new methods of management and overlook long-term
implications in order to reduce suffering and be able to ‘function’ in the present day.
Suffering may motivate long term change, but we learn from this study that the majority
of participants tend to use treatment and management methods in reaction to suffering
and disease activity. Patients identify some medications and overall stress reduction as
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important methods to avoid UC flares, yet treatment and management methods are
predominantly employed as efforts to recover from flares and reduce existing symptoms.
Research is needed to design and evaluate methods and interventions to shift treatment
and management approaches away from reactive measures and promote preventative selfmanagement behaviors.
This research also observed a difference between taking ownership for one’s
health condition and action to take ownership of one’s illness experience. Although UC
follows an unpredictable disease course, we learn that self-advocacy for treatment
satisfaction and patient-provider communication, individual-based decision making, and
health behavior changes are evident among patients who take ownership of their
experience living with UC. Findings from this study can inform providers on factors that
influence patient decision making and support improved patient-provider communication.
Collaborative care between patients and providers helps patients feel a sense of control
over their illness verses their illness controlling them, which, in turn, improves selfmanagement overall (Plevinsky et al., 2016). Additionally, these findings can aid in
framing patient education and behavioral interventions that assist patients in adopting and
sustaining self-management behaviors to reduce and prevent disease activity.
Integrated clinics are needed for IBD care to support treatment for patients with
UC. Physicians typically lack the capacity to train patients on self-management during
an office visit, as well as professional training in nutrition, health behavior change,
psychology, and other interdisciplinary fields. Professional training of IBD-specific
patient educators may benefit patients with UC needing support beyond physician care.
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Insurance coverage of integrated care services is needed to increase patient access to selfmanagement skill development.
Most self-management interventions for people with UC target decision-making
skills and partnering with healthcare providers, but lack focus on symptom management,
employment, or other aspects of daily life affected by UC (Conley & Redeker, 2016).
This study offers added insight into the use of treatment and management methods to
manage the physical and psychosocial burden of illness on daily life. Additional future
studies are needed to explore beyond symptom management and examine methods for
improving emotional, social, and psychological well-being over the course of illness
(Conley & Redeker, 2016; Peters & Brown, 2022; Rozich et al., 2020). Study findings
will support future research that may expand models of patient care and creating
evidence-based health promotion programs to include anti-inflammatory dietary intake
and PA as complementary lifestyle methods that may reduce disease symptoms, maintain
remission, and improve psychosocial well-being among individuals with UC.
In summary, this research addresses gaps in the literature related to the impact of
treatment and management methods on the daily burden associated with Ulcerative
Colitis. This research provides patient perspectives on use of treatment and management
methods and insights on patient decision making over the course of illness. This research
identifies the potential impact of anti-inflammatory dietary intake and physical activity
on the burden of illness, and contributes to the development of dietary and physical
activity recommendations for the UC population. This work also identifies future lines of
research to expand models of patient care and promote behavioral health methods for
reducing the burden of UC in daily life.
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APPENDIX A.
INVITATION LETTER- AIM 1

Dear Patient,
You are eligible to participate in an exciting new research study aiming to learn
directly from patients about the impact of Ulcerative Colitis on everyday life. This
letter is to inform you of the study and invite you participate. This research is associated
with the Department of Health Promotion, Education, and Behavior at the University of
South Carolina. You are invited to participate because you are older than the age of 18,
diagnosed with Ulcerative Colitis, you have been living with Ulcerative Colitis for at
least 5 years, and have experienced at least one flare.
Your valuable contribution to this research will guide the Ulcerative Colitis
community, including patients and health care providers, towards a better understanding
of the experiences faced while managing UC in everyday life.
Participation is voluntary and confidential. If you decide to take part in this study,
you will participate in a private one-on-one interview with a trained researcher who has
a personal history of living with Ulcerative Colitis. During this interview, you will be
asked about your experiences during diagnosis, your challenges and successes managing
your illness, and how UC has impacted your daily life. The interview will be scheduled
to take place at a location and time that is convenient for you, and will last approximately
one hour. Please know that your participation in the study is not connected in any way to
your healthcare services, and no negative consequences can happen if you refuse to
participate.
You will not be identified by name on the interview transcripts or in any final
products that may result from the research. Risks associated with participation are
minimal. You have the right to refuse to answer any questions or stop participation at
any time. After the interview concludes, you will receive a $25.00 cash gift card in
appreciation of your time and participation.
For more information, or to participate in this study please contact the
researcher directly by phone or e-mail:
Kelli DuBois
806-206-5771
kdubois@email.sc.edu
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If you have questions or concerns about your rights as a research participant, you may call the
IRB manager at University of South Carolina at 803-777-6670.
Thank you for your consideration,
Dr. Anjani Jammula, M.D.
GHS Gastroenterology & Liver Center
890 W. Faris Road, Suite 100
Greenville, SC 29605
(864) 455-2888
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APPENDIX B.
RECRUITMENT FLYER FOR INTERVIEWS- AIM 1

Living with Ulcerative Colitis?

Share your story!
Take part in a unique research study.

You will receive

$25.00 in appreciation of your time.
Participant requirements:

✓ Age 18 or older
✓ Diagnosed with Ulcerative Colitis
✓ At least 5 years since initial diagnosis
✓ Experienced at least 1 flare
How does living with Ulcerative Colitis influence your daily life?
Volunteer for a confidential, one-on-one interview with a
trained researcher, who has a personal history of Ulcerative Colitis.

The interview will take place at a location and time that is
convenient for you, and will last no longer than one hour.

Interested? Please contact Kelli DuBois
806-206-5771 or kdubois@email.sc.edu
This study is associated with the University of South Carolina, Department of
Health Promotion, Education, and Behavior
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APPENDIX C.
PHONE SCRIPT FOR RECRUITING VOLUNTEER PARTICIPANTS- AIM 1
Hello,
I am so glad you are interested in sharing your story for this study. Did you hear about
this study from a letter or a flyer?
If Letter: Okay, great. Thank you so much for contacting me. The purpose of this study
is to learn about the daily experiences of those individuals living with Ulcerative Colitis.
You were identified by your physician as eligible to participate. Just to confirm your
eligibility, Are you over the age of 18? Have you been diagnosed with Ulcerative
Colitis? Have you been living with UC for over 5 years? Have you experienced at least
one flare?
If Flyer: Okay, great. Thank you so much for contacting me. The purpose of this study
is to learn about the daily experiences of those individuals living with Ulcerative Colitis.
The first step is to make sure you are eligible to participate. Are you over the age of 18?
Have you been diagnosed with Ulcerative Colitis? Have you been living with UC for
over 5 years? Have you experienced at least one flare?
If not eligible: Unfortunately, you are not eligible to participate in this particular study
because (reason). I really appreciate your interest. Do you know anyone with Ulcerative
Colitis who may be eligible to participate? Please share my contact information with
them if they are interested. Thank you.
If eligible: You are eligible to be a part of this study. Let me tell you about your role if
you choose to participate.
You would meet with me at a location convenient for you for a confidential, one on one
interview that would last approximately one hour. I could come to your home, we could
meet at your physician’s office, or meet somewhere else that has a quiet private space for
us to talk. I’ll ask you questions about your experiences during diagnosis, your
challenges and successes managing your illness, and how UC has impacted your daily
life.
Participation is voluntary and anonymous and is not connected in any way to your health
care services. Any identifying information will be excluded from the transcripts and final
reports. You also have the right to refuse to answer any questions I may ask or stop the
interview at any time. Everything you share will be kept confidential. I have had UC for
13 years myself, and I would be grateful for the opportunity to learn from your
173

experiences and interview you as a part of my research study. Plus, you’ll receive a cash
gift card of $25.00 as an expression of gratitude for your time and participation.
I would enjoy meeting with you to learn about your experiences. Would you be willing
to meet with me for an interview?
I’ll be in your area from ‘date’ to ‘date. Which day would work best for you? I can meet
with you at ‘time slots’, which would be best?
I can come talk with you in the comfort of your own home, but we can also meet in a
room at Dr. Jammula’s office or any other preferred quiet and private space. Where
would you prefer I visit with you?
Thank you. Just to confirm, I’ll be meeting you on (date, time, location). I look forward
to meeting you.
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APPENDIX D.
PRE-INTERVIEW ELIGIBLITY SCREENER-AIM 1
Name:
Phone Number:
Age:
Gender:
Race/Ethnicity:
Approximate years since diagnosis:
Experienced at least one flare in last 5 years: Yes No
Currently in remission: Yes No
Disease Severity: Mild Moderate Severe
Current use of medications:
Surgery: Yes No
If yes, Type:
Interview Date:
Interview Time:
Interview Location:
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APPENDIX E.
IN-DEPTH INTERVIEW GUIDE- AIM 1
“Thank you for your time and consideration of the invitation to participate in this
research study. I am a student from the University of South Carolina and I am here to
learn from you about your experiences living with Ulcerative Colitis. I have lived with
UC for 13 years myself, with struggles in managing my illness over the years. I know
that I’m not alone, and I am excited about the opportunity to learn about your story and
understand how Ulcerative Colitis influences your life.
You have been invited to participate in this study because you were identified as
eligible by your physician. Just confirm, you over the age of 18 you have been diagnosed
with Ulcerative Colitis, and you have been living with Ulcerative Colitis for at least 5
years. Is that correct?
Our conversation will take approximately 60 minutes. The conversation is
voluntary and anonymous. You have the right to refuse to answer any question or stop
the interview at any time. Everything you share will be kept confidential and reported
anonymously. Information on names or any other piece that may reveal your identity will
be excluded from any transcripts and reports. Nothing you say will be shared with your
healthcare provider or any other individuals who provide care or services for you. If you
have any questions after I leave today, you may contact Kelli DuBois at
kdubois@email.sc.edu.
Remember, everything you say is confidential, so please feel comfortable in
sharing your experiences. Don’t hold back. Do I have your permission to audio record
this conversation so that I may review your story again after we finish? [Consent
given/denied]” Okay, let’s get started.
Experience with Ulcerative Colitis
To begin, tell me about how long you’ve been living with Ulcerative Colitis.
Probes: Has your UC changed in any way over the years?
How often would you say that you experience flares?
For how long does a flare last?
Do you feel that you’re in control of your UC or that your UC is in control of you?
Probes: What has been the biggest difficulty living with UC?
Have you ever experienced remission?
Describe a flare, what does a flare look like for you?
Follow up: How do you know when you’re having a flare?
What do you do next?
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Management Methods
How do you manage your UC?
Probes: What medication, if any, are you taking now?
What medications, if any, have you taken in the past?
How do you feel about taking medication?
When you experience a flare, what are the steps you take to reduce your symptoms?
Follow up: How would you describe how *step* helps you manage a flare?
Probes: For how long does this help?
Duration/Dose
How did you know to do *step*?
Where did you learn about that?
Follow up: What else do you do to recover from a flare?
Have you found any kinds of things you can do to help avoid a flare?
Probes: Tell me more about how that helps you avoid a flare.
Duration, dose, Type
Where did you learn to do that?
What role does food play in your UC?
Probe: How do you choose what to eat?
Have you tried other treatment methods outside of medication for UC in the past?
If none of the following are mentioned:
Sometimes people participate in other health practices such as acupuncture,
aroma therapy, herbal therapies, massage, or yoga to help manage their UC.
What are your experiences with alternative treatments to manage the challenges
associated with your UC?
When complementary/alternative treatments are mentioned:
Probes: Type, Duration, Dose
Tell me about how you use that to manage your UC.
Are there any other methods you have tried?
What other things do you do to help manage the impact of UC on your daily life? Even
the things your doctor doesn’t know about, and even if you think it’s crazy, how do you
manage the impact of UC on your life?
Follow up: Over the years, in what ways have you made changes, if any, to your
lifestyle as a result of your UC?
Probes: What led to that change?
What were you expecting that change to do for you?
How has that change impacted your life with UC?
Are there other treatments or methods to manage living with UC that you’ve heard of or
been interested in, but haven’t tried?
Probes: For what reasons have you not used this?
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Do you know others who do things differently than you?
What have you learned about their experiences?
How do the things you do that you’ve told me about (eg. acupuncture, etc) fit with
treatments from your doctor?
What else were you expecting me to ask about today that you haven’t been able to share
yet?
Demographics
Age:
Gender:
Race/Ethnicity:
Age of Diagnosis/Years with UC:
Surgery: Yes No
Level of Education:
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APPENDIX F.
SIMPLE CLINICAL COLITIS ACTIVITY INDEX (SCCAI) - AIM 2

Figure F.1 Simple Clinical Colitis Activity Index (S. L. Jowett et al., 2003)
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APPENDIX G.
SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (SIBDQ)- AIM 2
1. How often has the feeling of fatigue, or of being tired and worn out, been a problem
for you during the last 2 weeks?
1 = All of the time
2 = Most of the time
3 = A good bit of the time
4 = Some of the time
5 = A little of the time
6 = Hardly any of the time
7 = None of the time
2. How often during the last 2 weeks have you had to delay or cancel a social
engagement because of your bowel problem?
1 = All of the time
2 = Most of the time
3 = A good bit of the time
4 = Some of the time
5 = A little of the time
6 = Hardly any of the time
7 = None of the time
3. How much difficulty have you had, as a result of your bowel problems, doing leisure or
sports activities you would have liked to have done during the last 2 weeks?
1 = A great deal of difficulty, activities made impossible
2 = A lot of difficulty
3 = A fair bit of difficulty
4 = Some difficulty
5 = A little difficulty
6 = Hardly any difficulty
7 = No difficulty; the bowel problems did not limit sports or leisure activities
4. How often during the last 2 weeks have you been troubled by pain in the abdomen?
1 = All of the time
2 = Most of the time
3 = A good bit of the time
4 = Some of the time
5 = A little of the time
6 = Hardly any of the time
7 = None of the time
5. How often during the last 2 weeks have you felt depressed or discouraged?
1 = All of the time
2 = Most of the time
3 = A good bit of the time
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4 = Some of the time
5 = A little of the time
6 = Hardly any of the time
7 = None of the time
6. Overall, in the last 2 weeks, how much of a problem have you had with passing large
amounts of gas?
1 = A major problem
2 = A big problem
3 = A significant problem
4 = Some trouble
5 = A little trouble
6 = Hardly any trouble
7 = No trouble
7. Overall, in the last 2 weeks, how much of a problem have you had maintaining or
getting to the weight you would like to be?
1 = A major problem
2 = A big problem
3 = A significant problem
4 = Some trouble
5 = A little trouble
6 = Hardly any trouble
7 = No trouble
8. How often during the last 2 weeks have you felt relaxed and free of tension?
1 = None of the time
2 = A little of the time
3 = Some of the time
4 = A good bit of the time
5 = Most of the time
6 = Almost all of the time
7 = All of the time
9. How much of the time during the last 2 weeks have you been troubled by a feeling of
having to go to the bathroom even though your bowels were empty?
1 = All of the time
2 = Most of the time
3 = A good bit of the time
4 = Some of the time
5 = A little of the time
6 = Hardly any of the time
7 = None of the time
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10. How much of the time during the last 2 weeks have you felt angry as a result of your
bowel problem?
1 = All of the time
2 = Most of the time
3 = A good bit of the time
4 = Some of the time
5 = A little of the time
6 = Hardly any of the time
7 = None of the time
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APPENDIX H.
PROMIS MEASURES USED IN IBD PARTNERS COHORT STUDY- AIM 2
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Figure H.1. PROMIS Measures used in IBD Partners Cohort Study (Kappelman et al., 2014)

APPENDIX I.
GODIN-SHEPHARD LEISURE-TIME PHYSICAL ACTIVITY QUESTIONNAIRE

Figure I.1. Godin-Shephard Leisure-Time Physical Activity Questionnaire (Godin, 2011)
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APPENDIX J.
AVERAGE PORTION SIZE OR SERVING SIZE FOR REPRESENTATIVE FOODS NEEDED
TO CALCULATE NUTRIENT PROFILES
Table J.1. Average Portion or Serving Size Used to Calculate Nutrient Profiles
Representative Foods

Food Items

Fruit (including fresh, frozen or canned)
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Proportion Rate
31%
21%
10%
10%
10%
9%
9%

banana
apple
pineapple
grapes
watermelon
oranges
strawberries

68%

orange juice

32%

apple juice

NHANES DSQ see Median Portion size equivalents
for age groups
(IN CUP EQUIVALENTS)

47%
29%
24%

dry pinto
dry peas & lentils
black beans

NHANES DSQ see Median Portion size equivalents
for age groups
(IN CUP EQUIVALENTS)

18-25

26-35

0.76

0.733333

Source

NHANES DSQ Median Portion size equivalents for
age groups (IN CUP EQUIVALENTS)

Average Portion/Serving Size
Age (years) WOMEN
Age (years) MEN
36-45
46-60
61-69
>69
18-25
26-35
36-45
46-60
61-69
Mean intake in Cup Equivalents (=1 cup cut-up raw or cooked; 1/2 cup dried)

0.71

0.71

0.71

0.59875

0.99

0.76

>69

0.721667

0.94

0.764

0.63

1.06

1

0.981667

0.74

0.73

0.63

0.655

0.635

1 cup equivalent = 1 cup of fruit juice
100% pure fruit juices

0.99

0.94

0.826667 0.78375

0.62

0.62

1.305

1.305

1 cup equivalent = 1 cup cooked dry beans or peas
Refried beans, baked bean, beans in soups, cooked
dried beans

0.48

0.495

0.43

0.47

0.34

0.37

0.65

0.56

1 ounce equivalent = 1 ounce dry rice (approximately 1/2 cup cooked rice;
1 medium (1 ounce) slice of whole grain bread
NHANES DSQ see Median Portion size equivalents 1.83425 1.83425 1.7637 1.69315 1.51678 1.384503 2.08704 2.02596 1.97534 1.97534 1.83425 1.7637
for age groups
1.47 1.426283 1.364575 1.338867 1.195
1.2075 1.7653
1.975
1.723
1.64 1.581033 1.579375
(converted into ounces)
1 cup equivalent = 1 cup milk, yogurt, or fortified soymilk

Whole grain bread, not white bread
Brown rice or other cooked whole grains

Milk (specified)

NHANES DSQ see Median Portion size equivalents
for age groups (IN CUP EQUIVALENTS)

1

1

1

NHANES DSQ see Median Portion size equivalents
for age groups

0.67

0.67

0.6625

0.855

0.75

0.69

1.150833 1.0625

1.25

1

0.94

0.75

0.72875

0.74

0.67

1 cup equivalent= 1.5 ounces natural cheese or 2 ounces processed cheese
Cheese

53%
47%

cheddar cheese
mozzerella

0.67

0.625

0.65

0.89

0.76

0.74

1 cup equivalent=1 cup cut-up raw or cooked vegetables; 1/2 cup dried vegetables; 1 cup juice; 2 cups raw leafy greens
(Total Vegetables)
Green leafy or lettuce salad with or without other
vegetables

fresh head lettuce / fresh leaf
lettuce

0.28

0.28

0.4025

0.44

0.396667

0.38

0.25

0.3

0.265

0.38

0.33

0.38

Fried potatoes

Potatoes/frozen potatoes

0.535

0.535

0.435

0.4175

0.445

0.53

0.55

0.56

0.64

0.55

0.53

0.515

(converted into ounces)
1 cup equivalent = 1 cup milk, yogurt, or fortified soymilk

NHANES DSQ see Median Portion size equivalents
for age groups (IN CUP EQUIVALENTS)

Milk (specified)

1

1

1

0.855

0.75

0.69 1.150833 1.0625

1.25

1

0.94

0.75

0.72875

0.74

0.67

(Table J.1 Continued)
1 cup equivalent= 1.5 ounces natural cheese or 2 ounces processed cheese
Cheese

53%
47%

cheddar cheese
mozzerella

NHANES DSQ see Median Portion size equivalents
0.67
for age groups

0.67

0.6625

0.67

0.625

0.65

0.89

0.76

0.74

1 cup equivalent=1 cup cut-up raw or cooked vegetables; 1/2 cup dried vegetables; 1 cup juice; 2 cups raw leafy greens
(Total Vegetables)
Green leafy or lettuce salad with or without other
vegetables

fresh head lettuce / fresh leaf
lettuce

Fried potatoes
Other kinds of potatoes
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Other vegetables than salad or potatoes

15%
35%
17%
17%
16%

Tomato sauces, not including pizza sauce
Mexican type salsa made with tomato
Red Meat

Processed Meat

Pizza (including frozen, fast food pizza, or homemade)
Sweetened fruit drinks, sports drinks, or energy drinks
Soda, non diet
Coffee or Tea with added sugar or honey
Chocolate or other types of candy
Donuts, sweet rolls, Danish, muffins, or pop-tarts

45%
28%
11%
11%
5%

Potatoes/frozen potatoes
white potato fresh
canned sweet corn
NHANES DSQ see Median Portion size equivalents
onions
for age groups
canned chile peppers
fresh bell peppers
fresh carrots
Canned tomatoes/ Fresh
tomatoes
American Heart Association
lunch meat
hot dog
sausage
American Heart Association
ham
bacon
Reference Food Categories
Mixed Dishes- 'Not measurable
with cup, eg. ...pizza…'
juices, nectars, fruit drinks'
carbonated and noncarbonated
beverages…'
coffee or tea, flavored and
sweetened
all other candies'
…donuts, danish, sweet
rolls…muffins, toaster pastries'

0.28

0.28

0.4025

0.44 0.396667 0.38

0.25

0.3

0.265

0.38

0.33

0.38

0.535
0.57

0.535
0.54

0.435
0.59

0.4175
0.54

0.445
0.53

0.53
0.61

0.55
0.845

0.56
0.85

0.64
0.88875

0.55
0.77

0.53
0.81

0.515
0.815

0.4925 0.4775

0.5

0.5

0.51

0.48

0.525

0.545

0.555

0.56

0.57

0.515

0.47
0.14

0.47
0.17

0.4425 0.4875
0.09 0.11

0.425
0.08

0.56
0.11

0.605
0.17

0.68 0.496667 0.47
0.17 0.12 0.09

0.5675
0.08

0.505
0.14

3 oz = suggested serving size for all adults

Reference Amount of One Serving Size (for all age groups and sex combined)
140 g
240 mL (8 fl oz)
360 mL (12 fl oz)
360mL (12 fl oz)
30g
55 grams

17%
16%
Tomato sauces, not including pizza sauce
Mexican type salsa made with tomato
Red Meat

Processed Meat

(Table J.1 Continued)

Sweetened fruit drinks, sports drinks, or energy drinks
Soda, non diet
Coffee or Tea with added sugar or honey
Chocolate or other types of candy
Donuts, sweet rolls, Danish, muffins, or pop-tarts
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Ice cream or other frozen desserts

Popcorn

Cereal (specified cereal type)

0.47
0.14

0.505
0.14

0.47
0.17

0.4425
0.09

0.4875
0.11

0.425
0.08

0.56
0.11

0.605
0.17

0.68
0.17

0.496667
0.12

American Heart Association
45%
28%
11%
11%
5%

Pizza (including frozen, fast food pizza, or homemade)

Cookies, cake, pie, or brownies

fresh bell peppers
fresh carrots
Canned tomatoes/ Fresh
tomatoes

25% each

lunch meat
hot dog
sausage
ham
bacon

American Heart Association

Reference Food Categories
Mixed Dishes- 'Not measurable
with cup, eg. ...pizza…'
juices, nectars, fruit drinks'
carbonated and noncarbonated
beverages…'
coffee or tea, flavored and
sweetened
all other candies'
…donuts, danish, sweet
rolls…muffins, toaster pastries'
cookies
cakes, medium weight
brownies
FDA Reference
pies, cobblers…'
Amounts
ice cream, frozen yogurt,
sherbet, frozen flavored and Customarily
Consumed
sweetend ice and pops…all
types…'
Snacks- 'all varieties, chips,
pretzels, popcorns,…'
Breakfast cereals
(hot cereal type)
Breakfast cereals, ready-to-eat,
weighing <20 g per cup, eg.
Plain puffed cereal grains
Breakfast cereals, ready-to-eat
weighting 20g< x >43g per cup;
high fiber cereals containing
28g or more of fiber per 100g
Breakfast cereals, ready-to-eat,
weighing >43g or more per cup

3 oz = suggested serving size for all adults

Reference Amount of One Serving Size (for all age groups and sex combined)
140 g
240 mL (8 fl oz)
360 mL (12 fl oz)
360mL (12 fl oz)
30g
55 grams
30 g
80 g
40 g
125 g
2/3 cup

30 g
1 cup prepared; 40 g plain dry cereal; 55 g flavored, sweetened dry cereal
15 grams

40 grams

60 grams

0.47
0.09

0.5675
0.08

APPENDIX K.
REPRESENTATIVE FOOD SELECTED TO COMPUTE NUTRIENT PROFILES
Table K.1 Representative Foods Selected to Compute Nutrient Profiles
Representative Foods
Food Items

Fruit (including fresh, frozen or canned)

Top Consumed Foods

banana
apple
pineapple
grapes
watermelon
oranges
strawberries
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orange juice
100% pure fruit juices
apple juice

dry pinto
Refried beans, baked bean, beans in soups, cooked dried
beans

dry peas & lentils
black beans

Whole grain bread, not white bread

Brown rice or other cooked whole grains

Milk (specified)

Food Item selected from USDA
Data Type Food Code
Food Data Central

Measure for nutrient count

banana, raw
apple, raw
pineapple, raw
grapes, raw, NS as to type
watermelon, raw
orange, raw
strawberries, raw

FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS

63107010
6310100
63141010
63123000
63149010
61119010
63223020

orange juice, 100%, NFS

FNDDS

61210000

apple juice, 100%

FNDDS

64104010

Quantity not specified (248 g)
[248 g =1 fl oz (aka 31 g) x 8=1 cup]
Quantity not specified (248 g)
[248 g =1 fl oz (aka 31 g) x 8=1 cup]

FNDDS

41104000

1 cup (180 g)

FNDDS

41304980

1 cup (180 g)

FNDDS

41102000

1 cup (180 g)

Bread, whole wheat

FNDDS

51300110

100g

Rice, brown, cooked, NS as to
fat added in cooking

FNDDS

56205011

1 cup, cooked (196 g)
[1 ounce equivalents (1.47=1.47 servings
of 1/2 cup)]

Pinto, calico, or red Mexican
beans, dry, cooked, NS as to fat
added in cooking
Lentils, dry, cooked, NS as to fat
added in cooking
Black, brown, or Bayo beans,
dry, cooked, NS as to fat added
in cooking

Milk, whole
Milk, reduced fat (2%)
Milk, low fat (1%)
Milk, fat free (skim)
Soy milk
Almond milk, sweetened
Mllk, lactose free, fat free
(skim)
Goat's milk, whole
Rice milk

mathematical adjustment
to parameter amounts in
order to equal cup & oz
equivalents or
serving/portion size

1 cup, NFS (150 g)
1 cup, NFS (125 g)
1 cup, chunks, (165 g)
1 cup, NFS (151 g)
1 cup, NFS (152 g)
1 cup, sections (180 g)
1 cup, NFS, (152 g)

FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS

11111000
11112110
11112210
11113000
11320000
11350000

1 cup (244 g)
1 cup (244 g)
1 cup (244 g)
1 cup (244 g)
1 cup (244 g)
1 cup (244 g)

FNDDS
FNDDS
FNDDS

11114320
11116000
11360000

1 cup (244 g)
1 cup (244 g)
1 cup (244 g)

multiplied by 0.2835=1
ounce(or 28.35 g)

divided by 2 to = 1/2 cup
cooked

black beans

Whole grain bread, not white bread

Brown rice or other cooked whole grains

dry, cooked, NS as to fat added
in cooking

FNDDS

41102000

1 cup (180 g)

Bread, whole wheat

FNDDS

51300110

100g

Rice, brown, cooked, NS as to
fat added in cooking

FNDDS

56205011

1 cup, cooked (196 g)
[1 ounce equivalents (1.47=1.47 servings
of 1/2 cup)]

(Table K.1 Continued)
Milk, whole
Milk, reduced fat (2%)
Milk, low fat (1%)
Milk, fat free (skim)
Soy milk
Almond milk, sweetened
Mllk, lactose free, fat free
(skim)
Goat's milk, whole
Rice milk
Buttermilk, low fat (1%)
Cream, half

FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS

11111000
11112110
11112210
11113000
11320000
11350000

1 cup (244 g)
1 cup (244 g)
1 cup (244 g)
1 cup (244 g)
1 cup (244 g)
1 cup (244 g)

FNDDS
FNDDS
FNDDS
FNDDS
FNDDS

11114320
11116000
11360000
11115100
12120100

1 cup (244 g)
1 cup (244 g)
1 cup (244 g)
1 cup (244 g)
1 cup (240 g)

cheddar cheese
mozzerella

cheese, cheddar
cheese, mozzarella, NFS

FNDDS
FNDDS

14104100
14107010

1 cup, NFS (113 g)
1 cup, NFS (113 g)

(Total Vegetables)
Green leafy or lettuce salad with or without other
vegetables

fresh head lettuce /
fresh leaf lettuce

mixed salad greens, raw

FNDDS

75114000

1 cup (assume loosely packed) (35 g)

Fried potatoes

Potatoes/frozen
potatoes

potato, french fries, NFS
FNDDS
potato, NFS (cat: white, baked
or broiled)
FNDDS
corn, canned, cooked, no added
fat
FNDDS
onions, cooked, from fresh, fat
not added in cooking
FNDDS
Pepper, chili, green, canned
SR Legacy
peppers, green, cooked, NS as
to fat added in cooking
FNDDS
Carrots, raw
FNDDS
spaghetti sauce (cat: pasta
sauces, tomato-based)
FNDDS
Salsa, NFS
FNDDS

71400990

1 cup (60 g)

71000100

1 cup (160 g)

75216113

1 cup (165 g)

75221011
168577

1 cup (210 g)
1 cup (139 g)

75226000
73101010

1 cup (141 g)
1 cup (120 g)

74404010
74402100

1 cup (260 g)
1 cup (248 g)

ground beef, cooked

FNDDS

21500100

1 oz, cooked (28.35 g)

Ham, prepackaged or deli,
luncheon meat

FNDDS

25230210

1 slice, NFS (28 g)

Frankfurter or hot dog, NFS

FNDDS

25210110

100 g

Sausage, NFS
Ham, smoked or cured, cooked,
NS as to fat eaten
Bacon, NS as to type of meat,

FNDDS

25221400

1 oz, cooked (28.35 g)

FNDDS

22311000

1 oz, boneless, ooked (28.35 g)

Milk (specified)

Cheese
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Other kinds of potatoes

white potato fresh
canned sweet corn
onions

Other vegetables than salad or potatoes

canned chile peppers
fresh bell peppers
fresh carrots

Tomato sauces, not including pizza sauce
Mexican type salsa made with tomato

Canned tomatoes/ Fresh
tomatoes

Red Meat

lunch meat

hot dog
Processed Meat
sausage
ham

multiplied by 0.2835=1
ounce(or 28.35 g)

divided by 2 to = 1/2 cup
cooked

multiplied by 2

multiplied by 3 for
recommended serving size
multiplied by 3 for rec.
serving size of 3 oz meat
(based on grams of other
meat ounces)
1 oz= 28.35 g. Multiplied by
85.5% to =3 oz equivalent.
multiplied by 3 for rec.
serving size of 3 oz meat
multiplied by 3 for rec.
serving size of 3 oz meat
multiplied by 3 for rec.

onions, cooked, from fresh, fat
not added in cooking
FNDDS
Pepper, chili, green, canned
SR Legacy
peppers, green, cooked, NS as
to fat added in cooking
FNDDS
Carrots, raw
FNDDS
spaghetti sauce (cat: pasta
sauces, tomato-based)
FNDDS
Salsa, NFS
FNDDS

onions
Other vegetables than salad or potatoes

canned chile peppers
fresh bell peppers
fresh carrots

Tomato sauces, not including pizza sauce
Mexican type salsa made with tomato

Canned tomatoes/ Fresh
tomatoes

(Table K.1 Continued)
Red Meat

lunch meat

hot dog
Processed Meat
sausage
ham
bacon
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Pizza (including frozen, fast food pizza, or homemade)
Sweetened fruit drinks, sports drinks, or energy drinks
Soda, non diet
Coffee or Tea with added sugar or honey
Chocolate or other types of candy

Donuts, sweet rolls, Danish, muffins, or pop-tarts

Cookies, cake, pie, or brownies

Ice cream or other frozen desserts
Popcorn

FDA Reference Food
Categories
Mixed Dishes- 'Not
measurable with cup, eg.
...pizza…'
juices, nectars, fruit drinks'
carbonated and
noncarbonated beverages…'
coffee or tea, flavored and
sweetened
all other candies'
…donuts, danish, sweet
rolls…muffins, toaster
pastries'
cookies
cakes, medium weight
brownies

75221011
168577

1 cup (210 g)
1 cup (139 g)

75226000
73101010

1 cup (141 g)
1 cup (120 g)

74404010
74402100

1 cup (260 g)
1 cup (248 g)

ground beef, cooked

FNDDS

21500100

1 oz, cooked (28.35 g)

Ham, prepackaged or deli,
luncheon meat

FNDDS

25230210

1 slice, NFS (28 g)

Frankfurter or hot dog, NFS

FNDDS

25210110

100 g

Sausage, NFS
Ham, smoked or cured, cooked,
NS as to fat eaten
Bacon, NS as to type of meat,
cooked

FNDDS

25221400

1 oz, cooked (28.35 g)

FNDDS

22311000

1 oz, boneless, ooked (28.35 g)

FNDDS

22600100

1 oz, cooked (28.35 g)

Pizza with pepperoni, from
restaurant or fast food, NS as to
type of crust
FNDDS
Sports drink (Gatorade G)
FNDDS
soft drink, NFS (same as soft
drink, cola)
FNDDS

58106540
95320200

1 piece, extra-large pizza (134 g)
1 bottle (12 fl oz) (372 g)

92400000

1 can (12 fl oz (372 g)

coffee, NS as to type
Chocolate, sweet or dark

FNDDS
FNDDS

92100000
91705300

1 small (360 g)
1 bar (1.45 oz) (41g)

doughnut, NFS (Cat: doughnuts,
sweet rolls, pastries)
FNDDS
cookie, NFS
FNDDS

53520000
53201000

1 cup (60 grams)
1 medium (30 g)

cake or cupcake, NS as to type
cookie, brownie, NS as to icing

pies, cobblers…'
pie, NFS
ice cream, frozen yogurt,
sherbet, frozen flavored and
sweetend ice and pops…all
types…'
ice cream, NFS
Snacks- 'all varieties, chips,
pretzels, popcorns,…'
Popcorn, NFS

multiplied by 3 for
recommended serving size
multiplied by 3 for rec.
serving size of 3 oz meat
(based on grams of other
meat ounces)
1 oz= 28.35 g. Multiplied by
85.5% to =3 oz equivalent.
multiplied by 3 for rec.
serving size of 3 oz meat
multiplied by 3 for rec.
serving size of 3 oz meat
multiplied by 3 for rec.
serving size of 3 oz meat

1mL=1 g

FNDDS

multiplied by 2 = 80 g
53100100 1 piece (1/10 of 8" or 9" diameter) (39 g) serving size
53204000
1 medium (40 g)
multiplied by 1.25 for 125 g
53300100
100 g
serving size

FNDDS

13110000

100 g

FNDDS

54403001

1 100 calorie package (30 grams)

FNDDS
FNDDS

(2/3 cup is 90 g)

APPENDIX L.
DSQ CEREAL LISTINGS, CEREAL SELECTED FROM USDA FOOD DATA CENTRAL,
AND MEASURE FOR CALCULATING NUTRIENT PROFILES- AIM 2
Table L.1 DSQ cereal listings, cereal match selected from USDA Food Data Central, and measure for calculating nutrient profiles
# of times weight per
selected by cup (g)
participants (cooked)

DSQ Cereal Listing
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417

240 g

229 = Oatmeal

42

240 g

94 = Cream of Wheat

12
1
9
22
1

240 g
240 g
35 g dry
43 g dry
240g

253 = Quaker Multigrain Oatmeal
255 = Quaker Oatmeal Nutrition for Women
251 = Quaker Fruit and Cream Oatmeal
254 = Quaker Oatmeal Express
211 = Multigrain Oatmeal

13

240 g

151 = Grits

1
12
6
4
2
11
3
2

240g
240 g

50 = Cheese grits
252 = Quaker Instant Grits, all flavors
225 = Oat bran cereal
223 = Oat Bran Cereal, Quaker
90 = Cracklin' Oat Bran
92 = Cream of Rice
325 = Whole wheat cereal
316 = Wheat cereal

2

268 g

194 = Malt-O-Meal

1
5
1
1
1
8
24
48
19
24
16
13
2

240 g
233 g
170g
170 g
140g
122 g
116 g

195 = Malt-O-Meal, chocolate
108 = Farina
30 = Buckwheat groats
201 = Millet
31 = Bulgur
142 = Granola, homemade
147 = Grape-Nuts
141 = Granola
6 = 100% Natural Granola, Oats & Honey
3 = 100% Lowfat Natural Granola
5 = 100% Natural Cereal, with oats, honey and raisins
143 = Granola, lowfat
144 = Granola, lowfat, Kellogg's

240 g
240 g
240 g

111 g
102 g
98 g

Food Item selected from USDA Food Data Central

Measure for nutrient Calculated adjustment to
Food Code
count (based on Cereal
paramter amounts to
(FNDDS)
Data Type
density and FDA
equal FDA Reference
NBD # (SR Legacy)
Reference Amounts
Amount of One Serving
FDC ID (Branded)
Customarily Consumed based on cereal density

Oatmeal, NS as to regular, quick, or instant, NS as to fat
FNDDS
added
Cream of wheat, NS as to regular, quick, or instant, NS
FNDDS
as to fat
Oatmeal, multigrain, NS as to fat
Cereals, Quaker, Instant Oatmeal, fruit and cream
variety, dry
Oatmeal, multigrain, NS as to fat
Grits, NS as to regular, quick, or instant, NS as to fat
(cooked)
Grits, with cheese, NS as to fat
Grits, instant, made with water, NS as to fat

56202960
56206990

1 cup, cooked (240 g)
1 cup, cooked (240 g)

FNDDS

56203600

1 cup, cooked (240 g)

SR Legacy

8225

1 packet dry (35 g)

FNDDS

56203600

1 cup, cooked (240g)

FNDDS

1 cup cooked (240 g)

FNDDS
FNDDS

56200990
56201090
56201230

Oat bran cereal, cooked, NS as to fat

FNDDS

56208520

1 cup cooked (240 g)

Rice, cream of, cooked, NS as to fat

FNDDS

56205092

1 cup cooked (240 g)

Whole wheat cereal, cooked, NS as to fat

FNDDS

56207190

1 cup, cooked (240 g)

Cereals, Malt-O-Meal, original, plain, prepared with
SR Legacy
water without salt
Wheat cereal, chocolate flavored, cooked
FNDDS
Cereals, farina, enriched, cooked with water, with salt SR Legacy
Buckwheat groats, NS as to fat
FNDDS
Millet, NS as to fat
FNDDS
Bulgur, NS as to fat
FNDDS
Granola, homemade
FNDDS
Cereal, (Post Grape-Nuts)
FNDDS

8511
56207370
8173
56200490
56201990
56207130
57228000
57230000

1 cup, cooked (240g)
1 cup cooked (240 g)

1 serving (3T dry cereal
plus 1 cup water (268 g)
1 cup, cooked (240 g)
1 cup cooked (233 g)
1 cup, cooked (170g)
1 cup, cooked (170 g)
1 cup, cooked (140g)
1 cup (122 g)
divided by 2 = 60 g portion
1 cup (116 g)
divided by 2 = 60 g portion

Cereal, granola

FNDDS

57227000

100 g

multiplied by 0.60 for 60 g

Cereal (Quaker Granola with Oats, Honey, and Raisins)

FNDDS

57320500

100 g

multiplied by 0.60 for 60 g

Cereal (Kellogg's Low Fat Granola)

FNDDS

57229000

100g

multiplied by 0.60 for 60 g

Cereals ready-to-eat, Quaker, 100% Natural Granola,

2
11
3
2
2
1
5
1
1
(Table
1
8
24
48
19
24
16
13
2

240 g
240 g
268 g

90 = Cracklin' Oat Bran
92 = Cream of Rice
325 = Whole wheat cereal
316 = Wheat cereal
194 = Malt-O-Meal

240 g
195 = Malt-O-Meal, chocolate
233 g
108 = Farina
170g
30 = Buckwheat groats
g
201 = Millet
L.1170Continued)
140g
31 = Bulgur
122 g
142 = Granola, homemade
116 g
147 = Grape-Nuts
141 = Granola
111 g
6 = 100% Natural Granola, Oats & Honey
3 = 100% Lowfat Natural Granola
102 g
5 = 100% Natural Cereal, with oats, honey and raisins
143 = Granola, lowfat
98 g
144 = Granola, lowfat, Kellogg's
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8

96 g

4 = 100% Natural Cereal

3
2
6
4
1

90 g
90 g

x

145 = Granola, lowfat, with Raisins, Kellogg's
9 = All-Bran Bran Buds
209 = Muesli
210 = Muesli(x)
154 = Healthy Choice

5

83.3 g

7 = 100% Natural Wholegrain Cereal with raisins, lowfat

1
5

82g
81 g

1

80 g

1
6

80 g
72 g

3

69.3 g

4
8
14
1
6
2
1
1

65 g
63 g

4

62 g

2

61 g

182 = Kashi Organic Promise

34
4
42
4
4
13
1
4
4
5
34

61 g
60 g
60 g
60 g
59 g
59 g
58 g
57 g
57 g
57 g google
56 g

259 = Raisin Bran, Kellogg's
230 = Oatmeal Crisp
110 = Fiber One
310 = Uncle Sam's Hi Fiber Cereal
18 = Banana Nut Crunch Cereal
260 = Raisin Bran, Post
315 = Wheat bran, unprocessed (miller's bran)
313 = Weetabix Whole Wheat Cereal
91 = Cranberry Almond Crunch Cereal
307 = Total Raisin Bran
262 = Raisin bran

85 g

62 g
x
x

Rice, cream of, cooked, NS as to fat

FNDDS

56205092

1 cup cooked (240 g)

Whole wheat cereal, cooked, NS as to fat

FNDDS

56207190

1 cup, cooked (240 g)

Cereals, Malt-O-Meal, original, plain, prepared with
SR Legacy
water without salt
Wheat cereal, chocolate flavored, cooked
FNDDS
Cereals, farina, enriched, cooked with water, with salt SR Legacy
Buckwheat groats, NS as to fat
FNDDS
Millet, NS as to fat
FNDDS
Bulgur, NS as to fat
FNDDS
Granola, homemade
FNDDS
Cereal, (Post Grape-Nuts)
FNDDS

8511
56207370
8173
56200490
56201990
56207130
57228000
57230000

1 serving (3T dry cereal
plus 1 cup water (268 g)
1 cup, cooked (240 g)
1 cup cooked (233 g)
1 cup, cooked (170g)
1 cup, cooked (170 g)
1 cup, cooked (140g)
1 cup (122 g)
divided by 2 = 60 g portion
1 cup (116 g)
divided by 2 = 60 g portion

Cereal, granola

FNDDS

57227000

100 g

multiplied by 0.60 for 60 g

Cereal (Quaker Granola with Oats, Honey, and Raisins)

FNDDS

57320500

100 g

multiplied by 0.60 for 60 g

Cereal (Kellogg's Low Fat Granola)

FNDDS

57229000

100g

multiplied by 0.60 for 60 g

100 g

multiplied by 0.60 for 60 g

100 g
100 g

multiplied by 0.60 for 60 g
multiplied by 0.60 for 60 g

100 g

multiplied by 0.60 for 60 g

100 g

multiplied by 0.60 for 60 g

100g
100 g

multiplied by 0.60 for 60g
multiplied by 0.60 for 60 g

100 g

multiplied by 0.60 for 60 g

100 g
100g

multiplied by 0.60 for 60 g
multiplied by 0.60 for 60 g

Cereals ready-to-eat, Quaker, 100% Natural Granola,
SR Legacy
Oats, Wheat and Honey
Kellogg Low Fat Granola with Raisins 10.6 oz
Branded
Kellogg's All Bran Cereal Buds 17.7 oz
Branded
Cereal, muesli

Cereals ready-to-eat, Quaker, Low Fat 100% Natural
Granola with Raisins
214 = Nature Valley Granola
Cereal (Nature Valley Granola)
236 = Oats, raw
Oats, raw
Cereals, Quaker, Oat Bran, Quaker/Mother's Oat Bran,
208 = Mother's Natural Foods Cereal, Quaker
prepared w/ water, no salt
241 = Old Wessex Irish Style Oatmeal
Old Wessex Ltd., Irish-Style Oatmeal High Fiber Cereal
150 = Great Grains, Raisins, Dates, and Pecans Whole Grain Cereal Cereal (Post Great Grains Raisins, Dates, and Pecans)
Cereals ready-to-eat, Post, Great Grains Crunchy Pecan
149 = Great Grains Crunchy Pecan Whole Grain Cereal
Cereal
261 = Raisin Nut Bran
Cereal (General Mills Raisin Nut Bran)
61 = Chex, Wheat
Cereal (General Mills Chex Wheat)
8 = All-Bran
10 = All-Bran with Extra Fiber
2 = 100% Bran (Post)
Cereal (Kellogg's All Bran)
24 = Bran
59 = Chex, Multi-Bran
27 = Bran, Nabisco
Gmills Oatmeal Crisp Flakes Cluster Cereal Hearty
233 = Oatmeal Crisp, Raisin
Raisins

FNDDS

SR Legacy
FNDDS
FNDDS
SR Legacy
Branded
FNDDS
SR Legacy

57308190

8220
57309100
57602100
8236
370328
57231200

100 g

multiplied by 0.60 for 60 g

FNDDS
FNDDS

42261
57332100
57411000

100 g
1 cup (63 g)

multiplied by 0.60 for 60 g

FNDDS

57101000

1 cup (62 g)

Branded

Kashi Organic Cereal Promise Cinnamon Harvest 16.3 oz Branded
Cereal (Kellogg's Raisin Bran)
Cereal (General Mills Oatmeal Crisp with Almonds)
Cereal (General Mills Fiber One)
Cereal (Uncle Sam)
Cereal (Post Great Grains Banana Nut Crunch
Cereal (Post Raisin Bran)
Wheat bran, unprocessed
Cereals ready-to-eat, WEETABIX whole grain cereal
Cereal (Post Great Grains, Cranberry Almond Crunch
Total Raisin Bran Cereal (General Mills Sales Inc)
Cereal, raisin bran

8054
751958
751234

FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
SR Legacy
FNDDS
Branded
FNDDS

348845
751670
57330000
57316450
57206700
57408100
57106050
57331000
57601100
42237
57143500
758010
57329000

1 cup (62 g)
31 biscuits (61 g)
1 cup (61 g)
1 cup (60 g)
1 cup (60 g)
1 cup (60 g)
1 cup (59 g)
1 cup (59 g)
1 cup (58 g)
1 cup (57 g)
1 cup (57 g)
100g
1 cup (56 g)

multiplied by 0.60 for 60 g

1
6
2
1
1

x
x

10 = All-Bran with Extra Fiber
2 = 100% Bran (Post)
24 = Bran
59 = Chex, Multi-Bran
27 = Bran, Nabisco

4

62 g

233 = Oatmeal Crisp, Raisin

2

61 g

182 = Kashi Organic Promise

62 g

34 L.1
61 Continued)
g
259 = Raisin Bran, Kellogg's
(Table
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4
42
4
4
13
1
4
4
5
34
22
11
1
3
11
59
22
3
1

60 g
60 g
60 g
59 g
59 g
58 g
57 g
57 g
57 g google
56 g
56 g
56 g
55g
55 g
53 g
53 g

6

52 g

119 = Frosted Shredded Wheat

53

52 g

176 = Kashi GOLEAN

2

50g

228 = Oat flakes

5
25
7
7
3
5

50 g

281 = Smart Start
277 = Shredded Wheat Spoon Size
275 = Shredded Wheat
279 = Shredded Wheat, Original
278 = Shredded Wheat, 100%
203 = Mini-Wheats

4

47.2 g

276 = Shredded Wheat 'N Bran

4
37
51
32
15
6

44 g
44 g
43 g
43 g
43 g
42.6 g

22 = Blueberry Morning
179 = Kashi Heart to Heart Cereal
189 = Life (plain and cinnamon)
158 = Honey Bunches of Oats with Almonds
284 = Special K Fruit & Yogurt
285 = Special K Low Carb Lifestyle Protein Plus

7

41.3 g

156 = Honey Bunches of Oat with Strawberry

51
9
8
18
29
16
12

53 g

50 g

41 g
41 g
40 g
40 g
40 g

230 = Oatmeal Crisp
110 = Fiber One
310 = Uncle Sam's Hi Fiber Cereal
18 = Banana Nut Crunch Cereal
260 = Raisin Bran, Post
315 = Wheat bran, unprocessed (miller's bran)
313 = Weetabix Whole Wheat Cereal
91 = Cranberry Almond Crunch Cereal
307 = Total Raisin Bran
262 = Raisin bran
256 = Quaker Oatmeal Squares
234 = Oatmeal Squares
163 = Honey Nut Clusters
20 = Basic 4
258 = Raisin Bran Crunch
118 = Frosted Mini Wheats
204 = Mini-Wheats Frosted Bite Size
205 = Mini-Wheats Frosted Original
120 = Frosted Wheat Bites

114 = Frosted Flakes, Kellogg's
123 = Frosted flakes
73 = Cocoa Krispies
155 = Honey Bunches of Oat Honey Roasted
157 = Honey Bunches of Oats
139 = Golden Grahams
38 = Cheerios, Apple Cinnamon

Cereal (Kellogg's All Bran)

FNDDS

Gmills Oatmeal Crisp Flakes Cluster Cereal Hearty
Raisins

Branded

Kashi Organic Cereal Promise Cinnamon Harvest 16.3 oz Branded

57101000

348845

Cereal (Kellogg's Raisin Bran)
Cereal (General Mills Oatmeal Crisp with Almonds)
Cereal (General Mills Fiber One)
Cereal (Uncle Sam)
Cereal (Post Great Grains Banana Nut Crunch
Cereal (Post Raisin Bran)
Wheat bran, unprocessed
Cereals ready-to-eat, WEETABIX whole grain cereal
Cereal (Post Great Grains, Cranberry Almond Crunch
Total Raisin Bran Cereal (General Mills Sales Inc)
Cereal, raisin bran
Cereal (Quaker Oatmeal Squares)
Cereal (Quaker Oatmeal Squares)
Cereal (General Mills Honey Nut Clusters)
Basic 4 Ceral (General Mills Sales Inc)
Cereal (Kellogg's Raisin Bran Crunch)

FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
SR Legacy
FNDDS
Branded
FNDDS
FNDDS
FNDDS
FNDDS
Branded
FNDDS

751670
57330000
57316450
57206700
57408100
57106050
57331000
57601100
42237
57143500
758010
57329000
57327500
57327500
57125900
758584
57330010

Cereal (Kellogg's Frosted Mini-Wheats)

FNDDS

57214000

Cereals ready-to-eat, POST, Shredded Wheat, lightly
frosted, spoon-size
Cereal (Kashi GOLEAN)
Cereals ready-to-eat, OAT BRAN FLAKES, HEALTH
VALLEY
Cereal (Kellogg's Smart Start Strong)
Cereal (Post Shredded Wheat) (1 cup spoon size
biscuits)
Cereals ready-to-eat, Post, Shredded Wheat n' Bran,
spoon size
Cereals ready-to-eat, Post Selects Blueberry Morning
Cereal (Kashi Heart to Heart Honey Toasted Oat)
Cereal (Quaker Life)
Cereal (Post Honey Bunches of Oats with Almonds)
Cereal (Kellogg's Speical K Fruit & Yogurt)
Kellogg's Special K Cereal Low Carb Protein Plus
Cereals ready-to-eat, Post, Honey Bunches of Oats with
real strawberries

SR Legacy
FNDDS
SR Legacy

8191
57301510

FNDDS

43495
1101802

FNDDS

57417000

SR Legacy
SR Legacy
FNDDS
FNDDS
FNDDS
FNDDS
Branded
SR Legacy

43393
8192
57301530
57304100
57237300
57344015
752152
8662

1 cup (62 g)

1 cup (62 g)
31 biscuits (61 g)
1 cup (61 g)
1 cup (60 g)
1 cup (60 g)
1 cup (60 g)
1 cup (59 g)
1 cup (59 g)
1 cup (58 g)
1 cup (57 g)
1 cup (57 g)
100g
1 cup (56 g)
100 g
1 cup (56 g)
100g
100 g
100 g
100 g

multiplied by 0.60 for 60 g
multiplied by 0.60 for 60 g
multiplied by 0.60 for 60g
multiplied by 0.60 for 60 g
multiplied by 0.60 for 60 g
multiplied by 0.60 for 60 g

100 g
100g

multiplied by 0.60 for 60 g

100g

multiplied by 0.60 for 60g

100g

1 cup, crushed (58 g)

100 g

multiplied by 0.60 for 60 g

100 g
100 g
1 cup (43 g)
1 cup (43 g)
1 cup (43 g)
100 g

multiplied by 0.60 for 60 g
multiplied by 0.60 for 60 g

100 g

multiplied by 0.40 for 40 g

Cereal (Kellogg's Frosted Flakes)

FNDDS

57349000

1 cup (41 g)

Cereal (Kellogg's Cocoa Krispies)

FNDDS

57126000

1 cup (41 g)

Cereal (Post Honey Bunches of Oats Honey Roasted)

FNDDS

57237100

1 cup (40 g)

Cereal (General Mills Golden Grahams)
Cereal (General Mills Cheerios Apple Cinnamon)

FNDDS
FNDDS

57224000
57103100

1 cup (40 g)
1 cup (40 g)

multiplied by 0.40 for 40 g

7
3
5
4
4
37
51
32
15
(Table
6
7
51
9
8
18
29
16
12
36
21
2
17
15
9
8

50 g

47.2 g

279 = Shredded Wheat, Original
278 = Shredded Wheat, 100%
203 = Mini-Wheats
276 = Shredded Wheat 'N Bran

44 g
22 = Blueberry Morning
44 g
179 = Kashi Heart to Heart Cereal
43 g
189 = Life (plain and cinnamon)
43 g
158 = Honey Bunches of Oats with Almonds
g
284 = Special K Fruit & Yogurt
L.143 Continue)
42.6 g
285 = Special K Low Carb Lifestyle Protein Plus
41.3 g

156 = Honey Bunches of Oat with Strawberry

194

40 g
40 g
40 g
40 g
x
40 g
40 g
40 g
40 g

114 = Frosted Flakes, Kellogg's
123 = Frosted flakes
73 = Cocoa Krispies
155 = Honey Bunches of Oat Honey Roasted
157 = Honey Bunches of Oats
139 = Golden Grahams
38 = Cheerios, Apple Cinnamon
67 = Cinnamon Toast Crunch
58 = Chex, Honey Nut
55 = Chex Morning Mix Honey Nut
287 = Special K Vanilla Almond
26 = Bran flakes
137 = Fruity Pebbles
122 = Frosted corn flakes

2

40g

97 = Crispy Brown Rice Cereal

1

40g

62 = Chocolate frosted cereal

40g
40 g
39 g
39 g
38.6 g
x
38 g
37 g
37 g
36 g
x
x
x
x
x
36 g
36g
36 g
36 g
36 g
36 g
36 g

115 = Frosted Flakes, Malt-O-Meal
266 = Rice Krispies, Treats Cereal
53 = Chex Morning Mix Cinnamon
74 = Cocoa Pebbles
148 = Grape-Nuts Flakes
146 = Grape Nut O's
320 = Wheat, puffed, presweetened with sugar
45 = Cheerios, Honey Nut
44 = Cheerios, Frosted
39 = Cheerios, Berry Burst
43 = Cheerios, Berry Burst, Strawberry Banana
41 = Cheerios, Berry Burst Triple Berry
40 = Cheerios, Berry Burst Strawberry
48 = Cheerios, Yogurt Burst, Strawberry
47 = Cheerios, Team
280 = Smacks
166 = Honey Smacks
190 = Lucky Charms
32 = Cap'n Crunch
322 = Wheaties
75 = Cocoa Puffs
36 = Cap'n Crunch's Peanut Butter Crunch
237 = Oh's
240 = Oh's, Honey Graham
81 = Cookie-Crisp (all flavors)
34 = Cap'n Crunch's Crunch Berries

1
1
3
6
3
1
1
165
7
1
2
1
1
2
2
1
1
29
17
12
8
7
3
2
3
12

41 g
41 g
40 g

36 g
35 g
35 g

biscuits)
Cereals ready-to-eat, Post, Shredded Wheat n' Bran,
spoon size
Cereals ready-to-eat, Post Selects Blueberry Morning
Cereal (Kashi Heart to Heart Honey Toasted Oat)
Cereal (Quaker Life)
Cereal (Post Honey Bunches of Oats with Almonds)
Cereal (Kellogg's Speical K Fruit & Yogurt)
Kellogg's Special K Cereal Low Carb Protein Plus
Cereals ready-to-eat, Post, Honey Bunches of Oats with
real strawberries

FNDDS

SR Legacy
SR Legacy
FNDDS
FNDDS
FNDDS
FNDDS
Branded
SR Legacy

57417000

43393
8192
57301530
57304100
57237300
57344015
752152
8662

1 cup, crushed (58 g)

100 g

multiplied by 0.60 for 60 g

100 g
100 g
1 cup (43 g)
1 cup (43 g)
1 cup (43 g)
100 g

multiplied by 0.60 for 60 g
multiplied by 0.60 for 60 g

100 g

multiplied by 0.40 for 40 g

Cereal (Kellogg's Frosted Flakes)

FNDDS

57349000

1 cup (41 g)

Cereal (Kellogg's Cocoa Krispies)

FNDDS

57126000

1 cup (41 g)

Cereal (Post Honey Bunches of Oats Honey Roasted)

FNDDS

57237100

1 cup (40 g)

Cereal (General Mills Golden Grahams)
Cereal (General Mills Cheerios Apple Cinnamon)
Cereal (General Mills Cinnamon Toast Crunch)

FNDDS
FNDDS
FNDDS

57224000
57103100
57125000

1 cup (40 g)
1 cup (40 g)
1 cup (40 g)

Cereal (General Mills Chex Honey Nut)

FNDDS

57240100

1 cup (40 g)

Cereal (Kellogg's Special K Vanilla Almond)
Cereal (Post Bran Flakes)
Cereal (Post Fruity Pebbles)
Cereal, frosted corn flakes
DELICIOUS WHOLE GRAIN BROWN RICE CRISPS CEREAL,
CRISPY RICE
FROSTED CORN FLAKES, CHOCOLATE (Kellogg
Company)
Cereal (Malt-O-Meal Frosted Flakes)
Cereal (Kellogg's Rice Krispies Treats Cereal)
Cereal (General Mills Chex Cinnamon)
Cereal (Post Cocoa Pebbles)
Cereals ready-to-eat, Post, Grape-Nuts Flakes
discontinued
Cereal, puffed wheat, sweetened
Cereal (General Mills Cheerios Honey Nut)
Cereal (General Mills Cheerios Frosted)

FNDDS
FNDDS
FNDDS
FNDDS

57344020
57209000
57223000
57348000

1 cup (40 g)
1 cup (40 g)
1 cup (40 g)
1 cup (40 g)

Branded
Branded

740026

multiplied by 0.40 for 40 g

1 cup (40g)
100g

multiplied by 0.40 for 40g

FNDDS
FNDDS
FNDDS
FNDDS

651996
57305210
57339500
57124050
57127000

40g
1 cup (40 g)
1 cup (39 g)
1 cup (39 g)

SR Legacy

8093

100 g

FNDDS
FNDDS
FNDDS

57416010
57241000
57213850

1 cup (38 g)
1 cup (37 g)
1 cup (37 g)

FNDDS

57106260

100 g

multiplied by 0.40 for 40 g

Discontinued
Cereal (Kellogg's Honey Smacks)
Cereal (Kellogg's Honey Smacks)
Cereal (General Mills Lucky Charms)
Cereal (Quaker Cap'n Crunch)
Cereal (General Mills Wheaties)
Cereal (General Mills Cocoa Puffs)
Cereal (Quaker Cap'n Crunch's Peanut Butter Crunch)

FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS

57243000
57243000
57305100
57117000
57418000
57128000
57120000

100 g
100g
100 g
100 g
100 g
100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

Cereal (Quaker Honey Graham Oh's)

FNDDS

57316710

100 g

multiplied by 0.40 for 40 g

Cereal (General Mills Cookie Crisp)
Cereal (Quaker Cap'n Crunch's Crunchberries)

FNDDS
FNDDS

57130000
57119000

100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

Cereal (General Mills Cheerios Berry Burst)

muliplied by 0.40 for 40 g

195

1
165
7
1
2
1
1
2
2
1
(Table
1
29
17
12
8
7
3
2
3
12
1
1
5
3
3
1
1
80
46
26
75
1
16
14
1
11
9
257
38
18
1
50
15
13
3
3
68
8
26
1
2
9
5
24
1
2

38 g
320 = Wheat, puffed, presweetened with sugar
37 g
45 = Cheerios, Honey Nut
37 g
44 = Cheerios, Frosted
36 g
39 = Cheerios, Berry Burst
x
43 = Cheerios, Berry Burst, Strawberry Banana
x
41 = Cheerios, Berry Burst Triple Berry
x
40 = Cheerios, Berry Burst Strawberry
x
48 = Cheerios, Yogurt Burst, Strawberry
x
47 = Cheerios, Team
g
280 = Smacks
L.136 Continued)
36g
166 = Honey Smacks
36 g
190 = Lucky Charms
36 g
32 = Cap'n Crunch
36 g
322 = Wheaties
36 g
75 = Cocoa Puffs
36 g
36 = Cap'n Crunch's Peanut Butter Crunch
237 = Oh's
36 g
240 = Oh's, Honey Graham
35 g
81 = Cookie-Crisp (all flavors)
35 g
34 = Cap'n Crunch's Crunch Berries
34.6 g google 188 = Kix, Berry Berry
34g
14 = Amaranth Flakes
33 g
227 = Oat cereal
32 g
308 = Trix
32 g
12 = Alpha-Bits
140 = Golden Puffs, Malt-O-Meal
32g
291 = Sweet Puffs
31 g
283 = Special K
31 g
286 = Special K Red Berries
31 g
57 = Chex, Corn
30 g
46 = Cheerios, Multi Grain
30 g
247 = Product 19
29 g
84 = Corn Pops
29 g
96 = Crispix
x
64 = Cinnamon Crunch Crispix
113 = Froot Loops
29 g
132 = Fruit Loops
28 g
37 = Cheerios
28 g
83 = Corn Flakes, Kellogg's
28 g
15 = Apple Jacks
28 g
296 = Toasted oat cereal
60 = Chex, Rice
27 g
51 = Chex
268 = Rice cereal
27 g
269 = Rice flakes
27 g
138 = Golden Crisp
26 g
264 = Rice Krispies
26 g
98 = Crispy Rice
86 = Corn flakes
25 g
305 = Total Corn Flakes
87 = Corn flakes, low sodium
24 g
187 = Kix
22 g
167 = Honeycomb
175 = Kashi
19 g
186 = Kashi, Puffed
19g
85 = Corn Puffs

Cereal, puffed wheat, sweetened
Cereal (General Mills Cheerios Honey Nut)
Cereal (General Mills Cheerios Frosted)

FNDDS
FNDDS
FNDDS

57416010
57241000
57213850

1 cup (38 g)
1 cup (37 g)
1 cup (37 g)

FNDDS

57106260

100 g

multiplied by 0.40 for 40 g

Discontinued
Cereal (Kellogg's Honey Smacks)
Cereal (Kellogg's Honey Smacks)
Cereal (General Mills Lucky Charms)
Cereal (Quaker Cap'n Crunch)
Cereal (General Mills Wheaties)
Cereal (General Mills Cocoa Puffs)
Cereal (Quaker Cap'n Crunch's Peanut Butter Crunch)

FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS
FNDDS

57243000
57243000
57305100
57117000
57418000
57128000
57120000

100 g
100g
100 g
100 g
100 g
100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

Cereal (Quaker Honey Graham Oh's)

FNDDS

57316710

100 g

multiplied by 0.40 for 40 g

Cereal (General Mills Cookie Crisp)
Cereal (Quaker Cap'n Crunch's Crunchberries)
Berry Berry Kix Cereal
ARROWHEAD MILLS, ORGANIC AMARANTH FLAKES
Cereal, oat, NFS
Cereal (General Mills Trix)
Cereal (Post Alpha-Bits)
Cereal (Malt-O-Meal Golden Puffs)
discontinued "golden puffs of wheat'
Cereal (Kellogg's Special K)
Cereal (Kellogg's Special K Red Berries)
Cereal (General Mills Chex Corn)
Cereal (General Mills Cheerios Multigrain)
Kellogg Product 19 12 oz
Cereal (Kellogg's Corn Pops)

FNDDS
FNDDS
Branded
Branded
FNDDS
FNDDS
FNDDS

57130000
57119000
1146799
364068
57000100
57407100
57103000

100 g
100 g
100g
100g
100 g
100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40g
multiplied by 0.40 for 40g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

FNDDS

57306500

100g

multiplied by 0.40 for 40g

FNDDS
FNDDS
FNDDS
FNDDS
Branded
FNDDS

57344000
57344010
57132000
57308400
751930
57347000

100 g
100 g
100 g
100 g
100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

Cereal (Kellogg's Crispix)

FNDDS

57148000

100 g

multiplied by 0.40 for 40 g

Cereal (Kellogg's Froot Loops)

FNDDS

57213000

100 g

multiplied by 0.40 for 40 g

Cereal (General Mills Cheerios)
Cereal (Kellogg's Corn Flakes)
Cereal (Kellogg's Apple Jacks
Cereal, toasted oat

FNDDS
FNDDS
FNDDS
FNDDS

57123000
57135000
57104000
57401100

100 g
100 g
100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

Cereal (General Mills Chex Rice)

FNDDS

57336000

100 g

multiplied by 0.40 for 40 g

Cereal, rice flakes

FNDDS

57337000

100 g

multiplied by 0.40 for 40 g

Cereal (Post Golden Crisp)
Cereal (Kellogg's Rice Krispies
Cereal, crispy rice

FNDDS
FNDDS
FNDDS

57355000
57339000
57151000

100 g
100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

Cereal, corn flakes

FNDDS

57134000

100 g

multiplied by 0.40 for 40 g

Cereal (General Mills Kix)
Cereal (Post Honeycomb)

FNDDS
FNDDS

57303100
57238000

100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

Cereal (Kashi 7 Whole Grain Puffs)

FNDDS

57301500

100 g

multiplied by 0.15 for 15 g

Cereal, corn puffs

FNDDS

57137000

100g

multiplied by 0.15 for 15g

Cereal (General Mills Cheerios Berry Burst)

257
38
18
1
50
15
13
3
3
68
(Table
8
26
1
2
9
5
24
1
2
1
4
2

28 g
28 g
28 g
28 g

37 = Cheerios
83 = Corn Flakes, Kellogg's
15 = Apple Jacks
296 = Toasted oat cereal
60 = Chex, Rice
27 g
51 = Chex
268 = Rice cereal
27 g
269 = Rice flakes
27 g
138 = Golden Crisp
g
264 = Rice Krispies
L.126 Continued)
26 g
98 = Crispy Rice
86 = Corn flakes
25 g
305 = Total Corn Flakes
87 = Corn flakes, low sodium
24 g
187 = Kix
22 g
167 = Honeycomb
175 = Kashi
19 g
186 = Kashi, Puffed
19g
85 = Corn Puffs
15 g
319 = Wheat, puffed
271 = Rice, puffed
14 g
248 = Puffed Rice, Malt-O-Meal

Cereal (General Mills Cheerios)
Cereal (Kellogg's Corn Flakes)
Cereal (Kellogg's Apple Jacks
Cereal, toasted oat

FNDDS
FNDDS
FNDDS
FNDDS

57123000
57135000
57104000
57401100

100 g
100 g
100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

Cereal (General Mills Chex Rice)

FNDDS

57336000

100 g

multiplied by 0.40 for 40 g

Cereal, rice flakes

FNDDS

57337000

100 g

multiplied by 0.40 for 40 g

Cereal (Post Golden Crisp)
Cereal (Kellogg's Rice Krispies
Cereal, crispy rice

FNDDS
FNDDS
FNDDS

57355000
57339000
57151000

100 g
100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

Cereal, corn flakes

FNDDS

57134000

100 g

multiplied by 0.40 for 40 g

Cereal (General Mills Kix)
Cereal (Post Honeycomb)

FNDDS
FNDDS

57303100
57238000

100 g
100 g

multiplied by 0.40 for 40 g
multiplied by 0.40 for 40 g

Cereal (Kashi 7 Whole Grain Puffs)

FNDDS

57301500

100 g

multiplied by 0.15 for 15 g

Cereal, corn puffs
Cereal, puffed wheat, plain

FNDDS
FNDDS

57137000
57416000

100g
1 cup (15 g)

multiplied by 0.15 for 15g

Cereal, puffed rice

FNDDS

57340000

1 cup (14 g)
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